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Abstract 
 
Extraintestinal pathogenic E. coli (ExPEC) is the major aetiological agent of 
urinary tract infections (UTIs) in humans. The emergence of the CTX-M 
producing E. coli ST131 clone represents a major challenge to public health 
worldwide because of its ability to cause a wide range of difficult-to-treat 
infections in the healthcare and community settings. The key aim of this 
study was to characterise the traits that give E. coli ST131 a competitive 
fitness advantage over other potential ExPEC clones. Comparative 
phenotypic characterisation of a collection of ExPEC strains showed that 
there was no difference between ST131 and non-ST131 strains in terms of 
their growth rates in different culture media, their capacity to associate 
with, invade and form intracellular bacterial communities within T24 human 
bladder epithelial cells and their ability to persist within U937 human 
macrophages. Afterwards, this study tested and compared the metabolic 
activity of a collection of ST131 and non-ST131 strains using two different 
testing methodologies: API strips and phenotypic microarray (PM) 
technology. Our API data showed that ST131 strains had a lower metabolic 
activity for 5 substrates. Further testing of the metabolic activity of E. coli 
using phenotypic microarray demonstrated the absence of a specific 
metabolic profile for ST131 strains suggesting that ST131 is not a 
metabolically distinct lineage of ExPEC and thus altered metabolism might 
not contribute to the fitness of this clone. The gene content of a group of E. 
coli including ST131 and non-ST131 strains was investigated to identify the 
presence of other loci that are uniquely associated with ST131 H30Rx clade, 
which involves ST131 isolates belonging to the fimH30 lineage and 
  II 
associated with fluoroquinolones resistance and CTX-M-15 production. Our 
data identified the presence of 150 loci unique to ST131 H30Rx strains, and 
the most striking finding at a genomic level was the identification of the 
secondary flagellar locus Flag 2 as a region uniquely associated with ST131 
H30Rx strains. The ability of a collection of ST131 and non-ST131 strains 
to resist human serum was tested and compared. Our data showed that all 
ST131 and ST73 strains were associated with high serum resistance 
phenotype, and this might suggest serum resistance as an important factor 
in driving the current success of this ST131 as a major cause of bloodstream 
infections worldwide. Given many reports showing that polysaccharide 
capsules might be a major factor allowing E. coli to resist the human serum, 
and based on many studies demonstrating the genetic and biochemical 
diversity in the capsule region of ST131 strains, the capsule region of a 
collection of ExPEC belonging to ST131 H30Rx clade and non-ST131 was 
tested in more detail at a genomic and biochemical level. Our capsule 
genetics data showed a surprising level of diversity within the capsule locus 
of the H30Rx clade with a phylogenetic distribution highly suggestive of 
frequent recombination at the locus. Subsequent analysis demonstrated 
that this recombination had no obvious detectable effect on virulence-
associated phenotypes in-vitro. Given the level of diversity observed at the 
capsule locus of ST131 H30Rx strains, it is tempting to speculate that there 
is significant selective pressure occurring at this site during the life cycle of 
the H30Rx clade, and that frequent recombination allows the clade to 
subvert that pressure and might provide a fitness advantage to ST131. This 
study provided detailed insights into the phenotypic, metabolic and genetic 
traits of ST131 and highlighted the factors that might drive its success.  
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1. Introduction 
1.1 The species Escherichia coli  
Escherichia coli (E. coli) was first discovered, as “Bacterium coli commune”, 
in the gut in 1885 by the German bacteriologist-paediatrician Theodore von 
Escherich (Escherich 1988). In 1897, Alphonse Lesage proposed that E. coli 
comprised harmless strains as well as other strains with distinct pathogenic 
potential (Lesage 1897). Over the past decades, E. coli has been the subject 
of an enormous number of studies and become one of the best-
characterised prokaryotic organisms (Kunin 1962). However it remains a 
major cause of a wide range of intestinal and extraintestinal infections in 
humans (Pitout 2012a). E. coli is a member of the genus Escherichia which 
is one of the key genera of the Enterobacteriaceae family (Madigan et al. 
2009). E. coli is a facultatively anaerobic, gram-negative, nonsporulating 
bacillus. It can either be motile or non-motile, depending on the possession 
of peritrichous flagella (Madigan et al. 2009). Additionally, E. coli grows in 
temperatures ranging from 7°C to 50°C and can tolerate acidic condition 
below pH 2.5 (Richard and Foster 2003, Kaper et al. 2004, Kramer et al. 
2006, Kuhnert et al. 2006). E. coli is one of the most commonly isolated 
organisms from clinical specimens (Russo and Johnson 2003), and it can be 
recovered from these specimens using simple culture media incubated at 
37°C either with or without oxygen (Weintraub 2007). 
 
1.2 The classification of E. coli strains   
Human-associated E. coli strains can be broadly classified, according to 
their genetic and clinical features, into three groups: commensal E. coli 
strains, enteric or intestinal pathogenic E. coli (IPEC) strains and 
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extraintestinal pathogenic E. coli (ExPEC) strains (Russo and Johnson 
2000). Commensal E. coli strains constitute part of the normal intestinal 
flora in human and mammal hosts, and they are usually incapable of 
causing intestinal tract infections since they lack the specialized virulence 
factors that allow pathogenic E. coli strains to cause disease. However 
commensal E. coli may cause extraintestinal infections in some patient 
groups such as immunocompromised patients (Russo and Johnson 2003). 
The E. coli K-12 is an example of commensal E. coli strains (Kuhnert et al. 
1995). 
Intestinal pathogenic E. coli (IPEC) strains are associated with causing 
gastrointestinal infections such as enteritis and colitis (Russo and Johnson 
2003). On the basis of their pathogenic features, IPEC strains are classically 
categorised into six major pathotypes: enteropathogenic E. coli (EPEC), 
Shiga toxin-producing E. coli (STEC) including the enterohaemorrhagic E. 
coli (EHEC) subset, enterotoxigenic E. coli (ETEC), enteroaggregative E. coli 
(EAEC), enteroinvasive E. coli (EIEC) and diffusely adherent E. coli (DAEC) 
(Nataro and Kaper 1998). However the use of recent molecular approaches 
for the detection of strains belonging to some IPEC pathotypes has 
demonstrated that these strains can be further classified into subtypes 
within a particular pathotype (Croxen et al. 2013). For example, it has been 
found that EPEC is classified into typical (tEPEC) and atypical (aEPEC) 
subtypes based on the presence or absence of the E. coli adherence factor 
plasmid (pEAF) (Trabulsi et al. 2002). Additionally, recent advances in 
whole-genome sequencing have led to an increasing knowledge of the 
plasticity of E. coli genome, with the classification of some IPEC strains now 
becoming even more complicated (Croxen et al. 2013). For example, 
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previous studies published prior to 2011 showed that the Shiga toxin-
producing EAEC was associated with causing a few cases of bloody 
diarrhoea and haemolytic uremic syndrome (HUS) (Morabito et al. 1998, 
Iyoda et al. 2000). However characterisation of EAEC O104:H4, the 
causative agent of the 2011 outbreak in Germany, identified major 
virulence traits of different IPEC pathotypes, such as an aggregative 
adhesive phenotype in vitro, lack of the enterocyte effacement (LEE) 
pathogenicity island, and expression of a Shiga toxin (Bielaszewska et al. 
2011). Therefore, these isolates can be considered a hybrid of both EAEC 
and EHEC, suggesting that the Shiga toxin-producing EAEC strain O104:H4 
associated with the 2011 German outbreak can be rather called 
enteroaggregative haemorrhagic E. coli (EAHEC) (Brzuszkiewicz et al. 
2011).  
Extraintestinal pathogenic E. coli (ExPEC) strains are part of the normal 
intestinal flora that asymptomatically colonise the gut of healthy individuals 
(Köhler and Dobrindt 2011). However when ExPEC strains get access to 
niches outside the gastrointestinal tract of the host, they have the capability 
to colonise these niches and subsequently cause a range of infections such 
as urinary tract infections (UTIs), neonatal meningitis, cellulitis, 
pneumonia, sepsis and bacteraemia (Russo and Johnson 2003, Köhler and 
Dobrindt 2011, Pitout 2012b). Despite their clinical importance, ExPEC 
strains have not been well categorised compared to IPEC strains (Johnson 
and Russo 2002a). However traditional designations for ExPEC strains can 
be used on the basis of to the type of infection they cause, and they include: 
uropathogenic E. coli (UPEC), sepsis-associated E. coli (SEPEC) and 
neonatal meningitis-associated E. coli (NMEC) (Johnson and Russo 2002a, 
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Johnson and Russo 2002b). Comparison of the pathogenic behaviours of 
the three main categories of E. coli is shown in Table 1.1. 
 
Table 1.1: The pathogenic behaviours of the three main categories of E. 
coli, as obtained from Johnson and Russo (2002a). 
 
 Clinical manifestation1 
E. coli category Asymptomatic 
intestinal 
colonisation 
 
Gastrointestinal 
infections 
Extraintestinal 
infections 
Commensal  +++ - + 
IPEC - +++ - 
ExPEC + - +++ 
1Relative involvement of each E. coli category in the specific clinical manifestation 
is indicated on a semi-quantitative scale, from - (absent) to +++ (maximal). 
 
1.3 The genetic structure and phylogenetic history of E. coli  
It has been shown that the balance between recombination and mutation 
basically defines the population structure of bacteria (Tenaillon et al. 2010). 
Based on the level of recombination, bacterial population structure can 
either be clonal, when the recombination level is low, or panmitic, when the 
recombination level is high (Smith et al. 1993). Many previous studies 
showed that the population structure of E. coli is generally clonal. Initially, 
the use of serotyping to identify E. coli strains based on the polymorphism 
of their O (somatic), K (capsular) and H (flagellar) antigens showed the 
strong association of some serotypes with causing certain diseases, 
providing the first description of the clonal population structure of E. coli 
(Orskov and Orskov 1983, Orskov and Orskov 1992). Afterwards, the 
application of multilocus enzyme electrophoresis (MLEE), based on 
detecting the allelic variation in multiple chromosomal genes encoding 
bacterial enzymes by measuring the electrophoretic mobility patterns of 
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enzymes derived from different E. coli strains, demonstrated that there are 
only a few distinctive genotypes, despite the large global genetic diversity, 
and that clones isolated from geographically and temporally distinct hosts 
were identical (Selander and Levin 1980). These findings suggested that 
the rate of recombination in E. coli populations was low and therefore 
supported the previous description that the population structure of E. coli 
is clonal.  
Early phylogenetic analysis of MLEE profiles of the E. coli Reference 
Collection (ECOR) showed that E. coli strains can be defined into six 
phylogenetic groups, designated A, B1, B2, C, D and E (Selander et al. 
1987, Whittam et al. 1993). A subsequent MLEE analysis of similar data 
using 38 enzyme loci found that E. coli strains clustered into five 
phylogenetic groups: A, B1, B2, D and few unclassified lineages belonging 
to group E (Herzer et al. 1990). Commensal E. coli strains typically derive 
from phylogenetic groups A or B1 (Johnson et al. 2001a). Intestinal 
pathogenic E. coli strains derive from the phylogenetic groups A, B1, D or 
E (Pupo et al. 1997), while ExPEC strains derive from phylogenetic groups 
B2 or D (Boyd and Hartl 1998, Johnson and Kuskowski 2000, Johnson et 
al. 2001a).  
Several subsequent studies demonstrated that the use of MLEE is not ideal 
for phylogenetic analysis since enzymes with little sequence similarity may 
show comparable electrophoretic mobility (Bisercić et al. 1991). Nucleotide 
and amino acid sequences can rather be used to provide a platform for 
more refined phylogenetic analysis because they are unlikely to suffer from 
convergence (Chaudhuri and Henderson 2012). In this regard, many 
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nucleotide sequence-based approaches were developed to resolve MLEE 
limitations. For example, Milkman and Crawford (1983) compared the 
nucleotide sequence of a 1648bp region of the trp operon, which controls 
the biosynthesis of tryptophan in the cell, from 12 E. coli K-12 strains. The 
authors found 11 of the 12 K-12 strains to be derived from the phylogenetic 
groups A and B1, with the other strain found to be more divergent since its 
trp sequence differed from that of E. coli K-12 at 44 positions and therefore 
placed it in group B2. This was interpreted as a possible occurrence of 
recombination events (Milkman and Crawford 1983). 
Multilocus sequence typing (MLST) has been used to describe the clonal 
diversity and genetic structure of bacterial populations (Maiden et al. 1998). 
MLST data can also be used as an alternative to MLEE and other existing 
methods for determining the phylogenetic relationships among deep 
lineages, providing a complementary view of the population structure (Feil 
2004). For example, Escobar-Páramo et al. (2004) investigated the 
phylogenetic distribution of a collection of 98 commensal and pathogenic E. 
coli strains from different pathotypes using an MLST scheme including 6 
housekeeping genes (trpA, trpB, pabB, putP, icd and polB). The authors 
found the same phylogenetic groups described previously by MLEE analysis, 
however an additional group, designated group C (although unrelated to 
the group C from the original MLEE analysis), was identified between group 
D and groups A and B1. They also found some of the hyper-virulent E. coli 
pathotypes such as EHEC and ETEC to be restricted to specific phylogenetic 
groups, suggesting that a specific genetic background is essential for the 
expression and maintenance of genes associated with pathogenesis 
(Escobar-Páramo et al. 2004). However a different MLST scheme including 
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7 housekeeping genes: adk, icd, fumC, recA, mdh, gyrB and purA was used 
to analyse 462 E. coli isolates and found that the phylogenetic grouping of 
these isolates was different to that seen either in MLEE analysis (Herzer et 
al. 1990) or in the aforementioned MLST analysis (Escobar-Páramo et al. 
2004). This finding suggested the presence of high levels of recombination 
in E. coli, and it was further supported by the identification of strains from 
the large MLST dataset that were found to be hybrids between groups A 
and B1 (AxB1), or with multiple sources of ancestry (ABD) (Wirth et al. 
2006). The inconsistent findings obtained from using different MLST 
schemes questioned their suitability for phylogenetic studies. To overcome 
this problem, whole genome phylogenetic analysis (phylogenomics) of E. 
coli strains is now being used as an alternative of MLST, although its validity 
depends on the core genome disruption by homologous recombination 
between lineages (Chaudhuri and Henderson 2012). For example, Touchon 
et al. (2009) constructed a whole genome phylogeny for a number of E. coli 
genomes and found that they clustered into the same phylogenetic groups 
predicted by earlier MLEE (Herzer et al. 1990) and MLST studies (Escobar-
Páramo et al. 2004). However using Escherichia fergusonii (E. fergusonii) 
to determine the root of the tree showed that it was placed within group D, 
splitting this group into two clades: D1 and D2 (Touchon et al. 2009). This 
was the first spilt in E. coli phylogenetic history, which might suggest the 
robustness of phylogenomics as tool for studying the phylogenetic structure 
of E. coli. The Phylogenetic relationships amongst selected E. coli strains, 
as determined by phylogenetic analysis of complete and draft genome 
sequences are shown in Figure 1.1. 
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Figure 1.1: Phylogenetic relationships amongst selected E. coli strains, as 
determined by phylogenetic analysis of complete and draft genome sequences 
available in GenBank. The tree illustrates the major phylogenetic groups, and 
shows the close relationship between the German EHEC O104:H4 outbreak strains 
(TY2482, LB226692) and the EAEC strain 55989 [Taken from (Chaudhuri and 
Henderson 2012)]. 
1.4 Introduction to ExPEC  
ExPEC strains are the major aetiological agents of a broad range of 
infections in the community and hospital settings (Rogers et al. 2011). They 
are also associated with causing community-wide outbreaks such as the 
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community-acquired UTIs and septicaemia outbreak caused by E. coli 
O15:K52:H1 in South London between 1986-1987 (Manges et al. 2008). 
ExPEC has now overtaken methicillin-resistant Staphylococcus aurous 
(MRSA) as the leading cause of healthcare-associated infections (HAIs) 
(HPA 2010). Therefore, infections due to ExPEC have a great impact not 
only on public health, but also on the global economy (Russo and Johnson 
2003).  
 
1.4.1 Overview of the medical and economic impact of major 
infections due to ExPEC  
 
Urinary tract infections 
Urinary tract infections (UTIs) are among the most common bacterial 
infectious diseases acquired in community and hospital settings (Foxman 
2010). Worldwide approximately 150 million people are diagnosed with UTI 
each year, costing the global economy more than 6 billion US dollars 
(Akram et al. 2007). UTIs occur in all age groups and in both genders 
(McCormick et al. 1995, Litwin et al. 2005). However their incidence 
increases with age, and the annual incidence of UTI in the elderly population 
ranges from 10% in the community to as high as 30% of hospitalised 
patients (Cove Smith and Almond 2007). UTIs are more common in women 
than men (McCormick et al. 1995), with an estimated 33% of women 
suffering from a UTI by the age of 24 (Foxman 2002). UTIs can be clinically 
presented as one of three syndromes: cystitis, acute pyelonephritis or 
asymptomatic bacteriuria (Kumazawa and Matsumoto 1997). In addition, 
UTIs are divided into uncomplicated and complicated infections. 
Uncomplicated UTIs occur in otherwise healthy individuals who have normal 
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urinary tracts without any abnormalities or foreign bodies within the urinary 
tract (Hooton and Stamm 1997). However complicated UTIs occur in 
patients who have anatomical abnormalities in the urinary tract or are 
catheterised, which is frequently the case in the elderly population, and it 
has been shown that the presence of complicating factors in the infection is 
usually associated with high levels of antimicrobial resistance (Melekos and 
Naber 2000).  
 
UPEC is the major causative agent of UTIs, accounting for as much as 90% 
of all UTIs among non-hospitalized patients and up to 50% of all nosocomial 
UTIs (Srinivasan et al. 2003, Tartof et al. 2005).  Additionally, UPEC is 
associated with causing more than 85% of uncomplicated cystitis in 
premenopausal women (Stamm and Hooton 1993, Hooton and Stamm 
1997), and the estimated number of cases of uncomplicated cystitis per 
year is more than 130 million worldwide costing the global economy more 
than 1 billion US dollars (Russo and Johnson 2003). UPEC also cause 90% 
of uncomplicated pyelonephritis in premenopausal women (Talan et al. 
2000). In the US, the number of uncomplicated pyelonephritis cases per 
year is 250000 and the estimated annual healthcare costs associated with 
pyelonephritis due to UPEC are 175 million dollars (Russo and Johnson 
2003).  
 
 
Bloodstream infections  
E. coli is the leading cause of a range of bloodstream infections (BSIs), such 
as bacteraemia, septicaemia and urosepsis, in nursing facilities (Mylotte et 
al. 2002), hospitalized individuals (Yardena et al. 2002) and children (Ron 
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2010). According to previous studies from all continents, E. coli comprises 
17–37% of all clinically significant bacteria isolated from bloodstream 
infections (Russo and Johnson 2003). Recently, the number of reported 
bloodstream infections due to ExPEC has increased markedly (Rogers et al. 
2011). Bloodstream infections usually result from principal extraintestinal 
infections, especially UTIs (Russo and Johnson 2003). Urosepsis, which is 
defined as a bacteraemia infection caused by an organism previously 
causing an infection in the urinary tract of a patient, represents a large 
number of the recently reported BSIs due to ExPEC (McNally et al. 2013a). 
Several studies have shown that bloodstream infections are major causes 
of mortality. For example, previous hospital-based reports demonstrated 
that the mortality rates in patients of bacteraemia due to ExPEC ranged 
from 5% to 30% (Laupland et al. 2008). Another study found that the 
mortality rates in elderly hospitalized patients from urosepsis can be as high 
as 33% (Tal et al. 2005). With respect to the impact of bloodstream 
infections on the economy, previous data showed that the estimated 
healthcare costs associated with sepsis are approximately 7.6 billion euros 
and 16 billion US dollars per year in Europe and US, respectively (Robson 
and Daniels 2008).  
 
Neonatal Meningitis  
ExPEC is one of the major causes of neonatal meningitis, accounting for 20-
40% of the annual cases in the US (de Louvois 1994, Murphy 2000). 
However it has been reported that the excessive use of ampicillin to reduce 
the vertical transmission of group B streptococcus, the principal cause of 
neonatal meningitis, can lead to an increase in the prevalence of neonatal 
meningitis due to E. coli because of the increased resistance to ampicillin 
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among E. coli strains (Stoll et al. 2002). Meningitis due to E. coli can also 
be associated with high healthcare costs because of the prolonged 
hospitalization and the extensive rehabilitative care required for patients 
suffering from this infection (Russo and Johnson 2003). 
1.4.2 Virulence factors of ExPEC 
The virulence capacity of all pathogenic bacteria is generally determined by 
the possession of several specific virulence factors (VFs) (Dobrindt 2005). 
ExPEC is associated with the possession of a range of virulence factors 
including adhesins, toxins, lipopolysaccharides, polysaccharide capsules, 
proteases and iron-acquisition determinants. These VFs allow ExPEC to 
colonise key anatomical sites, evade and/or subvert host defences, increase 
acquisition of limiting nutrients such as iron, and stimulate a harmful host 
inflammatory response, cumulatively leading to infections outside the 
gastrointestinal tract (Rogers et al. 2011, Da Silva and Mendonça 2012). 
Many of these VFs are encoded on pathogenicity islands (PAIs) (Groisman 
and Ochman 1996). PAIs, which are defined as chromosomally inserted 
genetic elements with a distinct G + C content, harbour virulence-
associated genes that are absent from commensal E. coli (Hacker et al. 
1990). PAIs are typically acquired via horizontal gene transfer that might 
be a crucial step in the evolution of the pathogen (Hacker et al. 1990). 
 
The expression of several VFs is more common among UPEC isolates 
compared to E. coli faecal isolates, and is more common among UPEC 
isolated from upper urinary tract (kidney and ureter) than UPEC isolated 
from lower urinary tract (bladder and urethra) (Johnson 1991). A recent 
study used RNA-sequencing (RNA-seq) and comparative transcriptional 
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analysis to identify novel fitness genes exclusively expressed by UPEC 
isolates during human infection, and found genes involved in ion transport, 
including copper efflux, nickel and potassium import systems, as key fitness 
factors of UPEC that can promote survival within the urinary tract of the 
host (Subashchandrabose et al. 2014). This suggests that the possession 
of these factors can be important for the ability of ExPEC to overcome the 
host defences and establish extraintestinal infections. 
 
Phylogenetic analysis has shown that ExPEC strains belong to the 
phylogroups B2 and D (Boyd and Hartl 1998, Johnson and Kuskowski 2000, 
Johnson et al. 2001a), and it is suggested that group B2 E. coli strains are 
associated with the possession of more virulence factors than E. coli strains 
belonging to other phylogroups (Russo and Johnson 2000). Bacterial 
genomics has become a powerful tool for defining the genes encoding for 
factors that contribute to ExPEC fitness and virulence (Dobrindt 2005). In 
this regard, two previous studies demonstrated that a large fraction of 
genetic information of ExPEC, which has so far been thought to be 
virulence-associated, could also be found in commensal E. coli strains 
(Grozdanov et al. 2004, Hejnova et al. 2005). Therefore, some of these 
features, such as bacteriocins, proteases, iron-acquisition systems, fimbriae 
and other adhesins, can contribute to fitness and thus increasing 
adaptability, competitiveness and the effective colonisation of the host, 
rather than being specific virulence factors directly involved in infection 
(Wold et al. 1992, Herias et al. 1995, Herias et al. 1997). This demonstrates 
the thin line between virulence and fitness factors as well as the importance 
of having a definition of ExPEC virulence factors that directly contribute to 
its pathogenesis (Dobrindt 2005).  
Introduction 
 15 
 
Adhesins 
Adhesion to host structures is a crucial virulence factor of many bacterial 
pathogens (Klemm and Schembri 2000). Bacteria attach to host tissues to 
avoid being removed by the normal flow of body fluids such as blood and 
urine (Slavchev et al. 2013). Bacterial attachment is an essential first step 
in the colonisation of host mucosal surfaces and a precedent to invasive 
infection (Johnson 1991). In E. coli, attachment to uroepithelial cells is a 
characteristic by which uropathogenic E. coli strains are differentiated from 
faecal E. coli strains (Edén 1986). UPEC attachment to different host tissues 
is mediated by a number of fimbrial and afimbrial adhesins, each of which 
has its specific role in the pathogenesis (Slavchev et al. 2013). Among all 
adhesins expressed by UPEC, the type 1 fimbriae and P fimbriae are the 
most common (Johnson 1991). 
Type 1 fimbriae were first recognised by their ability to mediate mannose-
sensitive agglutination of some cell types such as erythrocytes, 
macrophages and yeast cells (Stentebjerg-Olesen et al. 1999). Type 1 
fimbriae are found in more than 90% of all E. coli, including commensal and 
pathogenic strains (Arthur et al. 1989, Slavchev et al. 2013). A type 1 
fimbria is a thin rod-shape surface organelle and comprises four adherence-
associated fimbrial subunits: the major subunit FimA, and the minor 
components FimF, FimG, and FimH (Stentebjerg-Olesen et al. 1999). The 
export system of type 1 fimbriae involves the chaperone FimC and the outer 
membrane usher FimD (Krogfelt et al. 1990), while the expression of type 
1 fimbriae is regulated by the FimB and FimE recombinases (Stentebjerg-
Olesen et al. 1999). The structural components and the biosynthesis 
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machinery of type 1 fimbriae are encoded by the chromosomally located 
fim gene cluster (Klemm et al. 1985). Type 1 fimbriae mediate the 
interaction between UPEC and lower urinary tract of the host via the 
adhesive tip protein FimH. This protein binds to mannosylated uroplakin 
lining the bladder lumen leading to invasion of the superficial umbrella cells 
of bladder epithelium (Mulvey et al. 1998). Many studies have shown the 
important role of type I fimbriae in enhancing UPEC adherence, colonisation 
and invasion of host bladder epithelial cells. For example, a previous study 
on the ExPEC strain UTI89 found that type 1 fimbriae-mediated adherence 
to superficial bladder facet cells leads to invasion, rapid bacterial 
multiplication in the cytoplasm and formation of intracellular bacterial 
communities (IBCs) (Hannan et al. 2012). Additionally a transcriptome 
analysis of the UPEC strain CFT073 has suggested that the expression of 
type 1 fimbriae is required for the effective colonisation of the urinary tract 
of the host (Snyder et al. 2004). Another study has demonstrated that type 
1 fimbriae may contribute to bacterial persistence in patients with UTI due 
to E. coli associated with the use of an indwelling bladder catheter (Mobley 
et al. 1987). Type I fimbriae can also mediate the inactivation of host innate 
immune pathways in the murine UTI model, and promote biofilm formation 
and host cell invasion (Nielubowicz and Mobley 2010).  
P-fimbriae are the second most common adhesin in UPEC (Johnson 1991). 
They were originally identified by the ability to agglutinate human type O 
erythrocytes without inhibition by mannose, distinguishing it from type 1 
fimbriae (Whitt and Salyers 2002). P-fimbriae are commonly associated 
with UTI and pyelonephritis (Katouli 2010), and they can be found in 36% 
of cystitis isolates and in more than 70% of pyelonephritis isolates (Johnson 
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1991). A P-fimbria is composed of many adherence-associated fimbrial 
subunits including the major subunit PapA and five other minor components 
PapC, PapH, PapE, PapF and PapG (Mu and Bullitt 2006). There are also 
some accessory Pap proteins that are not directly involved in adhesion such 
as the fimbrial assembly protein PapD (Whitt and Salyers 2002). The pap 
gene cluster encodes the structural and accessory components of P-
fimbriae (Johnson 1991). P-fimbriae bind specifically to the α-D-Galp-(1-
4)-β-D-Galp carbohydrate portion of P-blood group antigen-specific 
glycosphingolipids receptors, that are found in uroepithelial and renal 
epithelial cells, via the adhesive tip protein PapG (Korhonen et al. 1982). 
This binding can therefore mediate UPEC colonisation and infection of upper 
urinary tract of the host (Katouli 2010), and can also promote the activation 
of immune cell response leading to the development of severe local 
inflammation in the urinary tract (Johnson 1991). 
ExPEC strains can also possess some other fimbrial adhesins such as S and 
F1C fimbriae as well as afimbrial adhesins such as the Dr-binding adhesin 
Afa/draBC (Bien et al. 2012). Various ExPEC-associated adhesins and their 
proposed role in pathogenesis are shown in Table 1.2. 
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Table 1.2: Summary of ExPEC-associated adhesins and their role in 
pathogenesis. 
 
Adhesin Activity/role in pathogenesis 
S/F1C fimbriae (sfa/foc) Bind to epithelial and endothelial cells of urinary tract 
and kidney, and associated with causing ascending 
UTIs, sepsis and meningitis (1)  
 
Dr-adhesin (afa/draBC) Bind to type IV collagen and decay-accelerating factor 
(DAF) in the kidney, and associated with ExPEC strains 
causing gestational pyelonephritis and recurring 
cystitis (2). 
 
M-agglutinin (bma) Agglutinates human erythrocytes carrying the M blood 
group antigen and associated with few 
pyelonephritogenic ExPEC strains (3). 
 
N-acetyl-d glucosamine-
specific fimbriae (gaf)  
 
Responsible for the glucosamine-sensitive 
hemagglutination of endo-β-galactosidase-treated 
human erythrocytes, and it is associated with few 
pyelonephritogenic ExPEC strains (4). 
 
Enterobactin 
receptor/adhesin (iha) 
Contributes to the establishment of UTIs in mouse 
model by enhancing the adherence to uroepithelial 
cells (5). 
Summarised from: (1): (Mulvey 2002, Bien et al. 2012); (2): (Bien et al. 2012); 
(3): (Rhen et al. 1986); (4): (Saarela et al. 1995) and (5): (Johnson et al. 2000, 
Johnson et al. 2005). 
 
 
Toxins 
ExPEC strains are associated with the secretion of several bacterial toxins, 
such as α-haemolysin (HlyA), the cytotoxic necrotising factor 1 (CNF1) and 
the secreted autotransporter toxin (SAT). These toxins can play a major 
role in the virulence of ExPEC. The HlyA is a pore-forming toxin that has a 
major role in the pathogenesis of ExPEC (Ulett et al. 2013). This toxin is 
encoded by the chromosomally located hlyA gene (Welch 1991), and found 
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to be mainly possessed by ExPEC strains associated with causing upper 
UTIs (Johnson 1991). A previous study showed that 50% of E. coli strains 
that are associated with causing pyelonephritis produce HlyA toxin (Bien et 
al. 2012). Another study found that HlyA mediates the lysis of host 
erythrocytes and renal epithelial cells, promoting the release of nutrients 
such as iron that can be utilised by UPEC for growth and/or survival (Ulett 
et al. 2013). Additionally, HlyA can also induce apoptosis of target host cells 
such as neutrophils and renal cells, and can stimulate the exfoliation of 
bladder epithelial cells (Russo et al. 2005, Chen et al. 2006a, Smith et al. 
2006).  
The CNF1 is a virulence factor produced by approximately 30% of E. coli 
strains that cause pyelonephritis, and it may play a major role in the UPEC 
invasion of renal cells (Bien et al. 2012). CNF1 toxin is chromosomally 
encoded by cnf1 (Johnson 1991). A previous study showed that CNF1 
stimulates actin stress fibres formation and membrane ruffle formation in a 
Rho GTPase-dependent manner, which can therefore facilitate the entry of 
E. coli into the cells (Bien et al. 2012). Another study found that CNF1 toxin 
facilitates the dissemination of UPEC by promoting apoptosis of bladder 
epithelial cells and inhibiting the phagocytic and chemotactic activities of 
neutrophils (Mills et al. 2000, Davis et al. 2006).  
Secreted autotransporter toxin (SAT) is a toxin produced mainly by 
pyelonephrogenic E. coli strains (Bien et al. 2012). Many studies have 
shown that this toxin has a proposed role in pathogenesis of UTIs (Guyer 
et al. 2000, Guyer et al. 2002). For instance, a previous study found that 
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SAT could induce cytopathic effects on bladder and kidney cells and elicit 
glomerular damage in a mouse UTI model (Guyer et al. 2002). 
Iron-acquisition determinants 
 
Iron is an essential nutrient for most microorganisms and is required for 
many biological processes such as energy generation, oxygen transport and 
DNA replication (Skaar 2010). In the mammalian hosts, the availability of 
free extracellular iron is limited because it is tightly bound to proteins such 
as transferrin in the serum and lactoferrin on mucosal surfaces (Lewis 
2010). Iron is primarily intracellular and can be found as heme and heme 
proteins such as haemoglobin, iron-sulfur proteins or the iron-storage 
protein ferritin (Katouli 2010, Lewis 2010). In order to acquire iron from 
the host, ExPEC strains use a variety of iron uptake mechanisms such as 
the synthesis and transport of low-molecular-weight iron chelators, called 
siderophores (Neilands 1976, Crosa 1989). Siderophores are important not 
only for scavenging iron, but also for competing with host defences to 
release iron from transferrin and lactoferrin (Litwin and Calderwood 1993). 
ExPEC strains possess several iron uptake systems such as the 
yersiniabactin siderophore system (irp-fyuA), the salmochelin siderophore 
system (iroN) and the aerobactin siderophore system (iuc-iutA) (Johnson 
et al. 2007). A previous study demonstrated that yersiniabactin is involved 
in the establishment of UTI as it plays a major role in iron uptake in vivo 
and promotes biofilm formation in human urine (Hancock et al. 2008, Garcia 
et al. 2011). Additionally, it has been shown that salmochelin is important 
in virulence of UPEC strain CP9 and NMEC strain S88 (Russo et al. 2002, 
Nègre et al. 2004, Feldmann et al. 2007, Peigne et al. 2009). It has also 
been found that the iroN gene is overexpressed in intracellular bacterial 
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communities (IBCs) found in bladder epithelium cells infected with UPEC 
strain UTI89 in a mouse UTI model (Reigstad et al. 2007). The aerobactin 
siderophore system contributes to iron uptake in vivo in a UTI model and 
promotes bacterial growth in conditions with low iron concentrations (Garcia 
et al. 2011). 
 
Flagella 
Flagella are filamentous organelles that are responsible for bacterial motility 
(Terashima et al. 2008). Additionally, flagella can be involved in biofilm 
formation, protein export and adhesion to host cells (Haiko and Westerlund-
Wikström 2013). The flagellum comprises three main components: the 
filament, the hook, and the basal structure (Terashima et al. 2008). In E. 
coli, more than 50 genes are involved in the flagellum formation and 
regulation (Liu and Ochman 2007). These genes are clustered at three 
regions of the chromosome and grouped into three different classes: the 
single class I master operon that consists of flhDC genes responsible for 
transcriptional regulation of flagellar genes, the class II genes responsible 
for the synthesis of the flagellar basal body and hook (flgMNBCDEFGHIJKL, 
flhBAE, and fliAZYDSTEFGHIJKLMNOPQR), and the class III genes involved 
in flagellin synthesis (fliC) and motility (motAB, cheAW, and cheRBYZ) 
(Parthasarathy et al. 2007). Although flagella are common to commensal 
E. coli strains such as the K-12 MG1655 strain (Gauger et al. 2007), several 
studies have demonstrated the important role of flagella in the virulence of 
ExPEC. It has been shown that flagella can allow E. coli to ascend from the 
lower urinary tract to cause pyelonephritis, and that flagellated UPEC can 
cause 70-90% of all UTIs (Bien et al. 2012). Another study on 
pyelonephritogenic E. coli strains has demonstrated that flagellin can 
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mediate their invasion of renal collecting duct (Pichon et al. 2009). 
Additionally, flagella can be an important factor in the pathogenesis of 
meningitis caused by E. coli O18:K1:H7 strain (Parthasarathy et al. 2007). 
 
Surface polysaccharide coatings 
Bacterial surface polysaccharides such as lipopolysaccharides (LPS), 
polysaccharide capsules, and exopolysaccharide colanic acid are important 
virulence factors of ExPEC strains (Kusecek et al. 1984, Russo et al. 1996, 
Miajlovic and Smith 2014). Several reports have shown the role of these 
surface polysaccharides in ExPEC pathogenesis. For example a previous 
study found that LPS is important in the stimulation of a proinflammatory 
response in uncomplicated UTIs, however its role in mediating acute 
ascending UTIs is unclear (Bien et al. 2012). Additionally it has been shown 
that mutations affecting LPS synthesis might affect E. coli ability to adhere 
to abiotic surfaces, suggesting a role of LPS in adhesion processes 
(Genevaux et al. 1999). It has also been proposed that polysaccharide 
capsules provide protection against phagocytosis (Howard and Glynn 1971, 
Weiss et al. 1982, Sarkar et al. 2014), and that some ExPEC capsule types 
may be protective against the bactericidal effect of human serum (Leying 
et al. 1990, Buckles et al. 2009). Another study found a high overexpression 
of genes responsible for the capsular polysaccharide and LPS biosynthesis 
in the UPEC strain CFT073 during experimental UTI, which suggests the 
important role of these surface coatings in ExPEC pathogenesis (Snyder et 
al. 2004). Additionally, several studies have recently shown that 
exopolysaccharide colanic acid can contribute to E. coli survival in human 
serum (Phan et al. 2013, Miajlovic et al. 2014), and can also be implicated 
in fitness of an ExPEC strain in a mouse bacteraemia model 
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(Subashchandrabose et al. 2013).  
1.4.3 Antimicrobial resistance of ExPEC 
Over the past decade, the antimicrobial resistance of ExPEC to many front-
line antibiotics, such as cephalosporins, fluoroquinolones, and 
trimethoprim–sulfamethoxazole, has increasingly been reported (Gupta et 
al. 1999). Several studies during the 2000s across Europe, North and South 
America demonstrated that resistance to ciprofloxacin and trimethoprim–
sulfamethoxazole was observed in as many as 20-45% of ExPEC isolates 
(Foxman 2010). More recently the spectrum of antimicrobial resistance of 
ExPEC has also increased to include additional antimicrobial agents due to 
the emergence of extended-spectrum β-lactamases (ESBLs) producing E. 
coli (Johnson et al. 2010b). ESBLs are a group of enzymes that have the 
ability to hydrolyse the oxyimino-cephalosporins such as cefotaxime and 
the oxyimino-monobactams such as aztreonam and therefore render them 
inactive (Peirano and Pitout 2010). ESBLs were initially detected in 1985 
and they comprise many plasmid-mediated derivatives such as TEM-1, 
TEM-2 and SHV-1 (Nicolas-Chanoine et al. 2008). Since 2000, a new group 
of ESBLs, called CTX-M (i.e. ‘active on CefoTaXime, first isolated in 
Munich’), has emerged (Peirano and Pitout 2010). This group of ESBLs have 
shown an extensive pattern of antimicrobial resistance to many antibiotics, 
including β-lactam agents such as penicillin, cephalosporins (expect 
cephamycins) and monobactams (Rogers et al. 2011). In addition, CTX-M-
producing E. coli strains are often associated with co-resistance to other 
antimicrobial agents such as aminoglycosides and fluoroquinolones (Rogers 
et al. 2011). CTX-M ESBLs are classified according to amino acid sequence 
similarity, into five subgroups (1-5). The CTX-M-15 enzyme, which belongs 
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to CTX-M subgroup 1, is the most common ESBL type globally and it is 
commonly found in E. coli strains (Dhanji et al. 2011). CTX-M-producing E. 
coli clones have recently emerged as important pathogens with a broad 
dissemination, posing a threat to public health worldwide (Rogers et al. 
2011). Consequently the increasing prevalence of antimicrobial resistance 
of E. coli has limited the therapeutic options prescribed frequently by health 
care centres (Leflon-Guibout et al. 2008). Nowadays, few antimicrobial 
agents such as nitrofurantoin, pivmecillinam and carbapenems can be used 
to treat infections due to ExPEC (Vigil et al. 2010, Nicolas-Chanoine et al. 
2014).  
1.5 Microbial typing methods for the identification of pathogenic E. 
coli clones 
Microbial typing is used for differentiating epidemiologically related from 
unrelated isolates within a bacterial species (Hallin et al. 2012). It can also 
be used for the identification of emerging bacterial strains or clones 
belonging to a same species, for determining bacterial population structure 
and genetic diversity, and for elucidating the source of transmission of 
bacteria associated with causing outbreaks (Van Belkum et al. 2007). 
Microbial typing methods may be classified into either phenotypic or 
genotypic methods. These methods vary greatly in terms of their 
discriminatory power, reproducibility, cost and time consumption (Van 
Belkum et al. 2001, Johnson and Russo 2005, Soll et al. 2006). 
1.5.1 Phenotypic methods 
Phenotypic methods, such as biotyping, antibiogram-based typing, phage 
typing and serotyping, are used to qualitatively and quantitatively assess 
the products of gene expression in order to differentiate bacterial strains to 
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a species or even to a subspecies level (Van Belkum et al. 2001, Van Belkum 
et al. 2007). Although the implementation of these methods is relatively 
easy and inexpensive, most of them are known of their poor discriminatory 
power and therefore they are considered unreliable for epidemiological 
studies (Hallin et al. 2012). 
1.5.2 Genotypic methods 
Genotypic methods, such as pulsed-field gel electrophoresis (PFGE) 
(Goering 2010), multilocus sequence typing (MLST) (Maiden et al. 1998) 
and ribotyping, are based on identifying the genetic variation between 
strains (Van Belkum et al. 2007). They include techniques that are used to 
detect the genetic composition (presence or absence of certain genes or 
plasmids), overall structure (restriction endonuclease profiles) and 
nucleotide-based sequence similarity of a number of housekeeping genes 
(Van Belkum et al. 2007). Several molecular typing methods can be used 
for describing pathogenic bacterial clones, which are defined as a group of 
bacterial isolates showing a high degree of similarity, based on near-identity 
of multilocus enzyme profiles and multilocus sequence types (Rogers et al. 
2011). Among these methods, MLST is the “gold standard” for 
identification, and it requires the sequencing of pre-specified internal 
regions of 6-8, typically 7, highly conserved housekeeping genes, allowing 
comparison of the nucleotide sequences within publicly accessible 
databases (Maiden et al. 1998, Rogers et al. 2011). In 2008, MLST was 
used for the identification of globally disseminated ESBL-producing ExPEC 
clones, and was a useful tool in describing the extraintestinal pathogenic 
CTX-M producing E. coli sequence type 131 (E. coli ST131) clone (Woodford 
et al. 2009). 
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1.6 E. coli ST131 
Although E. coli ST131 was first identified in 2008 using MLST (Woodford 
et al. 2009), analysis of the E. coli MLST database demonstrates that E. coli 
ST131 isolates have been found in circulation since 1992 
(http://mlst.warwick.ac.uk/mlst/dbs/Ecoli/GetTableInfo_html). However it 
is only recently that this pathogen has emerged as a major rapidly-
disseminated pandemic E. coli clone, responsible for widespread 
community-onset infections (Rogers et al. 2011). 
1.6.1 Bacterial characteristics of E. coli ST131 
1.6.1.1 Serotyping and phylogenetic group  
 
Previous studies revealed that E. coli ST131 belongs to the serotype 
O25:H4, with a specific O25 type called O25b (Nicolas-Chanoine et al. 
2014). However many studies from different countries have identified some 
E. coli ST131 isolates of serotype O16:H5 (Platell et al. 2011, Matsumura 
et al. 2012, Dahbi et al. 2013, Kudinha et al. 2013, Olesen et al. 2013, 
Blanc et al. 2014, Habeeb et al. 2014), while others demonstrated that 
some E. coli ST131 strains were nontypeable for O or H antigens (Suzuki et 
al. 2009, Dahbi et al. 2013). Phylogenetic analysis of E. coli ST131 has 
shown that it belongs to the hyper-virulent phylogenetic group B2 (Leflon-
Guibout et al. 2008, Nicolas-Chanoine et al. 2008).  
1.6.1.2 fimH subtyping of E. coli ST131 
 
Like most E. coli, all E. coli ST131 strains carry the fimH gene (Johnson et 
al. 2001b) that shows high level of allelic diversity (Weissman et al. 2006, 
Tartof et al. 2007, Díaz et al. 2010). The fimH-typing region harbours a 
highly diverse set of alleles that can be considered phylogenetically 
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restricted (Weissman et al. 2012). A previous study investigated the clonal 
structure of 352 historical and recent ST131 isolates (1967-2009), and 
identified that these isolates belonged to seven fimH-based clonal lineages 
(fimH15, fimH22, fimH27, fimH30, fimH35, fimH41, fimH94) (Johnson et 
al. 2013). It also found that fimH30 was the most common among all fimH 
types (67%), followed by fimH22 (21%) (Johnson et al. 2013).  
 
1.6.1.3 Antimicrobial resistance of E. coli ST131    
 
E. coli ST131 is commonly associated with carrying the blaCTX-M-15 gene, 
encoding the CTX-M-15 ESBL enzyme, on the IncFII plasmids (Coque et al. 
2008). These plasmids are also capable of harbouring a variety of other 
antimicrobial resistance determinants such as OXA-1, TEM-1, SHV-12, 
CMY-2 β-lactamases and the aminoglycosides/fluoroquinolone 
acetyltransferase AAC (6’)-Ib-cr (Woodford et al. 2009, Rogers et al. 2011). 
However the blaCTX-M-15 gene in E. coli ST131 can be carried on other plasmid 
types such as FIA, FIB and FII (Rogers et al. 2011). The antimicrobial 
resistance of E. coli ST131 was first recognised amongst CTX-M-15 
producing E. coli strains (Nicolas-Chanoine et al. 2008). Further studies on 
this resistance revealed that E. coli ST131 is highly prevalent amongst 
fluoroquinolone-resistant, non-ESBL-producing E. coli strains (Cagnacci et 
al. 2008, Jones et al. 2008, Johnson et al. 2009a, Johnson et al. 2010c, 
Uchida et al. 2010). This suggests that CTX-M enzymes might have been 
acquired by E. coli ST131 strains that were already resistant to 
fluoroquinolones. Moreover, previous studies demonstrated that E. coli 
ST131 were more commonly resistant to amikacin, amoxicillin-clavulanic 
acid, and piperacillin-tazobactam than non-ST131 (Nicolas-Chanoine et al. 
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2014). However not all ST131 isolates are associated with antimicrobial 
resistance and some studies demonstrated the existence of antimicrobial- 
susceptible ST131 strains. For example, a previous study found that E. coli 
ST131 isolates were prevalent amongst extended-spectrum cephalosporins 
(ESC) and fluoroquinolone-susceptible urine isolates (Golding et al. 2012).  
The increasing spectrum of antimicrobial resistance of E. coli ST131 might 
be attributed to its ability to exchange diverse antimicrobial resistance 
genes and plasmids encoding these genes (Johnson et al. 2010b). Recent 
studies have discussed the evolution of E. coli ST131 and the role played 
either by its clonal spread or transferable plasmids and other resistance 
determinants, such as ESBL and fluoroquinolone resistance genes, in the 
worldwide dissemination of E. coli ST131 (Rogers et al. 2011). Lee et al. 
(2010) found no correlation between the acquisition of transferable 
resistance determinants and the global dissemination of E. coli ST131. 
However the spread of fluoroquinolone-resistant isolates, which then 
acquire a CTX-M gene, or probably the simultaneous spread of clonal 
organisms and genes, can provide potential explanations for the 
accelerated dissemination of E. coli ST131 (Oteo et al. 2009, Uchida et al. 
2010).  
1.6.1.4 Phylogeny of E. coli ST131 clinical isolates  
 
A previous study investigated the population structure of fluoroquinolone 
resistance in 352 ST131 isolates including historical (1967-2009) and 
recent (2010-2011) ST131 isolates, using PFGE profiling and the 
sequencing of fimH, gyrA and parC genes (Johnson et al. 2013). Comparing 
the events affecting the gyrA and parC genes with those of 737 non-ST131 
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isolates showed the presence of 185 unique pulsotypes among the 352 
ST131 isolates. The analysis also identified seven fimH-based clonal 
lineages within ST131 isolates (H15, H22, H27, H30, H35, H41 and H94), 
and found H30 to be the most common fimH allele (Johnson et al. 2013). 
Determining the association between ST131 H subclones and 
fluoroquinolone resistance showed that only fluoroquinolone-susceptible 
ST131 H subclones, particularly H22, were identified at the start of study 
period, 1967-1999. Fluoroquinolone-resistant ST131 isolates were first 
detected between 2000-2005, and nearly all of these isolates belonged to 
the H30 subclone. Additionally, it was found that the H30 subclone was 
strongly associated with fluoroquinolone resistance in the historical ST131 
isolates, and also with the ESBL blaCTX-M-15 production (Johnson et al. 2013). 
The history of single nucleotide polymorphism (SNP) and mutations of gyrA 
and parC genes leading to amino acid substitutions in ST131 and non-
ST131 isolates showed an association between the H30 subclone and a 
characteristic gyrA and parC allele combination arising from a single strain 
as little as 10 years ago (Johnson et al. 2013). Recently, a whole genome 
SNP-based study used 105 ST131 isolates to determine the phylogeny of 
ST131, and identified four large recombinant regions acquired by horizontal 
gene transfer (Price et al. 2013). The exclusion of SNPs from these four 
regions uncovered the presence of different clusters of O-type strains 
harbouring the fimH30 allele and gyrA and parC alleles. Strains carrying the 
fimH allele clustered as a single low-diversity clade, designated H30. This 
clade contained 95% of all fluoroquinolone-resistant ST131 isolates. 
Additionally, all the CTX-M-15 ESBL producing ST131 isolates belonged to 
a single distinct subclade within the H30 clade. To further resolve the 
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evolutionary history of the H30 subclone, a new phylogenetic tree was 
constructed based on genomic analyses of H30 strains and the ST131 
NA114 reference genome. The analysis found that the fimH30 allele was 
acquired before fluoroquinolone resistance, and that this acquisition was 
followed by the extensive clonal expansion of fluoroquinolone-resistant H30 
strains. The fluoroquinolone-resistant subclone within the H30 lineage was 
designated H30-R. Additionally, the analysis demonstrated that 91% of the 
CTX-M-15 producing ST131 isolates constituted a distinct single ancestor 
subclone within H30-R, and it was therefore designated H30-Rx (Price et al. 
2013). Taken together, these findings support the hypothesis that the 
spread of CTX-M-15 and fluoroquinolone resistance in ST131 depends 
mainly on clonal expansion. The phylogeny of ST131 including the three 
nested ST131 subclones: H30, H30-R, H30-Rx is shown in Figure 1.2. 
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Figure 1.2: High-resolution phylogenetic analysis of the emergence of 
fluoroquinolone-resistance and CTX-M-15 ESBL production. Approximately 51.8% 
of the reference genome was shared among all isolates and sequenced at ≥10 
coverage. Analysis of these shared genomic regions revealed 72 parsimony-
informative SNPs and 771 total SNPs from the core genome (excluding horizontally 
acquired regions) that were used to construct the phylogeny presented here. 
Homoplasy index (HI) = 0.000. The coloured blocks highlight the three nested 
ST131 subclones, H30 (purple), H30-R (blue), H30-Rx (yellow) [Taken from (Price 
et al. 2013)].  
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1.6.2 Pathogenic characteristics of E. coli ST131 
1.6.2.1 Scale of infection 
 
Many studies have shown that E. coli ST131 strains are a major cause of 
community- and hospital-acquired UTIs (cystitis and pyelonephritis) and 
bacteraemia worldwide (Adams-Sapper et al. 2012, Gibreel et al. 2012b, 
Williamson et al. 2013). Additionally, E. coli ST131 strains have been 
associated with causing a range of infections such as intra-abdominal and 
soft tissue infections (López-Cerero et al. 2013), meningitis 
(Assimacopoulos et al. 2012), osteoarticular infection (Johnson et al. 
2010a), myositis (Vigil et al. 2010) and septic shock (Ender et al. 2009). 
This scale of infection in addition to the multidrug resistance of E. coli ST131 
has increased the concern about this clone globally.  
1.6.2.2 Transmissibility  
 
The transmission of E. coli ST131 has been reported between members of 
the same household and also between family members and pets 
(particularly dogs and cats) (Johnson et al. 2009b). A previous study 
documented the transmission of a CTX-M-15 producing ST131 isolate, 
which was resistant to gentamicin, trimethoprim-sulfamethoxazole and 
fluoroquinolones, between a father and his daughter (Ender et al. 2009). 
Another study reported a fatal case of urosepsis including community-
associated intrafamilial spread of CTX-M-15 producing, fluoroquinolone-
resistant ST131 strain (Owens et al. 2011). Previous molecular 
epidemiological analysis found a multidrug-resistant (MDR) E. coli strain 
from a human-associated pulsotype within ST131 colonising three of five 
dogs and cats within a household suggesting that companion animals might 
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represent a reservoir of ST131 (Johnson et al. 2009b). The transmission of 
ST131 between human and animal members, probably by direct host-to-
host transmission, might considerably contribute to the community-wide 
dissemination of ST131 (Nicolas-Chanoine et al. 2014). 
1.6.2.3 Virulence potential of E. coli ST131    
 
As mentioned earlier, it has been shown that the ability of ExPEC to colonise 
and cause infection in the urinary tract results from the cumulative action 
of specific virulence factors which mediate adhesion, aid subversion of host 
immune defences, stimulate harmful host inflammatory responses and 
increase iron acquisition (Rogers et al. 2011). It has been widely thought 
that bacteria exhibiting high levels of antimicrobial resistance do so at the 
expense of a fitness advantage, which results in decreased pathogenesis 
(Foxman 2010). However initial studies on the virulence potential of E. coli 
ST131 strains showed high levels of virulence-associated gene (VAG) 
carriage (Coelho et al. 2010), and that E. coli ST131 strains have been 
responsible for causing large-scale disease outbreaks (Lau et al. 2008a, 
Coelho et al. 2010, Johnson et al. 2010b). Coelho et al. (2010) concluded 
that ST131 isolates were significantly associated with eleven VAGs (papG 
III, afaFM955459, cnf1, sat, hlyA, kpsM II-K2, kpsM II-K5, traT, ibeA, malX 
and usp), and they demonstrated that the worldwide dissemination of 
ST131 clone might be attributed to this high VAG carriage of ST131. 
Recently, although many comparative studies on the virulence capacity of 
strains belonging to different ExPEC STs found a number of VFs that are 
commonly possessed by ST131 strains (Table 1.3), these studies 
demonstrated that strains within the ST131 complex did not seem to 
possess any specific set of VAGs compared to other ExPEC STs. For 
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example, a previous study by our research group found that ST131 isolates 
did not exhibit higher VAG carriage than other ExPEC STs such as ST73 and 
ST127 (Croxall et al. 2011a). It also showed that some VAGs such as, papG 
III, sfa/focDE, focG and cnf1, were less prevalent in ST131 isolates 
compared to other ExPEC STs (Croxall et al. 2011a). Another study found 
that ST131 had moderate VAG profiles compared to other successful ExPEC 
STs such as ST69 and ST127 (Gibreel et al. 2012b). These studies suggest 
that the success of ST131 cannot be ascribed to the possession of any 
unique VAGs or the possession of any VAGs to a greater extent than in 
other ExPEC strains. 
 
Table 1.3: List of VAGs that are commonly associated with ST131. 
 
VAG Function 
sat Secreted autotransporter toxin  
fimH Type 1 fimbriae adhesin  
fyuA Yersiniabactin siderophore receptor 
kpsM II  Group 2 capsule synthesis 
usp Uropathogen specific protein 
malX Pathogenicity island marker 
iha Enterobactin receptor/adhesion 
ompT Outer membrane protein  
iucD Aerobactin 
iutA Aerobactin receptor 
traT Serum-resistance associated  
Summarised from: (Karisik et al. 2008, Nicolas-Chanoine et al. 2008, Johnson et 
al. 2010b, Mora et al. 2011, Johnson et al. 2012, Lavigne et al. 2012, Van der Bij 
et al. 2012). 
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A recent whole genome-based study examined the genetic architecture of 
isolates belonging to the E. coli ST131 H30Rx clade (Petty et al. 2014), 
paying particular attention to virulence associated genes of ExPEC and to 
mobile genetic elements not found in non-ST131 ExPEC. This study 
suggested the absence of an ST131 specific virulence gene repertoire, 
though did highlight the unique nature of the secondary flagellar cluster 
(Flag-2) that had been previously identified in E. coli ST131 genomes (Clark 
et al. 2012). Additionally, the analysis also demonstrated the role of intra-
ST131 recombination in shaping the lineage. It also identified a 
recombinant fragment common across ST131 within the group II capsule 
synthesis locus (Petty et al. 2014), with several variant region 2 gene 
clusters observed between region 1 (kpsFEDUCS) and region 3 (kpsTM) of 
ST131 H30Rx genomes. This variability in the capsule locus of ST131 H30Rx 
strains was consistent with the detectable diversity in K-antigen serotype 
of members of ST131 H30Rx strains (Olesen et al. 2013). 
1.6.2.4 Metabolic potential of ST131  
 
It has recently been suggested that high metabolic capacity enhances 
bacterial fitness and therefore contributes to pathogenesis (Le Bouguénec 
and Schouler 2011). With regard to the association between metabolic 
potential and increased E. coli ST131 fitness, a recent study tested the 
metabolic activity of a collection of 300 UPEC isolates representing the 
major STs using 47 biochemical tests (Gibreel et al. 2012a). The authors 
found that E. coli ST131 isolates have higher metabolic potential and 
biochemical profiles compared to other ExPEC ST isolates, which may 
contribute to the fitness of E. coli ST131. They also found a correlation 
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between metabolic activity and antibiotic susceptibility profiles, with 
resistant isolates showing the highest metabolic potential (Gibreel et al. 
2012a). Another study tested the ability of one E. coli ST131 strain to 
colonise the intestinal tract by measuring its maximal growth rate (MGR) 
using three different culture conditions: a rich medium and two minimal 
media containing either gluconate or glucose (Vimont et al. 2012). By 
comparing the metabolic activity of the ST131 strain with three other E. coli 
strains: the commensal E. coli strain K-12 MG1655 and the ExPEC CFT073 
and HT7 strains, the study found that the ST131 strain had a significantly 
higher MGR than the non-ST131 strains (Vimont et al. 2012). 
1.6.2.5 Adhesion and invasion capacity of ST131  
 
A previous study examined the similarity and divergence of a collection of 
adherent invasive E. coli (AIEC) and ExPEC strains, in terms of their genetic 
and phenotypic features, and identified two intestinal AIEC strains and one 
extraintestinal AIEC strain belonging to the O25:H4 ST131 clone (Martinez-
Medina et al. 2009). It also found that the extraintestinal AIEC ST131 strain 
had a similar AIEC adhesion, invasion of intestinal epithelial cells and intra-
macrophage replication phenotype, and that this strain showed distinct 
virulence and macrorestriction profiles compared to the other two intestinal 
AIEC ST131 strains (Martinez-Medina et al. 2009). Another study compared 
the capacity of four ExPEC, two ST131 and two non-ST131 strains, to 
adhere to human intestinal cell lines (Peirano et al. 2013), and found that 
the tested ST131 strains had lower adhesion capacity compared to the non-
ST131 strains. However carrying out these experiments in the presence of 
mannose, which inhibits adhesion mediated by type 1 fimbriae, could be 
the reason behind the weak adhesion capacity of ST131 strains (Peirano et 
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al. 2013). These conflicting data highlight the importance of testing and 
comparing the adherence and invasion capacity between ST131 and non-
ST131 strains.     
1.7 Introduction to the project 
Since the emergence of E. coli ST131 and in an attempt to identify the key 
factors that might contribute to its success, this clone has been the subject 
of numerous studies that have explored its antimicrobial resistance, 
virulence potential, metabolic capacity and the molecular epidemiological 
aspects of this clone. Early reports found an association between the rapid 
emergence and dissemination of E. coli ST131 and its increased 
antimicrobial resistance, however this resistance alone cannot provide an 
explanation for the ST131 dominance amongst other MDR uropathogens 
circulating worldwide in healthcare and community settings. Subsequently 
many comparative studies investigated the prevalence and virulence 
potential of ST131 and other successful ExPEC STs such as ST73, ST69, 
ST95 and ST127. Previous work by our research group showed that E. coli 
ST131 was the dominant strain type within a collection of elderly urine 
samples, that the E. coli ST131 was responsible for the high levels of 
antimicrobial resistance reported in the collection, and that there was 
variation in VAG profiles between strains, with no specific VAG profile 
associated with ST131 strains (Croxall et al. 2011a). The variable carriage 
of key virulence factors of E. coli ST131 suggests the presence of additional 
unidentified factors that can contribute to its fitness and therefore provide 
an explanation for what makes E. coli ST131 such a successful ExPEC clone. 
On the basis of our previous genome sequence data that identified a 
deletion of P fimbriae and a transposon insertion mutation in the fimB gene 
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of ten clinical E. coli ST131 isolates (Clark et al. 2012), it is important to 
examine the biological relevance and the effect of these mutations on the 
true virulence of ST131 isolates. The recent work by Gibreel et al. (2012a) 
highlighted the need to conduct comprehensive studies on the metabolic 
potential of E. coli ST131 and other ExPEC STs using different testing 
approaches to determine any link between metabolic potential and 
increased pathogenesis of E. coli ST131. Given that the comparative 
genomics performed to date on E. coli ST131 have mainly focussed on 
virulence associated genes (Petty et al. 2014), comparing the whole gene 
content of a collection of E. coli strains including ST131 and non-ST131 is 
important to identify the presence of other loci uniquely associated with the 
H30Rx clade of E. coli ST131. Finally, based on recent findings 
demonstrating the role of intra-ST131 recombination in shaping the lineage 
as well as diversity in the capsule region of ST131 H30Rx strains at both 
genetic (Petty et al. 2014) and biochemical (Olesen et al. 2013) levels, 
further investigation of the effect of this recombination and the reported 
diversity is essential to assess of their effects on the virulence of ST131 
H30Rx strains. 
1.8 Aims of the project 
This PhD project mainly aimed to characterise the traits that give E. coli 
ST131 a competitive fitness advantage over other potential ExPEC clones. 
This aim was achieved through carrying out a range of phenotypic and 
genotypic assays including: 
 Performing comparative bacterial growth assays in LB medium and 
in McCoy’s 5A modified tissue culture medium. 
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 Testing the ability of E. coli ST131 strains to express functional type 
1 fimbriae in presence of the aforementioned insertion mutation in 
the fimB gene. 
 Examining the effect of the fimB gene insertion mutation on the 
capacity of ST131 strains to associate with and to invade the T24 
human bladder epithelial cells by performing comparative association 
and invasion assays on ten green florescent protein (GFP)-tagged E. 
coli strains using T24 human bladder epithelial cells. 
 Investigating the metabolic potential of E. coli ST131 through 
carrying out comparative metabolic profiling assays on a collection of 
E. coli ST131 and non-ST131 strains. 
 Identifying the presence of other loci uniquely associated with the 
H30Rx clade of E. coli ST131 through comparing the gene content of 
a collection of E. coli including ST131 and non-ST131 strains.  
 Investigating the genetic architecture for the diversity observed in 
the capsule locus of E. coli ST131 strains belonging to the H30Rx 
clade, and the diversity in the biochemical profile of K antigens of 
these strains. 
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2. General Materials and Methods 
2.1 Bacterial strains  
A total of ninety-four E. coli strains were used in this project. Of these 
strains, forty-eight were isolated from urine samples of elderly patients and 
collected between October 2008 and June 2009 from Nottingham University 
Hospitals (NUH), Nottingham. Additionally, forty-one strains were collected 
between March 2011 and June 2011 from urine and blood samples of 
patients from Nottingham University Hospitals (NUH), Nottingham. The 
MLST of the strains and identification of virulence factors and antibiotic 
susceptibility profiles have been previously described (Croxall et al. 2011a, 
Croxall et al. 2011b, Alhashash et al. 2013). Three additional whole-
genome sequenced E. coli non-ST131 strains were included in the strain 
collection and they were obtained from different sources (Welch et al. 2002, 
Chen et al. 2006b, McNally et al. 2013a). The invasive ExPEC strain E. coli 
CFT073 and the E. coli K-12 MG1655 strain were used as positive and 
negative control strains. Additionally, Citrobacter koseri (C. koseri) SMT319 
strain (Townsend et al. 2003) was used as a positive control in U937 cell 
culture assays. Table 2.1 shows details on the strains used in this project.  
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Table 2.1: The characteristics of strains used in this project. 
 
Strain 
ID 
ST Strain history Sample 
source 
CTX-M  Reference 
UTI18 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI24 ST131 Monomicrobial UTI Urine - A 
 
UTI32 
 
ST131 Monomicrobial UTI Urine CTX-M-15 A 
UTI39 
 
ST131 Polymicrobial UTI Urine - A 
UTI62 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI144 
 
ST131 Polymicrobial UTI Urine - A 
UTI149 
 
ST131 Polymicrobial UTI Urine - A 
UTI182 
 
ST131 Polymicrobial UTI Urine - A 
UTI188 
 
ST131 Monomicrobial UTI Urine - A 
UTI190 
 
ST131 Polymicrobial UTI Urine - A 
UTI226 
 
ST131 Polymicrobial UTI Urine - A 
UTI233 
 
ST131 Polymicrobial UTI Urine - A 
UTI263 
 
ST131 Polymicrobial UTI Urine - A 
UTI275 
 
ST131 Polymicrobial UTI Urine - A 
UTI306 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI383 
 
ST131 Polymicrobial UTI Urine - A 
UTI423 
 
ST131 Polymicrobial UTI Urine - A 
UTI445 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI453 
 
ST131 Polymicrobial UTI Urine - A 
UTI514 
 
ST131 Polymicrobial UTI Urine - A 
UTI524 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI531 
 
ST131 Polymicrobial UTI Urine - A 
UTI555 
 
ST131 Polymicrobial UTI Urine - A 
UTI570 
 
ST131 Polymicrobial UTI Urine - A 
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Strain 
ID 
ST Strain history Sample 
source 
CTX-M  Reference 
UTI587 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI4 
 
ST95 Monomicrobial UTI Urine +3 A 
UTI14 ST10 Polymicrobial UTI Urine - A 
 
UTI35 ST141 Polymicrobial UTI Urine + A 
 
UTI36 ST1262 Polymicrobial UTI Urine - A 
 
UTI48 ST12 Polymicrobial UTI Urine - A 
 
UTI50 ST73 Polymicrobial UTI Urine + A 
 
UTI56 ST69 Polymicrobial UTI Urine - A 
 
UTI83 ST48 Polymicrobial UTI Urine - A 
 
UTI147 ST73 Polymicrobial UTI Urine - A 
 
UTI187 ST144 Monomicrobial UTI Urine - A 
 
UTI220 ST73 Polymicrobial UTI Urine - A 
 
UTI229 ST38 Polymicrobial UTI Urine - A 
 
UTI239 ST538 Polymicrobial UTI Urine - A 
 
UTI243 ST69 Polymicrobial UTI Urine - A 
 
UTI284 ST73 Monomicrobial UTI Urine - A 
 
UTI326 ST12 Polymicrobial UTI Urine - A 
 
UTI337 ST95 Monomicrobial UTI Urine + A 
 
UTI396 ST393 Polymicrobial UTI Urine - A 
 
UTI398 ST12 Polymicrobial UTI Urine - A 
 
UTI427 ST421 Polymicrobial UTI Urine - A 
 
UTI450 ST14 Polymicrobial UTI Urine - A 
 
UTI501 ST69 Polymicrobial UTI Urine - A 
 
UTI565 ST69 Polymicrobial UTI Urine - A 
 
UTI583 ST127 Polymicrobial UTI Urine + A 
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Strain ID ST Strain 
history 
Sample 
source 
CTX-M  Reference 
UTI89 ST95 Uncomplicated 
cystitis 
Urine - B 
 
 
CFT073 ST73 Acute 
pyelonephritis 
Urine - C 
 
 
P5B ST10 Bacteraemia Blood - D 
 
B3 ST131 Bacteraemia Blood - E 
 
B5 ST131 Bacteraemia Blood CTX-M-15 E 
 
B16 ST131 Bacteraemia Blood CTX-M-15 E 
 
B22 ST131 Bacteraemia Blood - E 
 
B37 ST131 Bacteraemia Blood - E 
 
B44 ST131 Bacteraemia Blood - E 
 
B64 ST131 Bacteraemia Blood CTX-M-15 E 
 
B65 ST131 Bacteraemia Blood CTX-M-15 E 
 
B75 ST131 Bacteraemia Blood CTX-M-15 E 
 
B89 ST131 Bacteraemia Blood CTX-M-15 E 
 
U2 ST131 UTI Urine CTX-M-15 E 
 
U5 ST131 UTI Urine - E 
 
U12 ST131 UTI Urine CTX-M-15 E 
 
U79 ST131 UTI Urine CTX-M-15 E 
 
B14 ST73 Bacteraemia Blood - E 
 
B12 ST73 Bacteraemia Blood - E 
 
U1 ST73 UTI Urine - E 
 
U7 ST73 UTI Urine - E 
 
B31 ST69 Bacteraemia Blood - E 
 
B33 ST69 Bacteraemia Blood - E 
 
U64 ST69 UTI Urine - E 
 
U67 ST69 UTI Urine - E 
 
B34 ST95 Bacteraemia Blood - E 
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Strain ID ST Strain history Sample 
source 
CTX-M  Reference 
B38 ST95 Bacteraemia Blood - E 
 
U22 ST95 UTI Urine - E 
 
U60 ST95 UTI Urine - E 
 
B9 ST10 Bacteraemia Blood - E 
 
B20 ST10 Bacteraemia Blood - E 
 
U19 ST10 UTI Urine - E 
 
U95 ST10 UTI Urine - E 
 
U18 ST3451 UTI Urine - E 
 
U58 ST91 UTI Urine - E 
 
U104 ST3452 UTI Urine - E 
 
MG1655 ST10 na1 Urine na A 
 
U9 ST69 UTI Urine - E 
 
U16 ST69 UTI Urine - E 
 
U23 ST69 UTI Urine - E 
 
U21 ST73 UTI Urine - E 
 
U24 ST73 UTI Urine - E 
 
U30 ST73 UTI Urine - E 
 
U74 ST95 UTI Urine - E 
 
U75 ST95 UTI Urine - E 
 
C. koseri  na Meningitis CSF2 - F 
1na: not available; 2CSF: cerebrospinal fluid; 3Positive CTX-M carriage by PCR but 
the CTX-M type is unavailable; A: (Croxall et al. 2011b); B:(Chen et al. 2006b); C: 
(Welch et al. 2002); D: (McNally et al. 2013a); E: (Alhashash et al. 2013) and F: 
(Townsend et al. 2003). 
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2.2 Antibiotics  
Upon requirement, antibiotics were added to culture media or agar plates 
in the following concentrations: hygromycin B 100μg/ml, gentamicin 
125μg/ml and 50μg/ml (Sigma Aldrich, UK). 
2.3 Culture media  
2.3.1 Luria-Bertani (LB) medium  
LB agar is composed of 10g/L tryptone, 5g/L yeast extract, 10g/L sodium 
chloride (NaCL) and 15g/L granulated agar (Fisher Scientific, UK). It was 
prepared by dissolving 40g of LB agar in 1L of dH2O followed by autoclaving 
at 121°C for 15 minutes. 
2.3.2 LB broth (LBB)  
LB broth is composed of 10g/L tryptone, 5g/L yeast extract and 5g/L sodium 
chloride (NaCL) (Sigma Aldrich, UK). It was prepared by dissolving 20g of 
LB broth in 1L of dH2O followed by autoclaving at 121°C for 15 minutes. 
 
2.3.3 Cysteine Lactose Electrolyte Deficient (CLED) agar  
CLED agar is composed of 4g/L Peptone, 3g/L Lab-Lemco powder, 4g/L 
tryptone, 10g/L Lactose, 0.128g/L L-cysteine and 0.02g/L bromothymol 
blue (Oxoid Limited, UK). It was prepared by dissolving 36.2g in 1L of dH2O 
followed by autoclaving at 121°C for 15 minutes. 
2.3.4 McCoy’s 5A modified medium  
McCoy’s 5A modified medium was used as a minimal defined medium in 
bacterial growth studies, and also as a growth and infection medium in cell 
culture assays. It is ready-to-use and contains 2.2g/L sodium bicarbonate 
(Sigma Aldrich, UK). 
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2.3.5 SOC medium  
SOC medium is a rich medium used primarily in the recovery step of E. coli 
competent cell transformation. It is ready to use and is composed of 20g/L 
tryptone, 5g/L yeast extract, 4.8g/L MgSO4, 3.603g/L dextrose, 0.5g/L NaCl 
and 0.186 g/L KCl (Sigma Aldrich, UK). 
2.4 Bacterial culture maintenance and growth conditions 
All E. coli stocks were maintained in -80°C freezer as 1ml aliquots in 20% 
glycerol LBB. The purity of E. coli stocks was routinely checked using CLED 
agar. Bacterial strains were grown in LB agar and incubated aerobically for 
18h at 37°C. Cultured strains were stored at 4°C for no more than 3 days. 
2.5 General media, buffers and reagents 
2.5.1 1X Tris-acetate EDTA (TAE) buffer  
1xTAE buffer is made up of 20ml of 50XTAE buffer diluted in 980ml of dH2O 
followed by autoclaving at 121°C for 15 minutes. 50XTAE buffer is 
composed of 242g Tris base, 57.1ml Glacial acetic acid and 100ml 0.5M 
Na2EDTA (Sigma Aldrich, UK).  
2.5.2 Dulbecco’s phosphate buffered saline (PBS)  
Dulbecco’s phosphate buffered saline (PBS) was used to wash cells during 
tissue culture work, and it is composed of sodium and magnesium chloride 
solution (Sigma Aldrich, UK).  
2.5.3 Saline solution  
Saline solution was used as a diluent of bacterial cultures. One saline tablet 
was added to 500ml dH2O followed by Autoclaving at 121°C for 15 minutes 
(Oxoid Limited, UK). 
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2.5.4 80% glycerol solution  
80% glycerol solution (Fisher Scientific, UK) was used to make bacterial 
stocks and it was prepared by adding 80ml of glycerol into 20ml dH2O 
followed by autoclaving at 121°C for 15 minutes. 
2.5.5 10% glycerol solution  
10% glycerol solution (Fisher Scientific, UK) was used to resuspend 
bacterial pellet during the preparation of electro-competent cells. It was 
made by adding 10ml of glycerol into 90ml dH2O followed by autoclaving at 
121°C for 15 minutes. 
2.5.6 3% α-D-mannose solution  
3% α-D-mannose (Sigma Aldrich, UK) solution was used to test the 
agglutination inhibition during the yeast cell agglutination assay. It was 
prepared by dissolving 3g of α-D-mannose in 100ml of dH2O (w/v). 
2.5.7 4% paraformaldehyde solution  
4% paraformaldehyde (Sigma Aldrich, UK) was used as a fixative in cell 
culture assays. It was prepared by dissolving 4g of paraformaldehyde in 
100ml PBS (w/v). 
2.5.8 1% triton X-100  
Triton X-100 (Sigma Aldrich, UK) was used during cell culture studies. 1% 
triton X-100 was prepared by adding 100μl of Triton X-100 to 10ml of dH2O 
(v/v), followed by autoclaving at 121°C for 15 minutes.  
2.5.9 Vectashield mounting medium with 4’, 6-diamidino-2-
phenylindole (DAPI)  
DAPI (Vector Laboratories, UK) was used to mount the chamber slides 
during cell culture studies prior to confocal microscopy visualisation, and it 
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contains the blue-fluorescent DAPI nucleic acid stain that specifically stains 
the cell nuclei. 
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3.1 Introduction 
3.1.1 The role of studying bacterial growth in pathogenesis 
Bacterial growth is an important factor for the establishment and 
development of bacterial infection. During the infection process, growth can 
directly or indirectly lead to tissue damage and disordered physiology in the 
host, and it has been shown that failure to control bacterial growth can be 
associated with disease severity (Barer 2001). Studying bacterial growth is 
essential for the development of modern microbial physiology as well as for 
the discovery of the regulation of gene expression (Klumpp and Hwa 2014). 
Cell growth is also important for studying systems biology (Neidhardt 1999, 
Schaechter 2010), since it is a system-level phenomenon that depends on 
the coordinated functions of many cellular components (Edwards et al. 
2001). With regard to the importance of studying bacterial growth in 
determining E. coli fitness, a comparative proteomics analysis investigated 
the expression of UPEC cytoplasmic proteins during growth in LB medium 
and in the urinary tract environment (Alteri et al. 2009). It found that UPEC 
grown in human urine expresses 84 cytoplasmic proteins, including those 
responsible for the import of short peptides and enzymes required for the 
transport and catabolism of sialic acid, gluconate and the pentose sugars 
such as xylose and arabinose, compared to that grown in LB medium (Alteri 
et al. 2009). This suggests that these proteins can act as main carbon 
sources for E. coli during infection of the urinary tract and therefore might 
be of importance in UPEC fitness in vivo (Alteri et al. 2009). 
From a practical perspective, determining bacterial growth rates in vitro can 
be important for the identification of bacterial species associated with 
causing disease, since it has been suggested that rapidly growing bacteria 
Comparative phenotypic characterisation of strains belonging to different ExPEC STs 
 52 
might be associated with causing acute diseases (Barer 2001). Many 
methods can be used to measure microbial growth such as turbidimetric 
measurement which is based on determining total cell mass, and the plate 
count method which measures the total viable cell number (Barer 2001, 
Madigan et al. 2009).   
3.1.2 UPEC attachment, invasion and intracellular survival in host 
bladder epithelial cells  
It has been shown that UPEC adherence to host uroepithelium is a crucial 
step for the colonisation of the urinary tract and is also precedent to 
invasive infection (Johnson 1991). UPEC strains possess many adherence 
factors, such as type 1 fimbriae and P fimbriae, which mediate UPEC 
attachment to the uroepithelium of the host through specific binding to 
different glycoconjugate receptors (Sakarya et al. 2003). Previous studies 
demonstrated the role of type 1 fimbriae in mediating UPEC adherence to 
host uroepithelium (Wu et al. 1996), invasion of superficial bladder 
epithelial cells (Martinez et al. 2000) and the formation of intracellular 
bacterial communities (IBCs) (Anderson et al. 2003). P fimbriae have also 
been implicated in the pathogenesis of UPEC, and previous studies showed 
its importance in mediating UPEC colonisation and infection of the upper 
urinary tract of the host (Katouli 2010). 
A previous study by our research group investigated and compared the 
virulence-associated gene (VAG) carriage of a collection of ST131 and non-
ST131 strains isolated from urine samples of elderly patients using 
multiplex PCR assay (Croxall et al. 2011a). It found that VAG carriage was 
variable between strains belonging to different ExPEC STs, with no specific 
VAG profile associated with ST131 strains. More importantly, although the 
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study found the type 1 fimbriae gene fimH to be highly prevalent in almost 
all ST131 and non-ST131 strains, it showed a low association between 
ST131 strains and some VAGs, particularly the pap gene cluster encoding 
the structural and accessory components of P-fimbriae (Johnson 1991). 
Consequently, to examine the impact of the presence or absence of a 
specific set of virulence factors on the invasive capacity of strains, the ability 
of E. coli strains to associate with and to invade T24 human bladder 
epithelial cells was determined using the gentamicin protection assay 
(Croxall et al. 2011a). Comparing the capacity of ST131 strains to invade 
T24 cells to that of the invasive E. coli reference strain CFT073 showed the 
presence of a hyper-invasive phenotype in 15 out of 27 (56%) of the tested 
E. coli ST131 isolates. However when compared with the rest of the 
population, ST131 strains did not invade the T24 cells to significantly higher 
numbers (Croxall et al. 2011a). 
Subsequently, a recent whole-genome based study by our research group 
identified the absence of the pap gene cluster and a transposon insertion 
mutation in the fimB gene, encoding the FimB recombinase that switches 
on the expression of type 1 fimbriae, of ten clinical ST131 strains (Clark et 
al. 2012). These findings highlight the importance of studying the biological 
relevance and the effect of these mutations on the true virulence nature of 
ST131 strains.  
3.1.3 UPEC intracellular survival in host macrophages  
It has been known that innate immunity plays an important role in host 
defences against UPEC (Svanborg et al. 2001). A previous study found that 
Gr1high CCR2high inflammatory monocytes were recruited in the bladder by 
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14h post-UPEC infection (Engel et al. 2008), suggesting that macrophages 
might contribute to the innate immune response against UPEC. 
Macrophages recognise many invasive bacterial pathogens by a set of 
pattern recognition receptors (PRRs), including the Toll-like receptors 
(TLRs), the Nod-like receptors and the C-type lectin receptors (Bokil et al. 
2011). It has been demonstrated that the TLR4, which recognises LPS of 
Gram-negative bacteria, is crucial for innate resistance to UPEC (Schilling 
et al. 2003). Additionally, the FimH adhesin of type I fimbriae can also be 
recognised by TLR4 (Ashkar et al. 2008, Mossman et al. 2008). Previous 
studies showed the ability of UPEC to subvert TLR-initiated pro-
inflammatory responses (Hilbert et al. 2008), and to secrete TIR domain-
containing proteins (Tcps) that bind to the TLR adaptor protein MyD88 to 
provoke TLR responses (Cirl et al. 2008). Several studies have suggested 
that the intracellular survival of UPEC can contribute to pathogenesis. For 
example, Rosen et al. (2007) demonstrated the existence of IBCs in human 
patients with UTI. This might enable bacterial evasion of the host immune 
response, permit reinfection and contribute to antibiotic resistance (Blango 
and Mulvey 2010). 
3.1.4 Aims of the study 
Since this PhD project aimed to determine the factors that give ST131 a 
competitive fitness advantage over other potential ExPEC clones, and given 
many reports showing the importance of bacterial growth in the 
establishment and development of bacterial infection, we aimed to 
determine and compare the growth rates of a collection of ExPEC including 
ST131 and non-ST131 to identify the presence of a distinct growth rate in 
ST131 strains. Additionally, based on a previous finding by our research 
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group identifying the absence of the pap gene cluster and a transposon 
insertion mutation in the fimB gene of ten clinical ST131 isolates (Clark et 
al. 2012), we sought to test the presence of the fimB insertion mutation in 
all our ST131 strains. Afterwards we investigate the biological relevance 
and the effect of this mutation on the virulence potential of ST131 strains. 
This was achieved by determining the ability of ST131 strains to express 
functional type 1 fimbriae in the presence of the fimB gene insertion 
mutation. On the basis of our previous study that tested the invasion 
capacity of a collection of ST131 and non-ST131 strains to invade T24 cells 
using gentamicin protection assay, and showed the presence of a hyper-
invasive phenotype in 15 out of 27 (56%) of the tested E. coli ST131 
isolates (Croxall et al. 2011a), we aimed to examine the dynamics of 
bacterial-cell interaction processes such as the bacterial survival and 
proliferation inside infected cells. This was achieved by performing 
comparative association and invasion assays on ten green florescent protein 
(GFP)-tagged E. coli strains using T24 human bladder epithelial cells, 
followed by visualisation of the attached or internalised bacteria using 
confocal microscopy. It has been shown that gentamicin protection assay 
is widely used for cell culture assays (Elsinghorst 1994), and it can only 
give an estimation of the number of attached or invaded bacteria and it is 
not suitable for studying the cellular outcome of bacterial infection (Saini et 
al. 1999). Therefore, this study used confocal microscopy to visualise the 
attached or internalised bacteria providing more information on the 
dynamics of bacterial-cell interaction processes such as the bacterial 
survival and proliferation inside infected cells (Sheppard et al. 2003). 
Finally, given that macrophages are utilised by several intracellular 
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pathogens as a host niche, and that these cells are recruited to the bladder 
in response to UPEC infection (Bokil et al. 2011), we sought to examine and 
compare the ability of a collection of ST131 and non-ST131 strains to persist 
and replicate in macrophages using U937 human macrophage cells. 
3.2 Materials and Methods 
3.2.1 Bacterial strains 
A total of fifty-three E. coli strains were included in this study. Firstly, forty-
nine E. coli strains, twenty-four ST131, twenty-four non-ST131, and the 
control E. coli strain CFT073 were used to determine the bacterial growth 
using turbidity measurement assay. Then, a subset including ten randomly 
selected E. coli strains, five ST131 and five non-ST131, and the control E. 
coli strain CFT073 was used to perform viable cell count assay. Afterwards, 
twenty-five E. coli ST131 strains were used to test the presence of the 
transposon insertion mutation in the fimB gene using conventional PCR and 
to investigate their ability to express functional type 1 fimbriae using yeast 
cell agglutination assay. The strain collection also included the control 
strains, E. coli CFT073 and the E. coli ST1461 strain UTI258, since they 
were previously tested for the presence of the fimB insertion giving negative 
and positive results, respectively. Additionally, ten E. coli strains, five 
ST131, five non-ST131 and the negative control strain E. coli MG1655, were 
used to carry out comparative cell culture assays using the T24 human 
bladder epithelial cells. Finally, the ability of E. coli strains to persist and 
replicate within U937 human macrophages was tested on a strain set 
including ten E. coli strains, five ST131 and five non-ST131 strains. The E. 
coli MG1655 and the C. koseri SMT319 were used as negative and positive 
controls, respectively. 
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Table 3.1: List of strains used to perform the experimental work in chapter 
3. 
 
Strain ID ST Strain history Sample 
source 
CTX-M 
carriage 
Reference 
CFT073 ST73 UTI Urine - A 
 
UTI18 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI24 ST131 Monomicrobial 
UTI 
Urine - A 
 
UTI32 
 
ST131 Monomicrobial 
UTI 
Urine CTX-M-15 A 
UTI39 
 
ST131 Polymicrobial UTI Urine - A 
UTI62 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI144 
 
ST131 Polymicrobial UTI Urine - A 
UTI149 
 
ST131 Polymicrobial UTI Urine - A 
UTI182 
 
ST131 Polymicrobial UTI Urine - A 
UTI188 
 
ST131 Monomicrobial 
UTI 
Urine - A 
UTI190 
 
ST131 Polymicrobial UTI Urine - A 
UTI445 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI453 
 
ST131 Polymicrobial UTI Urine - A 
UTI514 
 
ST131 Polymicrobial UTI Urine - A 
UTI524 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI531 
 
ST131 Polymicrobial UTI Urine - A 
UTI555 
 
ST131 Polymicrobial UTI Urine - A 
UTI570 
 
ST131 Polymicrobial UTI Urine - A 
UTI587 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI4 
 
ST95 Monomicrobial 
UTI 
Urine + A 
UTI14 ST10 Polymicrobial UTI Urine - A 
 
UTI35 ST141 Polymicrobial UTI 
 
Urine + A 
UTI36 ST1262 Polymicrobial UTI 
 
Urine - A 
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Strain ID ST Strain history Sample 
source 
CTX-M 
carriage 
Referenc
e 
UTI48 ST12 Polymicrobial UTI 
 
Urine - A 
UTI50 ST73 Polymicrobial UTI Urine + A 
 
UTI56 ST69 Polymicrobial UTI Urine - A 
 
UTI83 ST48 Polymicrobial UTI Urine - A 
 
UTI147 ST73 Polymicrobial UTI Urine - A 
 
UTI187 ST144 Monomicrobial UTI Urine - A 
 
UTI220 ST73 Polymicrobial UTI Urine - A 
 
UTI229 ST38 Polymicrobial UTI Urine - A 
 
UTI239 ST538 Polymicrobial UTI Urine - A 
 
UTI243 ST69 Polymicrobial UTI Urine - A 
 
UTI284 ST73 Monomicrobial UTI Urine - A 
 
UTI326 ST12 Polymicrobial UTI Urine - A 
 
UTI337 ST95 Monomicrobial UTI Urine + A 
 
UTI396 ST393 Polymicrobial UTI Urine - A 
 
UTI398 ST12 Polymicrobial UTI Urine - A 
 
UTI427 ST421 Polymicrobial UTI Urine - A 
 
UTI450 ST14 Polymicrobial UTI Urine - A 
 
UTI501 ST69 Polymicrobial UTI Urine - A 
 
UTI565 ST69 Polymicrobial UTI Urine - A 
 
UTI583 ST127 Polymicrobial UTI Urine + A 
 
UTI89 ST95 Uncomplicated 
cystitis 
Urine - B 
P5B ST10 Bacteraemia Blood - C 
 
MG1655 ST10 na1 Urine na A 
  
C. koseri  na Meningitis CSF2 - D 
 
1na: not available; 2CSF: cerebrospinal fluid; A: (Croxall et al. 2011b); B:(Chen et 
al. 2006b); C: (McNally et al. 2013a); D: (Townsend et al. 2003). 
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3.2.2 Plasmid and primer sets 
Details on the plasmids and primers used to carry out the molecular biology 
techniques in this study are given in Table 3.2. 
Table 3.2: List of plasmids and primers used in the molecular biology 
techniques. 
 
Plasmids Details Source 
pMN402 Hygr, CoIE1/PAL5000 ori, gfp+ A 
 
Primers 
 
Sequence (5’  3’) 
 
Source 
fimB-IS_F TCCTGACCCATAGTGAAATCG B 
fimB-IS_R GCTCTATCCCAGATGCCGTA 
GFP5 
GFP3  
GATATCGATGAAGGAGATATACATATGGCTAG  
GCTCGAATTCATTATTTGTAGAG  
C 
A: Dr. Michael Niederweis, University of Nurnberg; B: (Totsika et al. 2011); C: 
(McNally et al. 2006). 
 
3.2.3 Comparative bacterial growth assays 
Two different assays were used to determine and compare the growth of a 
collection of E. coli strains. Firstly, the growth curves of E. coli strains were 
determined using turbidity measurement assay. Afterwards, viable cell 
count or plate count assay was performed to accurately estimate and then 
compare the number of viable cells in bacterial samples. 
3.2.3.1 Turbidity measurement assay  
 
Bacterial strains were grown in LB agar plates and incubated for 18h at 
37°C. 5ml of LB broth and McCoy’s 5A modified medium was inoculated 
with a single bacterial colony from overnight agar plates and then incubated 
overnight under aerobic conditions at two different temperatures, 37°C 
(human body temperature) and 25°C (room temperature), with shaking at 
200 rpm. The optical density (OD) value of each bacterial culture was 
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measured and suitable dilutions were made after which 1ml of bacterial 
culture was transferred from the first set of tubes containing overnight 
bacterial cultures to the second set of tubes containing fresh 49ml LB broth 
and McCoy’s 5A modified medium (1:50 dilution). This was performed to 
maintain the same initial OD for all E. coli strains that corresponded to the 
same amount of cells. The bacterial cultures were then incubated 
aerobically at 37°C and 25°C with shaking at 200 rpm. Using a 
spectrophotometer, the OD values of strains were obtained after 1h of 
incubation (T0) and then in every 30 minutes for 6 hours at a wavelength 
of 600nm. Lastly, the OD values were used to generate growth curves for 
the tested strains. All bacterial strains were tested in triplicate in two 
independent occasions. 
3.2.3.2 Viable cell count assay 
 
The preparation of bacterial cultures was performed as for the turbidity 
measurement assay. A volume of 1ml of each sample was carefully 
removed from the flasks containing bacterial cultures after 1h of incubation 
(T0) and in the following 4 hours to determine the viable cell counts of the 
tested strains at different time points. This step was achieved by diluting 
20µl of bacterial cultures in 180µl of sterile saline and serial tenfold dilution 
was made up to 10-8. Three 20µl drops of each dilution were then placed 
on the surface of LB agar plate and incubated overnight for 18h at 37°C. 
Counting the average number of colonies which developed in the area of 
the drops allowed obtaining the viable cell count per 20µl of the dilution 
(Miles et al. 1938). The colony-forming unit per ml (CFU/ml) was calculated 
for each sample at different time points using this formula: 
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Viable cell count (CFU/ml) = average number of colonies for a dilution x 50 
x dilution factor. 
3.2.4 Genomic DNA extraction 
Bacterial strains were grown on LB agar plates for 18 hours at 37°C. A 
single colony from the plate was placed in 5ml of LB broth and then 
incubated overnight at 37°C with shaking. The instructions were then 
followed from the: GenElute™ Bacterial Genomic DNA Kits (Sigma-Aldrich, 
UK; Catalogue Number: NA2120-1KT). The quantity and quality of the 
extracted DNA were tested using the NanoDrop (Thermo Scientific; model 
reference: NanoDrop 2000 spectrophotometer). Acceptable DNA extraction 
was indicated by a clean peak on the absorbance graph, nucleic acid 
quantity of ≥50ng/µl and absorbance ratio reading values of ~1.8 and 1.8-
2.2, for ratios 260/280 and 260/230, respectively. 
3.2.5 Polymerase chain reaction (PCR) screening of the fimB 
insertion  
The presence of fimB insertion in E. coli ST131 strains was screened using 
the conventional PCR. The PCR mastermix was prepared as following: 5µl 
of 6X PCR buffer (Promega, UK), 5µl of 1.5mM MgCl2 (Promega, UK), 36µl 
sterile distilled water, 2µl of 10mM DNTPs mix, 0.5µl of fimB-IS_F primer 
(10pmol), 0.5µl of fimB-IS_R primer (10pmol), 0.3µl of 5U/µM taq 
polymerase (Promega, UK) and 1μl of DNA template. PCR condition was 
carried out as follows: initial denaturation at 94°C for 5 min, followed by 30 
cycles of denaturation at 95°C for 30 sec, annealing at 52°C for 30 sec, and 
extension at 72°C for 30 sec, with final extension at 72°C for 2 min and 30 
sec. PCR products were finally held at 4°C. Amplification of DNA was 
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performed using thermal cycler (Manufacturer: TECHNE; Model Reference: 
TC-4000). 
3.2.6 DNA analysis by agarose gel electrophoresis  
PCR products were visualised on a 2% agarose gel by adding of 2g 
molecular agarose (Fisher Scientific, UK) to 100ml of 1XTAE. 10μL (0.01%) 
of SYBR® SafeTM gel stain (Invitrogen, UK) was then added to the mixture. 
Afterwards, gel was poured into a gel tray with comb (Gene flow, UK) and 
let to set. The gel was then placed in an electrophoresis tank filled with 1X 
TAE. 10μl of PCR product was then loaded onto the gel along with a 1kb 
DNA ladder (Promega, UK). The gel was run for 45 minutes at 90V. The 
DNA band on the gel was then visualised under ultraviolet (UV) light using 
InGenius® gel documentation system (Syngene, UK). 
3.2.7 Preparation of Saccharomyces cerevisiae (S. cerevisiae) yeast 
suspension 
S. cerevisiae suspension was provided by Michael Brice, Nottingham Trent 
University Teaching Laboratory. It was prepared by inoculating a potato 
dextrose agar (PDA) slope with S. cerevisiae followed by incubation for 24h 
at 25°C. 10ml of sterile saline solution was then added to the slope and 
yeast cells were gently extracted using a sterile swab. The yeast suspension 
was transferred to a sterile universal tube and stored at 4°C. 
3.2.8 Yeast cell agglutination assay   
E. coli ST131 strains were grown in LB agar and incubated overnight at 
37°C. A single colony was then inoculated into 3ml of LB broth. Bacterial 
cultures were incubated overnight with shaking and statically at 37°C. 
Static cultures were then passaged by adding 30µl of a bacterial culture into 
2970µl of LB broth followed by two further rounds of static incubation. 
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Agglutination assay was carried out by mixing equal volumes of bacterial 
suspension with Saccharomyces cerevisiae yeast cells diluted to 5% (v/v) 
in PBS on a glass slide (Totsika et al. 2011). Mannose inhibition of 
agglutination was confirmed by adding 3% α-D-mannose to the yeast 
suspension. E. coli ST131 strains that failed to produce visible bacterial–
yeast cell agglutination after 3 minutes were scored negative. The E. coli 
CFT073 strain and a volume of PBS were used as positive and negative 
controls. All bacterial strains were tested in triplicate on three independent 
occasions. 
3.2.9 Mini prep Plasmid purification 
GFP-tagged bacteria were grown overnight in 5ml LB with 100µg/ml 
hygromycin B antibiotic at 37°C at 200 rpm. For medium to high copy 
numbers of plasmids, 1.5ml of culture was used to purify the plasmid with 
QIAGEN plasmid miniprep kit (Qiagen, UK) according to the manufactures 
instructions. All plasmid preps were then reconstituted in a final volume of 
50μl sterile dH2O. 
3.2.10 Preparation of electro-competent cells 
Overnight bacterial culture was prepared by inoculating a single colony of 
each E. coli strain in 5ml LB broth. 1ml of overnight bacterial cultures was 
transferred to fresh LB broth in 1:50 dilution followed by incubation at 37°C 
with shaking at 200 rpm until they reached the mid log phase, where the 
OD600 was between 0.6 and 1. Bacterial suspension was then transferred 
to a 50ml chilled falcon tube and left on ice for 15 minutes. Bacterial cells 
were harvested by centrifugation at 4,000 rpm for 10 minutes at 4°C. 
Supernatant was discarded and pellet was then gently resuspended in 25ml 
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of ice cold 10% glycerol. Bacteria were then harvested again and 
resuspended in 12.5ml of ice cold 10% glycerol. This step was followed by 
incubation for 1 hour on ice. Bacteria were harvested again and 
resuspended in 2ml of 10% glycerol. 50μl of bacterial suspension was then 
aliquoted into 1.5ml microcentrifuge tubes and stored in -80°C. 
3.2.11 Transformation of electro-competent cells by 
electroporation 
1μl of purified plasmid DNA was added into 50μl aliquot of cells, mixed by 
gentle pipetting and incubated on ice for 15 min. The mixture was 
transferred to a 2ml chilled electroporation cuvette (Flowgen, UK). The 
electroporator was set at 2.5kV, 2.5μF and 200Ω. Following the 
electroporation process, 950μl of SOC medium was immediately added to 
the suspension to increase the efficiency of transformation. Then, the 
mixture was transferred to a 1.5ml microcentrifuge tube and was incubated 
for 2 hours at 37°C with shaking at 200 rpm. A volume of 400μl was plated 
onto pre-dried LB agar plate with 100µg/ml hygromycin B antibiotic 
followed by overnight incubation at 37°C. Lastly, it is important to point out 
that an aliquot of electro-competent cells containing no plasmid DNA was 
used as a negative control. The entire aliquot was plated onto LB agar plate 
containing 100µg/ml hygromycin B antibiotic to check if the electro-
competent cells were contaminated with an antibiotic resistant strain of 
bacteria during carrying out this experiment. 
3.2.12 Confirmation of pMN402 plasmid transformation by PCR 
To confirm the transformation of pMN402 plasmid carrying gfp gene into E. 
coli electro-competent cells, the plasmid DNA was used as template to carry 
out conventional PCR assay using the GFP primer set (Table 3.2). The PCR 
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mastermix was prepared as following: 5µl of 6X PCR buffer (Promega, UK), 
5µl of 1.5mM MgCl2 (Promega, UK), 36µl sterile distilled water, 2µl of 10mM 
DNTPs mix, 0.5µl of GFP-5 primer (10pmol), 0.5µl of GFP-3 primer 
(10pmol), 0.3µl of 5U/µM taq polymerase (Promega, UK) and 1μl of plasmid 
DNA template. PCR condition was carried out as follows: initial denaturation 
at 94°C for 5 min, followed by 30 cycles of denaturation at 95°C for 30 sec, 
annealing at 58°C for 30 sec, and extension at 72°C for 30 sec, with final 
extension at 72°C for 2 min and 30 sec. PCR products were finally held at 
4°C. The PCR products were visualised using the same method described 
previously for the fimB insertion PCR with an exception of using 100bp 
ladder rather than 1kb ladder.  
3.2.13 Cell culture methods 
3.2.13.1 Cell lines  
Two different cell lines were used in this study (Table 3.3), and they were 
preserved in liquid nitrogen at -160°C until they were required.  
Table 3.3: Information on the cell lines used in this study. 
 
Cell line Passages Reference no. Source 
T24 human bladder 
epithelial cell line 
 
3-17 85061107 Public Health England 
(PHE) 
U937 human 
monocytic cell line  
6-15 CRL-1593.2 American Type Culture 
Collection (ATCC) 
3.2.13.2 Cell culture media 
Information on the type and composition of the cell culture media used in 
this study is given in Table 3.4. All media were stored at 4°C and pre-
warmed in a water bath prior to use. 
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Table 3.4: Cell culture media used in this study. 
 
Cell line Growth medium Infection medium 
T24 McCoy’s 5A modified medium 
supplemented with 10% foetal 
bovine serum (FBS), 1% 2mM L-
glutamine, and 1% penicillin-
streptomycin (Sigma Aldrich, UK). 
 
McCoy’s 5A modified medium 
supplemented with 1% 2mM L-
glutamine (Sigma Aldrich, UK). 
 
U937 RPMI medium containing 10% 
FBS, 1% 2mM L-glutamine, 1% 
non-essential amino acid (NEAA), 
and 1% penicillin-streptomycin 
(Sigma Aldrich, UK). 
RPMI medium containing 1% 
2mM L-glutamine and 1% NEAA 
(Sigma Aldrich, UK). 
 
3.2.13.3 Cell line growth and maintenance 
 
To grow a cell line, a vial of the appropriate cell line was taken from liquid 
nitrogen and kept on ice. A volume of 20ml of pre-warmed cell culture 
growth medium (Table 3.4) was added to 75-cm3 tissue culture flasks. The 
cell line vial was then thawed quickly and pipetted into the culture flask 
followed by overnight incubation at 37°C. Afterwards, the growth medium 
was replaced by 20ml of fresh medium to remove the residues of cell line 
preservatives. The flask was incubated for 48-72h to achieve confluent 
monolayer of cells. For cell line sub-culturing, cells were detached using 5ml 
of TrypLe™ express (Life Technologies, UK) and centrifuged for 3 minutes 
at 1500 rpm using CENTAUR2 centrifuge (MSE, UK). The supernatant was 
discarded and the pellet was resuspended in 4ml of growth medium from 
which 1ml was transferred into a new flask contained fresh growth medium. 
The cell lines of use were sub-cultured two times a week. T24 cells were 
seeded in triplicate into 8-well BD FalconTM culture slides (SLS, UK) two 
days prior to infection assays at approximately 5 x 104 cells/ml. U937 cells 
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were seeded in triplicate into 24-well plate three days prior to infection 
assays at approximately 2 x 105 cells/ml and treated with 10nmol phorbol-
myristate-acetate (PMA) (Sigma Aldrich, UK) in order to trigger U937 cell 
differentiation into active macrophages.  
3.2.13.4 Preparation of bacterial inocula 
 
Bacterial strains were grown in LB agar and incubated for 18h at 37°C. 
Bacterial broth cultures were prepared by inoculating a single colony of each 
strain into 5ml LB broth, and incubated aerobically for 18h at 37°C with 
shaking. To grow Green Florescent Protein (GFP)-tagged E. coli strains, 
100µg/ml hygromycin B antibiotic was added to LB agar and broth before 
making the bacterial cultures. The preparation bacterial inocula depended 
on the multiplicity of infection (MOI), which is commonly defined as the 
ratio of bacteria to eukaryotic cells (Gobert et al. 2002), required to infect 
the cell line of choice. Since this study used two different cell lines T24 and 
U937, two different inocula were prepared for E. coli strains. For T24 cell 
culture assays, bacteria were harvested by centrifugation and resuspended 
in 1ml of supplemented cell infection medium (Table 3.4) to ~ 2 x 106 
CFU/ml to achieve a MOI: 100. For U937 cell culture assays, bacteria were 
harvested by centrifugation and resuspended in 1ml of supplemented cell 
infection medium (Table 3.4) to ~ 2 x 106 CFU/ml to achieve a MOI: 10. 
3.2.13.5 Comparative T24 cell infection assays  
 
A collection of eleven GFP-tagged E. coli, including five ST131, five non-
ST131 and the E. coli MG1655 strains, was used to carry out the association 
and invasion assays on T24 cell line. For bacterial association assay, 1ml 
of bacterial suspension was added to pre-seeded 8-well chamber slides at 
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MOI: 100. The infected cells were incubated with 5% CO2 for 3h at 37°C. 
Then, the slides were washed 3 times with 500µl physiologically balanced 
PBS and fixed with 4% paraformaldehyde. For the 2h bacterial invasion 
assay, T24 cells were also infected with 1ml of bacterial suspension and 
incubated with 5% CO2 for 3h at 37°C. Then, cells were washed 3 times 
with 500µl physiologically balanced PBS, and fresh supplemented infection 
medium containing 125µg/ml gentamicin was added. This step was 
followed by 2h incubation with 5% CO2 at 37°C and paraformaldehyde 
fixation. For the 12h bacterial invasion assay, cells were infected and 
washed as for the 2h invasion assay, and fresh supplemented infection 
medium containing 50µg/ml gentamicin was added. Then, cells were 
incubated for 12h with 5% CO2 at 37°C and fixed with 4% 
paraformaldehyde. Finally, the chamber slide wells were mounted using 
Vectashield mounting medium with 4', 6-diamidino-2-phenylindole (DAPI) 
and stored in the dark at room temperature. The association and invasion 
of all bacterial strains were assayed in triplicate on three independent 
occasions. 
3.2.13.6 Confocal fluorescent microscopy  
Confocal fluorescent microscopy was performed on a Leica TCS SP5 
microscope with an excitation wavelength of 488 nm and an emission filter 
of 507 nm.  
3.2.13.7 Statistical analysis for T24 cell culture data 
The significance of difference between the number of associated and 
invasive bacterial cells for each tested strain and that of the negative control 
strain E. coli MG1655 strain was determined using the one-way ANOVA test 
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available in Prism software (version 6.0e), and the threshold for statistical 
significance was a P value of ≤0.05.  
3.2.13.8 Persistence of E. coli strains within U937 cell line  
A collection of ten E. coli, including five ST131 and five non-ST131 strains, 
was used to carry out this experiment. The E. coli MG1655 strain and the 
C. koseri SMT319 were used as negative and positive strains. Differentiated 
U937 cells were infected with 1ml of bacterial suspension in triplicate at a 
M.O.I: 10, and incubated for 1h with 5% CO2 at 37°C. Cells were washed 3 
times with 500µl physiologically balanced PBS and fresh supplemented 
infection medium containing 125µg/ml gentamicin was added. This was 
followed by incubation for 5h with 5% CO2 at 37°C. For further U937 
infection time points, cells were washed 3 times with 500µl physiologically 
balanced PBS and fresh supplemented infection medium containing 
50µg/ml gentamicin was added with a further incubation for 24h and 48h 
with 5% CO2 at 37°C. Infected U937 cells were washed twice in PBS and 
lysed by adding 200µl of 1% Triton X-100 solution for 10 min. Serial 
dilutions of the lysed infected cells were plated onto LB agar in triplicate 
and incubated at 37°C aerobically for 16h, and colonies were counted to 
determine the total number of intracellular bacteria, given in log (CFU/ml), 
at various time points. All bacterial strains were assayed in triplicate on 
three independent occasions. 
3.2.13.9 Statistical analysis for U937 cell culture data 
The significance of difference in the levels of U937 persistence between 
ST131 and non-ST131 strains, at different times points: T0, T5, T24 and 
T48, was determined using the unpaired t-test available in Prism software 
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(version 6.0e), and the threshold for statistical significance was a P value 
of ≤0.05.  
3.3 Results 
3.3.1 Growth curves of E. coli strains determined by OD 
measurement  
In order to compare the growth of forty-nine E. coli strains, turbidity 
measurement assay was carried out in the enriched medium LB broth, and 
in the minimal defined McCoy’s 5A modified medium, at two incubation 
temperatures, 37°C and 25°C. Firstly, The growth rates of E. coli strains 
grown in LB at 37°C were determined by measuring the OD values at 
different time points. The first OD value, taken at T0, was obtained after 1h 
of shaking incubation, and subsequently the OD values for strains at 
different time points were measured every 30 minutes for 6 hours. Figure 
3.1 showed that there was no detected lag time for all tested strains, and 
they were able to grow exponentially from the starting time point (T0). 
During the exponential growth phase, the curves showed that the increase 
in the growth rates of E. coli strains was very rapid, and this phase lasted 
for approximately 270 minutes. Then, all strains reached the stationary 
phase where there was no net increase or decrease in the growth rate. The 
growth curves also showed little to no difference in the growth rates 
between the E. coli CFT073 control strain and the tested strains. 
Additionally, E. coli ST131 strains did not show increased growth rates 
compared to E. coli non-ST131 strains (Figure 3.1).  
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Figure 3.1: Growth curves for 49 E. coli strains obtained from performing turbidity 
measurement assay on LB medium at 37°C. The curves were plotted using 
averaged OD values for the tested strains. 
 
 
Figure 3.2 shows the growth curves of E. coli strains grown in LB at 25°C. 
Similarly, the lag growth phase was undetectable and strains started to 
grow exponentially from T0. Generally, the growth rates of E. coli strains at 
25°C was lower than that of strains grown at 37°C and this was shown by 
the slightly longer exponential growth phase at 25°C compared to that at 
37°C. The exponential growth phase lasted for approximately 330 minutes 
after which E. coli strains entered the stationary growth phase. The growth 
of E. coli strains was almost similar to that of the E. coli CFT073 control 
strain, and there was no detectable difference between the growth rates of 
ST131 and non-ST131 strains when they were grown under this condition.  
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Figure 3.2: Growth curves for 49 E. coli strains obtained from performing turbidity 
measurement assay on LB medium at 25°C. The curves were plotted using 
averaged OD values for the tested strains. 
 
 
Figure 3.3 shows the growth curves of E. coli strains grown in McCoy’s 5A 
modified medium at 37°C. Although the growth curves of all strains showed 
the absence of lag growth phase, there was a reduction in the growth rates 
of E. coli strains compared to those determined using LB at different 
incubation temperatures. All strains were able to grow exponentially from 
T0 until approximately 330 minutes. Afterwards, strains reached the 
stationary growth phase. The growth of E. coli strains was almost 
comparable to that of the E. coli CFT073 control strain, and there was no 
difference between the growth rates of ST131 and non-ST131 strains. 
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Figure 3.3: Growth curves for 49 E. coli strains obtained from performing turbidity 
measurement assay on McCoy’s 5A modified medium at 37°C. The curves were 
plotted using averaged OD values for the tested strains. 
 
Figure 3.4 shows the growth curves of E. coli strains grown in McCoy’s 5A 
modified medium at 25°C. As for all previous condition, there was no lag 
growth phase for all strains. However E. coli strains had lowest growth rates 
in this condition compared to other aforementioned growth conditions used 
in this study. With regard to the growth rate of E. coli strains, the curves 
showed that there was no clear difference between E. coli ST131 and E. coli 
non-ST131 strains. 
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Figure 3.4: Growth curves for 49 E. coli strains obtained from performing turbidity 
measurement assay on McCoy’s 5A modified medium at 25°C. The curves were 
plotted using averaged OD values for the tested strains. 
 
3.3.2 Growth curves of E. coli strains determined by viable cell 
count measurement  
Using the same growth conditions, viable cell counts were also determined 
and compared between ten randomly selected E. coli strains, five E. coli 
ST131, five non-ST131 and the positive control E. coli strain CFT073, 
representing the whole strain collection. Figure 3.5 shows the viable cell 
count values, given in log (CFU/ml), of E. coli strains grown in LB medium 
at 37°C. The log (CFU/ml) values were obtained at five different time 
points: T0, T60, T120, T180 and T240. Looking at the growth curves of E. 
coli strains, our data showed that all strains were able to grow exponentially 
from T0 with no detected lag time. Additionally, it showed that the growth 
curve progression of the E. coli strains was very rapid during the 
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exponential growth phase, which is consistent with the growth rates 
determined by OD measurement. Measuring the viable cell count values at 
different time points showed that the increase in the viable cell count was 
directly proportional to the incubation period. In general, the data showed 
no difference in the viable cell counts between the tested E. coli strains and 
the control strain, and between the E. coli ST131 and E. coli non-ST131 
strains. 
Figure 3.5: Growth curves for 11 E. coli strains obtained from performing viable 
cell count assay on LB medium at 37°C. The curves were plotted using averaged 
log (CFU/ml) values for the tested strains. 
 
 
Figure 3.6 shows the viable cell count values, given in log (CFU/ml), of E. 
coli strains grown in LB medium at 25°C. As for the previous growth 
condition, the growth curves showed that all strains were able to grow 
exponentially from T0 with no detected lag time. However they showed that 
the growth of strains during the exponential growth phase was lower than 
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that of the previous growth condition. Our data evident undetectable 
difference in terms of the viable cell count values between the tested strains 
and the control strain, and between the E. coli ST131 and non-ST131 
strains. 
 
Figure 3.6: Growth curves for 11 E. coli strains obtained from performing viable 
cell count assay on LB medium at 25°C. The curves were plotted using averaged 
log (CFU/ml) values for the tested strains. 
 
Figure 3.7 shows the viable cell count values, given in log (CFU/ml), of E. 
coli strains grown in McCoy’s 5A modified medium at 37°C. Although the 
growth curves showed the absence of lag phase in all strains, there was a 
reduction in the growth rates of E. coli strains compared to those 
determined using LB at different incubation temperatures, 37°C and 25°C. 
The growth of E. coli strains was almost comparable to that of the control 
strain, and there was no difference between the growth rates of ST131 and 
non-ST131 strains. 
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Figure 3.7: Growth curves for 11 E. coli strains obtained from performing viable 
cell count assay on McCoy’s 5A modified medium at 37°C. The curves were plotted 
using averaged log (CFU/ml) values for the tested strains. 
 
Figure 3.8 shows the viable cell count values, given in log (CFU/ml), of E. 
coli strains grown in McCoy’s 5A modified medium at 25°C. In this growth 
condition, the tested E. coli strains had the lowest growth rates compared 
to the three aforementioned growth conditions. The growth rates of E. coli 
strains were almost similar to that of the E. coli CFT073 control strain, and 
there was no detectable difference between the growth rates of ST131 and 
non-ST131 strains. 
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Figure 3.8: Growth curves for 11 E. coli strains obtained from performing viable 
cell count assay on McCoy’s 5A modified medium at 25°C. The curves were plotted 
using averaged log (CFU/ml) values for the tested strains. 
 
3.3.3 Type 1 fimbriae expression results 
3.3.3.1 Screening of the fimB transposon insertion in E. coli ST131 
strains 
 
On the basis of previous genome analysis by our research group identifying 
the presence of a transposon insertion mutation in the fimB gene of ten 
whole-genome sequenced E. coli ST131 strains (Clark et al. 2012), twenty-
five E. coli ST131 strains were tested for the presence of this insertion 
mutation using conventional PCR. The strain collection also included two 
control strains: E. coli CFT073 and UTI258. These two strains were 
previously tested for the presence of the fimB insertion, thus they were 
used in this assay as negative and positive controls. Figure 3.9 shows the 
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fimB gene PCR amplification products, and our data demonstrated that E. 
coli CFT073 had a normal fimB gene, i.e. without insertion, and this was 
showed by the presence of a 500bp fimB band. However a 1.895kb fimB 
transposon insertion was detected in the UTI258 strain and in 21 of the 25 
ST131 strains (83.33%). Interestingly, the E. coli ST131 strain, UTI453, 
had a fimB insertion of lower size, which was about 1.3kb, compared to that 
detected in other E. coli ST131 strains. 
 
 
Figure 3.9: Gel electrophoresis of the fimB PCR products. E. coli strains with 
normal fimB gene had a band size of about 500bp. E. coli strains with detected 
transposon insertion were found to had a band size of about 1.895kb. The strains 
tested in each well were as follows: M: 1kb ladder, 1: E. coli CFT073, 2: UTI18, 3: 
UTI24, 4: UTI32, 5: UTI39, 6: UTI62, 7: UTI144, 8: UTI149, 9: UTI182, 10: 
UTI188, 11: UTI190, 12: UTI226, 13: UTI233, 14: UTI263, 15: UTI275, 16: 
UTI306, 17: UTI383, 18: UTI423, 19: UTI445, 20: UTI453, 21: UTI514, 22: 
UTI524, 23: UTI531, 24: UTI555, 25: UTI570, 26: UTI587, 27: UTI258, 28: PCR 
negative control. 
 
3.3.3.2 Testing the ability of E. coli ST131 to express functional type 
1 fimbriae  
 
The presence of a transposon insertion in 21 E. coli ST131 strains called 
into question the role of this insertion in inactivating the FimB recombinase 
that switches on the expression of type 1 fimbriae. Yeast cell agglutination 
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assay was carried out to investigate the ability of all E. coli ST131 strains, 
either with or without fimB transposon insertion, to produce functional type 
1 fimbriae. Table 3.5 shows the type 1 fimbriae expression profiles following 
shaking and static incubation conditions. For overnight shaking cultures, 
the control strain E. coli CFT073, which had no fimB insertion, was able to 
agglutinate the S. cerevisiae yeast suspension and thus produce type 1 
fimbriae. However all E. coli ST131 strains, either with or without fimB 
insertion, and the UTI258 strain were found to be negative for type 1 
fimbriae expression and this was shown by the inability of these strains to 
agglutinate the yeast cell suspension. When the overnight cultures of these 
strains were subjected to further two rounds of static incubation, all strains 
were able to agglutinate the yeast cell suspension and therefore express 
functional type 1 fimbriae. For all strains, there was variability in the yeast 
cell agglutination scores following the static growth, which reflected the 
difference in their ability to express functional type 1 fimbriae (Table 3.5). 
Generally, our data suggests no effect of the fimB insertion on the ability of 
ST131 strains to express functional type 1 fimbriae. 
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Table 3.5. The fimB transposon insertion and yeast cell agglutination 
profiles of E. coli strains.  
 
Strain 
ID 
 
E. coli ST fimB 
insertion 
aYA 
(Shaking) 
bYA 
(Static) 
E. coli 
CFT073 
ST73 - ++ +++ 
UTI18 
 
ST131 + - +++ 
UTI24 
 
ST131 + - +++ 
UTI32 
 
ST131 - - 
 
++ 
UTI39 
 
ST131 - - +++ 
UTI62 
 
ST131 + - ++ 
UTI144 
 
ST131 - - +++ 
UTI149 
 
ST131 + - +++ 
UTI182 
 
ST131 + - +++ 
UTI188 
 
ST131 + - ++ 
UTI190 
 
ST131 + - +++ 
UTI226 
 
ST131 - - +++ 
UTI233 
 
ST131 + - ++ 
UTI1263 
 
ST131 + - ++ 
UTI275 
 
ST131 + - + 
UTI306 
 
ST131 + - ++ 
UTI383 
 
ST131 + - +++ 
UTI423 
 
ST131 + - +++ 
UTI445 
 
ST131 + - ++ 
UTI453 
 
ST131 + - ++ 
UTI514 
 
ST131 + - +++ 
UTI524 
 
ST131 + - +++ 
UTI531 
 
ST131 + - +++ 
UTI555 
 
ST131 + - +++ 
UTI570 
 
ST131 + - ++ 
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Strain ID 
 
E. coli ST fimB 
insertion 
aYA 
(Shaking) 
bYA 
(Static) 
UTI587 
 
ST131 + - ++ 
UTI258 ST1461 
 
+ - ++ 
a Yeast agglutination (YA) following shaking growth. 
b Yeast agglutination (YA) following two rounds of static growth. 
 
3.3.4 Confirmation of plasmid transformation by PCR 
To confirm the transformation of the pMN402 plasmid carrying the gfp gene 
into the eleven E. coli strains included in this study, a PCR assay was carried 
out, using the GFP primer set designed previously by our research group 
(McNally et al. 2006), to detect the presence of the gfp gene in all strains. 
Figure 3.10 shows the gfp gene PCR amplification products of strains. Our 
data identified the absence of gfp band in the negative control, which was 
an aliquot of electro-competent cells containing no plasmid DNA. However 
it showed the presence of gfp band of the expected product size, 700bp, in 
all transformed E. coli strains. This therefore confirmed the successful 
transformation of the pMN402 plasmid carrying the gfp gene into all E. coli 
strains.   
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Figure 3.10: Gel electrophoresis of the gfp PCR products. E. coli strains that 
carried gfp gene had a band size of about 700bp. The strains tested in each well 
were as follows: M: 100bp ladder, 1: PCR negative control, 2: Aliquot of electro-
competent cell with no plasmid DNA, 3: E. coli CFT073, 4: UTI18, 5: UTI48, 6: 
UTI89, 7: UTI188, 8: UTI226, 9: UTI243, 10: UTI570, 11: UTI587, 12: P5B. 
 
3.3.5 T24 cell culture results  
3.3.5.1 Association profiles of GFP-tagged E. coli ST131 and non-
ST131 strains 
 
Prior to the start of performing comparative cell culture assays on GFP-
tagged E. coli strains using T24 cells, the viable cell counts of the overnight 
bacterial cultures were estimated in order to obtain a standard inoculum of 
about 2x106 CFU/ml for all tested strains. This allowed us to achieve an 
MOI: 100, i.e. 100 bacterial cells for each T24 cell. Subsequently, the eleven 
GFP-tagged E. coli ST131 and non-ST131 strains were tested in triplicate 
on three independent occasions to determine and compare their ability to 
associate with, to invade and to form intracellular bacterial communities 
(IBCs) inside T24 cells. Figures 3.11 and 3.12 show representative images 
obtained by confocal microscope for all ST131 and non-ST131 strains after 
performing bacterial association assay. For ST131 strains, our data 
demonstrated that all these strains were able to attach to T24 cells (Figure 
3.11). However there was variability in the capacity of ST131 strains to 
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associate with T24 cells. The levels of bacterial association in UTI18 strain 
were higher than that of other ST131 strains.  
Figure 3.11: Representative florescent confocal microscope images obtained after 
performing association assays using T24 cells for five GFP-tagged E. coli ST131 
strains, and show the ability of the strains to associate with the T24 cells. A: UTI18; 
B: UTI188; C: UTI226; D: UTI570 and E: UTI587. 
 
With regard to the non-ST131 strains, the capacity of the positive control 
E. coli ST73 strain CFT073 and the ST69 strain UTI243 to associate with 
T24 cells was higher than that of other non-ST131 strains (Figure 3.12). 
The negative control strain MG1655 was also able to associate with T24 
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cells. As with ST131 strains, there was also variability in the levels of 
association between non-ST131 strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Representative florescent confocal microscope images obtained after 
performing association assays using T24 cells for six GFP-tagged E. coli non-ST131 
strains, and show the ability of the strains to associate with the T24 cells. F: E. coli 
CFT073; G: UTI48; H: UTI89; I: P5B; J: UTI243 and K: MG1655. 
 
 
In summary, our T24 association data for eleven E. coli strains belonging 
to ST131 and other ExPEC STs showed that all strains, including the 
negative control strain E. coli MG1655, were able to associate with T24 cells 
(Figures 3.11 and 3.12). It also showed that there was variability in the 
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association levels between the tested strains, and that the ability of three 
strains belonging to different STs, E. coli CFT073, UTI243 and UTI18, to 
associate with T24 cells was higher than that of other strains. 
 
To quantitatively determine and compare the number of bacterial cells 
associated with T24 cells for all strains, the associated bacterial cells were 
counted in twenty microscopic fields. Our data showed that the CFT073, 
UTI18 and UTI243 strains had higher associated bacterial cell count 
compared to the rest of strains, and that there was a statistical significant 
difference in the associated bacterial cell count between these strains and 
the negative control strain E. coli MG1655 (P<0.01) (Figure 3.13). The 
average number of CFT073, UTI18 and UTI243 associated cells was 210, 
203 and 195, respectively, which was almost twice the number of 
associated cells for the negative control strain MG1655. The number of 
associated cells in other ST131 and non-ST131 was also variable and it was 
between 93 and 150 (Figure 3.13). This confirms the variability in the 
association capacity of strains seen previously in the confocal microscope 
images and also suggests the absence of specific T24 association profile in 
ST131 strains. 
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Figure 3.13: The total number of bacterial cells associated with T24 cells for each 
strain obtained from counting the bacterial cells in 20 microscopic fields. The 
associated cell count values are averaged values obtained from counting the 
number of associated bacterial cells in triplicate wells. The graph also shows the 
significance of difference between the number of associated bacterial cells for each 
tested strain and that of the negative control strain E. coli MG1655 strain as tested 
by the one-way ANOVA test. The presence of significant difference between is 
shown by the asterisks above each bar [* (P<0.05), ** (P<0.01), *** (P<0.001) 
and **** (P<0.0001)]. 
 
3.3.5.2 Invasion profiles of GFP-tagged E. coli ST131 and non-
ST131 strains 
 
To investigate the capacity of E. coli strains to invade T24 cells and to form 
intracellular bacterial communities (IBCs) inside these cells, comparative 
invasion assays were carried out using two different time points: 3h and 
12h. The first time point allowed for assessing the ability of strains to invade 
T24 cells while the second one was used to determine the ability of strains 
to form IBCs inside T24 cells. 
 
Figures 3.14 and 3.15 show representative images obtained for all ST131 
and non-ST131 strains after performing 3h bacterial invasion assay using 
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T24 cells. Our data demonstrated that the all tested ST131 strains were 
able to invade T24 cells (Figure 3.14). However the levels of invasion were 
variable between these strains. UTI18 and UTI570 strains had slightly 
higher invasion potential than other ST131 strains (Figure 3.14).  
 
Figure 3.14: Representative florescent confocal microscope images obtained after 
performing 3h invasion assays using T24 cells for five GFP-tagged E. coli ST131 
strains, and show the ability of the strains to invade the T24 cells. A: UTI18; B: 
UTI188; C: UTI226; D: UTI570 and E: UTI587. 
 
With respect to the non-ST131 strains, Figure 3.15 showed that all strains, 
including the negative control strain MG1655, were able to invade T24 cells. 
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As for the ST131 strains, there was a variable invasion capacity in non-
ST131 strains. The ST73 control strain E. coli CFT073 and the ST69 strain 
UTI243 had higher invasion capacity than other strains, while the negative 
control strain MG1655 was the lowest strain in terms of the ability to invade 
T24 cells (Figure 3.15). 
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Figure 3.15: Representative florescent confocal microscope images obtained after 
performing 3h invasion assays using T24 cells for six GFP-tagged E. coli non-ST131 
strains, and show the ability of the strains to invade the T24 cells. F: E. coli CFT073; 
G: UTI48; H: UTI89; I: P5B; J: UTI243 and K: MG1655. 
 
 
In summary, our data obtained from testing the invasion capacity for eleven 
E. coli strains belonging to ST131 and other ExPEC STs showed that all 
strains, including the negative control strain E. coli MG1655, were able to 
invade T24 cells (Figures 3.14 and 3.15). It also showed variability in the 
invasion levels between the tested strains, and that the ability of four 
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strains belonging to different STs, E. coli CFT073, UTI243 and UTI18 to 
invade T24 cells was higher than that of other strains. 
 
To quantitatively determine and compare the number of invasive bacterial 
cells for all strains, the invasive bacterial cells were counted in twenty 
microscopic fields. Our data showed that the non-ST131 strains CFT073 and 
UTI243, and the ST131 strain UTI18 had higher numbers of invasive 
bacterial cells compared to the rest of strains, and that there was a 
statistical significant difference in the invasive bacterial cell count between 
these strains and the negative control strain E. coli MG1655 (P<0.01) 
(Figure 3.16). The average number of invasive cells for the CFT073, UTI243 
and UTI18 strains was 55, 50 and 53, respectively. However the negative 
control strain MG1655 was the lowest strain in terms of the number of 
invasive cells, with only 10 invasive bacterial cells. The number of invasive 
cells in other ST131 and non-ST131 was also variable and it was between 
19 and 30 (Figure 3.16). This therefore confirms the variability in the 
invasion capacity of strains seen previously in the confocal microscope 
images and also suggests the absence of a specific invasion profile of ST131 
strains. 
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Figure 3.16: The total number of invasive bacterial cells for each strain obtained 
from counting the bacterial cells in 20 microscopic fields after performing 3h 
invasion assay. The invasive cell count values are averaged values obtained from 
counting the number of invasive bacterial cells in triplicate wells. The graph also 
shows the significance of difference between the number of invasive bacterial cells 
for each tested strain and that of the negative control strain E. coli MG1655 strain 
as tested by the one-way ANOVA test. The presence of significant difference 
between is shown by the asterisks above each bar [* (P<0.05), ** (P<0.01), *** 
(P<0.001) and **** (P<0.0001)]. 
 
 
Afterwards, to investigate the ability of the eleven E. coli strains to form 
IBCs inside T24 cells, 12h invasion assays were performed. Figures 3.17 
and 3.18 show representative images obtained for all ST131 and non-ST131 
strains after performing 12h bacterial invasion assays. Our data 
demonstrated that the all tested ST131 strains were able to form IBCs 
inside T24 cells (Figure 3.17). However the levels of bacterial replication 
were variable between these strains. UTI18 and UTI570 strains had slightly 
higher ability to replicate inside T24 than other ST131 strains (Figure 3.17).  
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Figure 3.17: Representative florescent confocal microscope images obtained after 
performing 12h invasion assays using T24 cells for five GFP-tagged E. coli ST131 
strains, and show the ability of the strains to invade the T24 cells. A: UTI18; B: 
UTI188; C: UTI226; D: UTI570 and E: UTI587. 
 
 
With respect to the non-ST131 strains, Figure 3.18 showed that all strains, 
except the negative control strain MG1655, were able to replicate within 
T24 cells. As for the ST131 strains, there was a variable replication capacity 
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in non-ST131 strains. The ST73 control strain E. coli CFT073 had higher 
ability to form IBCs inside T24 cells than other strains (Figure 3.18). 
 
Figure 3.18: Representative florescent confocal microscope images obtained after 
performing 12h invasion assays using T24 cells for six GFP-tagged E. coli non-
ST131 strains, and show the ability of the strains to invade the T24 cells. F: E. coli 
CFT073; G: UTI48; H: UTI89; I: P5B; J: UTI243 and K: MG1655. 
 
 
In summary, our data obtained from testing the capacity of eleven E. coli 
strains belonging to ST131 and other ExPEC STs to form IBCs inside T24 
cells showed that all strains, except the negative control strain E. coli 
MG1655, were able to replicate in T24 cells (Figures 3.17 and 3.18). It also 
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showed that there was variability in the replication levels between the 
tested strains, and that the ability of four strains belonging to different STs, 
E. coli CFT073, UTI18 and UTI570 to replicate in T24 cells was higher than 
that of other strains.  
 
To quantitatively determine and compare the number of replicated bacterial 
cells for all strains, the replicated bacterial cells were counted in twenty 
microscopic fields. Our data showed that the non-ST131 positive control 
strain CFT073, and the ST131 strains UTI18 and UTI570 had higher 
numbers of replicated bacterial cells compared to the rest of strains (Figure 
3.19). The average number of replicated cells for the CFT073, UTI18 and 
UTI570 strains was 73, 65 and 56, respectively. However the negative 
control strain MG1655 failed to replicate inside T24 cells. The number of 
replicated cells in the other ST131 and non-ST131 was also variable and it 
was between 33 and 46 (Figure 3.19). This is consistent with the variability 
in the IBCs formation capacity of strains seen previously in the confocal 
microscope images and also suggests the absence of specific ability of 
ST131 strains to form IBCs inside T24 cells. 
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Figure 3.19: The total number of invasive bacterial cells for each strain obtained 
from counting the bacterial cells in 20 microscopic fields after performing 12h 
invasion assay. The invasive cell count values are averaged values obtained from 
counting the number of invasive bacterial cells in triplicate wells. The graph also 
shows the significance of difference between the number of invasive bacterial cells 
for each tested strain and that of the negative control strain E. coli MG1655 strain 
as tested by the one-way ANOVA test. The presence of significant difference 
between is shown by the asterisks above each bar [* (P<0.05), ** (P<0.01), *** 
(P<0.001) and **** (P<0.0001)]. 
 
3.3.6 Persistence of E. coli strains within U937 cell line results  
Human differentiated U937 macrophages were used to determine and 
compare the ability of eleven E. coli strains to persist and replicate within 
human macrophages following phagocytosis. The C. koseri SMT319 strain 
was used as a positive control since it was previously shown to persist and 
replicate within U937 cells (Townsend et al. 2003), while the E. coli MG1655 
strain was used as a negative control because it was found to be totally 
cleared by U937 cells after 24h of cell infection (Townsend et al. 2007). 
Figure 3.20 shows the U937 survival curves of all tested strains. Our data 
demonstrated that all tested strains, except the negative control strain E. 
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coli MG1655, were able to persist within U937 cells up to 48h after cell 
infection. However this ability differed between strains over the different 
time points.  
Figure 3.20: Persistence of eleven E. coli strains and C. koseri STT319 strain 
within cultured U937 human macrophages over a 48h time course. Survival curves 
show the number of intercellular bacterial cells at each time point, given in log 
(CFU/ml) values. The log (CFU/ml) values were averaged values obtained from 
determining the intracellular bacterial cells in triplicate wells for each strain. 
 
At T0, the U937 uptake levels for all tested strains, including the positive 
and negative controls, were similar. The log CFU/ml values obtained for all 
strains at this time point was between 5.30 and 5.72 (Figure 3.20), and the 
statistical difference in the log CFU/ml values at this time point between 
ST131 and non-ST131 strains was insignificant (P = 0.915) (data not 
shown).  
 
At T5, there was a clear reduction in the intracellular bacterial cell count of 
all strains compared to that at T0 (uptake), and the log CFU/ml values 
obtained for all strains were between 3.58 and 5.14 (Figure 3.20). Among 
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all strains, the positive control strain C. koseri SMT319 was the highest in 
terms of the intracellular bacterial cell count. With regard to the E. coli 
strains, although there is a little difference in the log CFU/ml values of 
strains at this time point, the grouped statistical analysis showed that there 
was no significant difference between the intracellular bacterial counts of 
ST131 and non-ST131 strains (P = 0.159) (data not shown).  
 
At T24, the intracellular bacterial count for all tested strains began to 
increase. The negative control strain E. coli MG1655 was totally cleared at 
this time point. The number of intracellular bacterial counts of all persistent 
strains ranged from 4.37 to 5.87 (Figure 3.20). As with T5, the positive 
control strain C. koseri SMT319 was the highest in terms of the intracellular 
bacterial cell count among all tested strains. With respect to the E. coli 
ST131 and non-ST131 strains, although they were all able to persist within 
U937 cells, there was a slight variability in their persistence ability and this 
was observed even between strains belonging to the same ST. Generally, 
the difference in the intracellular bacterial cell count between E. coli ST131 
strains and non-ST131 at T24 was found to be statistically insignificant (P 
= 0.06) (data not shown). 
 
Finally, determining the intracellular bacterial cell count of all strains at T48 
showed that there was a reduction in their log CFU/ml values. All E. coli 
strains were able to persist within U937 cells, expect the negative control 
strain E. coli MG1655. The positive control strain C. koseri SMT319 was the 
only strain to show an increased capability to persist and replicate within 
U937 cells, and this was shown by its higher bacterial cell count compared 
to other persistent E. coli strains (Figure 3.20). Considering the persistence 
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levels of E. coli strains, there was variability in their persistence ability and 
this was observed even between strains belonging to the same ST. Although 
the intracellular bacterial cell count of the E. coli ST131 strains was not 
significantly higher than that of non-ST131 strains (P = 0.08) (data not 
shown), the graph shows that there was a noticeable difference between 
strains in terms of their intracellular bacterial cell count at this time point 
(Figure 3.20). The insignificant difference obtained from performing the 
statistical analysis might result from the way that the statistical test used 
to calculate the significance of difference between strains. 
 
In summary, determining and comparing the ability of eleven E. coli strains 
and the C. koseri SMT319 strain to persist and replicate within human 
differentiated U937 macrophages showed that all tested strains, except the 
negative control strain E. coli MG1655, were able to persist within U937 
cells up to 48h after cell infection. Additionally, there was no statistical 
significant difference in the intracellular bacterial cell count between ST131 
and non-ST131 at T0, T5, T24 and T48, suggesting that there was no 
specific U937 persistence profile of ST131 strains compared to non-ST131 
strains.  
3.4 Discussion 
It has been shown that the bacterial infection process depends on the ability 
of the organism to grow in the host. Additionally, higher growth rates are 
commonly associated with the ability of pathogenic bacteria to cause 
recognisable infection (Barer 2001). A previous study tested a collection of 
urine isolates, including six E. coli isolates and fourteen other isolates 
belonging to different species such as Staphylococcus saprophyticus (S. 
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saprophyticus) biotype3 and Proteus mirabilis (P. mirabilis), to determine if 
differential growth rates in urine may be a discriminatory factor allowing 
pathogenic E. coli strains to cause infection, and found that the growth rates 
of E. coli isolates were significantly higher than that of isolates belonging to 
other species (Anderson et al. 1979). Firstly, this study determined and 
compared the growth rates of E. coli, including E. coli ST131 and non-ST131 
strains, using two different growth assays, turbidity measurement assay 
and viable cell count assay. Our data obtained from measuring the OD value 
of 49 E. coli strains using 4 different growth conditions showed that all 
ST131 and non-ST131 strains had almost similar growth rates. With respect 
to the factors affecting the bacterial growth, testing the growth rates of the 
E. coli strains using two different types of culture media, LB medium and 
McCoy’s 5A modified medium, showed an increased ability of the all tested 
strains to grow in LB medium compared to the McCoy’s 5A modified 
medium. This was expected since the McCoy’s 5A medium is a minimal-
defined medium and it lacks some essential growth factors such as L- 
glutamine, which may affect the biosynthesis of macromolecules and 
energy production. This observation was supported by the previous finding 
showing the association between high bacterial growth rates and the 
availability of nutrients in culture media (Shehata and Marr 1971). In 
addition, the effect of using higher incubation temperature on the growth 
rates of strains was observed, and the growth rates of all strains incubated 
at 37°C were higher than those incubated at 25°C. This is consistent with 
many reports demonstrating the effect of temperature on the growth of 
bacterial strains (Madigan et al. 2009). 
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Growth curves obtained from performing viable cell counting assay on ten 
representative E. coli, five ST131 and five non-ST131 strains, showed that 
the difference in the growth rates of these strains remained also 
undetectable in all growth conditions. This confirms our observation from 
using turbidity measurement assay where there were almost similar growth 
rates of all tested strains. 
 
With regard to the limitation of the methods used to determine the growth 
of E. coli strains, we determined the growth of a collection of ExPEC strains, 
including ST131 and non-ST131, using two different types of culture media 
in order to examine if ST131 strains are associated with differential growth 
rates but we did not test that in human urine. Testing the presence of 
differential growth rates of ST131 in human urine is important since it might 
be a selective factor allowing this clone to cause UTIs (Anderson et al. 
1979). The importance of studying the bacterial growth in human urine was 
also highlighted by the previous finding showing that UPEC strains grown in 
human urine were able to express more cytoplasmic proteins than those 
grown in LB medium (Alteri et al. 2009), which suggests that these proteins 
can act as main carbon sources for E. coli during infection of the urinary 
tract and therefore might be of impotence in UPEC fitness in vivo.  
 
Considering the expression of type 1 fimbriae in E. coli ST131 strains, a 
previous whole genome-based study by our research group identified the 
presence of a transposon insertion mutation in the fimB gene of ten clinical 
ST131 isolates (Clark et al. 2012). Our data obtained from performing PCR 
screening for the presence of this fimB gene insertion in twenty-five ST131 
strains belonging to H30Rx clade identified a 1.895bp fimB insertion in 21 
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of the 25 E. coli ST131 strains (83.33%). In addition, one E. coli ST131 
strain, UTI453, had an insertion in the fimB gene but with a lower product 
size obtained for the rest of strains. This fimB gene insertion was firstly 
identified in the non-pathogenic E. coli strain, E. coli Nissle 1917 
(Stentebjerg-Olesen et al. 1999). Recently, Totiska and colleagues 
identified a fimB insertion of similar size in the E. coli ST131 H30Rx strain, 
EC958, and in 59% of the E. coli ST131 strains tested in that study (Totsika 
et al. 2011). Additionally, whole-genome analysis of the ST131 H30Rx 
strain NA114 and the ST131 strain SE15 showed the presence of insertion 
sequence (IS) element copy in the fimB gene of NA114 strain, while this 
insertion was undetectable in the SE15 strain (Paul et al. 2013). Given some 
previous studies showing that SE15 strain does not belong to ST131 H30Rx 
clade (McNally et al. 2013b, Petty et al. 2014), our data in addition to the 
two aforementioned studies demonstrating the presence of fimB insertion 
in ST131 strains belonging to H30Rx clade highlighted the importance of 
determining the effect of the fimB insertion on the ability of these strains 
to produce functional type 1 fimbriae. 
 
The effect of the fimB insertion on the ability of E. coli ST131 strains to 
produce functional type 1 fimbriae was tested using yeast cell agglutination 
assay. All E. coli ST131 strains failed to express type 1 fimbriae using 
overnight shaking cultures. However these strains were able to produce 
functional type 1 fimbriae after two rounds of static incubation. It is well 
known that the expression of type 1 fimbriae is phase variable, and cells 
can switch between fimbriated and nonfimbriated states. This characteristic 
depends on the “on or off” orientation of an invertible 314-bp DNA switch 
located upstream of the fimA gene, encoding the major subunit protein 
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FimA (Abraham et al. 1985). The inability of all E. coli ST131 strains to 
produce type 1 fimbriae following overnight shaking incubation condition 
was due to the off orientation of the DNA switch. Unlike the shaking growth, 
static aerated growth in liquid media strongly selects for expression of type 
1 fimbriae as this would turn on the orientation of the DNA switch by the 
action the FimB recombinase (Totsika et al. 2011), and this was clearly 
observed in the tested E. coli ST131 strains. Generally, the ability of all 
ST131 strains to produce functional type 1 fimbriae after static growth 
suggests that the presence of a fimB transposon insertion did not affect the 
capability of the E. coli ST131 strains to express functional type 1 fimbriae. 
 
A previous study by our research group tested and compared the ability of 
ST131 strains to attach to and to invade T24 cells to that of the invasive E. 
coli reference strain CFT073 using gentamicin protection assay, and found 
the presence of a hyper-invasive phenotype in 15 out of 27 (56%) of the 
tested E. coli ST131 isolates. However when compared with the rest of the 
population, ST131 strains did not invade the T24 cells to significantly higher 
numbers (Croxall et al. 2011a). The gentamicin protection assay can 
provide only a rough estimation of the dynamics of bacterial-cell interaction 
processes (Saini et al. 1999), and so comparative association and invasion 
assays were performed on eleven GFP-tagged E. coli strains using T24 cells 
followed by using confocal microscopy to visualise the attached or 
internalised bacteria.  
 
Our bacterial association data showed that all ST131, non-ST131 and the 
negative control strain E. coli MG1655 were able to associate with T24 cells. 
Confocal microscope images showed that the level of bacterial association 
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was variable between strains belonging to different ExPEC STs. To 
quantitatively assess this variability, counting the number of attached 
bacterial cells in 20 microscopic fields showed the presence of only strain-
specific differences. Taken together, our data showed no increased ability 
of ST131 strains to associate with T24 cells compared to non-ST131 strains. 
This corroborates with our previous finding obtained from using gentamicin 
protection assay and showing no significant difference between ST131 and 
non-ST131 in terms of their T24 association profiles (Croxall et al. 2011a).  
 
The capacity of eleven GFP-tagged ST131 and non-ST131 strains to invade 
and to form IBCs within T24 cells was also determined and compared using 
two different time points, 3h and 12h. Our data demonstrated that all 
strains were able to invade the T24 cells after 3h of incubation. The level of 
bacterial invasion was variable between strains belonging to different ExPEC 
STs. Invasive cell count showed also no difference at ST-level between 
strains. As with the bacterial association profiles, there was no increased 
ability of ST131 strains to invade T24 cells compared to non-ST131 strains 
which is in agreement with our previous data obtained from using 
gentamicin protection assay and showing no significant difference between 
ST131 and non-ST131 in terms of their T24 invasion profiles (Croxall et al. 
2011a). 
With respect to the 12h invasion assay, our data showed that all strains, 
except the negative control MG1655, were able to form IBCs within T24 
cells. However the variability seen previously in the attachment and 3h 
invasion profiles for all strains was also detected here, and there was no 
difference at ST-level between strains in terms of their ability to form IBCs 
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within T24 cells. This finding was in agreement of a previous report showing 
that the pyelonephritis- and cystitis-associated E. coli strains CFT073 and 
UTI89 were more able to survive in human T24 bladder epithelial cells at 
24h post-infection than the asymptomatic E. coli strains VR50 and 83972 
(Bokil et al. 2011). Taken together, these observations might support the 
assertion that the establishment of IBCs within host epithelial cells is crucial 
for UPEC host evasion and reinfection, and thus UTI chronicity (Hunstad et 
al. 2005, Nielubowicz and Mobley 2010). Additionally, our data showing the 
ability of the negative control strain E. coli MG1655 to associate with T24 
cells suggests the unsuitability of using this strain as a negative control for 
this assay. However it was shown that E. coli MG1655 strain was a good 
control for invasion assays since it was the lowest in terms of its ability to 
invade the T24 and it failed to form IBCs inside T24 cells. 
It has been shown that macrophages are widely used by professional 
intracellular pathogens as an intracellular niche to evade host immune 
response (Bokil et al. 2011). Given many studies showing that macrophages 
might contribute to the innate immune response against UPEC (Engel et al. 
2008), and that the intracellular survival of UPEC can contribute to 
pathogenesis (Blango and Mulvey 2010), the ability of E. coli ST131 and 
non-ST131 strains to persist within U937 human macrophages was 
determined and compared. Our data demonstrated that all E. coli strains, 
with an exception of the negative control strain MG1655, were able to 
persist within U937 up to 48h after cell infection. However this ability was 
variable between strains over the different time points. Additionally, it 
showed that the difference between strains was not significantly detected 
at ST-level, and that ST131 strains were not associated with U937 
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persistence profile. 
Although our study was the first to investigate the UPEC persistence within 
U937 macrophages, there were previous studies that tested the ability of 
some successful UPEC strains to survive within macrophages. For example, 
Bokil et al. (2011) tested and compared the ability of the UPEC strain E. coli 
CFT073, the laboratory E. coli strain XL1-blue and the intracellular pathogen 
Salmonella typhimurium (S. typhimurium) strain SL1344, to persist and 
replicate within the murine bone marrow-derived macrophages (BMM). 
They found that intracellular CFT073, but not XL1- blue, were recovered 
from BMM 24h after infection. However the intracellular survival of CFT073 
was lower than that of S. typhimurium SL1344 strain. Our data showing the 
ability of E. coli strains to persist within U937 macrophages up to 48h of 
infection might suggest that the long-term macrophage survival can be 
used by these strains to escape immune detection. However the absence of 
ST131 specific U937 persistence profile suggests that intramacrophage 
survival is not a specific trait of this clone, suggesting the presence of other 
factors that might contribute to its fitness.     
3.5 Conclusion  
On the basis of many reports showing the importance of bacterial growth 
in pathogenesis, this study determined and compered the growth rates of 
a collection of E. coli strains belonging to ST131 and non-ST131 using 
different growth measurement methods and conditions. It found that there 
was no difference between ST131 and non-ST131 strains in terms of their 
growth rates, suggesting that bacterial growth is not a factor contributing 
to the ST131 fitness. Screening the presence of the previously identified 
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fimB insertion in twenty-five E. coli ST131 strains showed that 21 of 25 
ST131 strains (83.33%) had this insertion. Testing the effect of this 
insertion on the ability of E. coli ST131 strains to produce type 1 fimbriae 
showed that all strains were able to express functional type 1 fimbriae after 
two rounds of static growth. Testing the attachment, invasion and IBCs 
formation capacity of GFP-tagged ST131 and non-ST131 strains using 
confocal microscopy showed the presence of strain-specific differences 
between strains, with no difference at ST-level. Finally, determining the 
ability of ST131 and non-ST131 strains to persist within U937 macrophages 
showed also only strain-specific difference between strains, with no specific 
ST131 persistence profile.  
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4.1 Introduction 
It has been suggested that the ability of ExPEC strains to colonise and cause 
infection in the urinary tract results from the cumulative action of specific 
virulence factors such as adhesins and iron acquisition determinants 
(Johnson 1991). Since the emergence of E. coli ST131 in 2008, many 
studies on its virulence potential have been conducted. Initial studies 
reported an increased virulence associated gene (VAG) carriage in E. coli 
ST131 isolates (Coelho et al. 2010), and also found them responsible for 
causing a range of severity in disease cases (Lau et al. 2008b, Johnson et 
al. 2010b). However many comparative whole-genome (Toh et al. 2010, 
Avasthi et al. 2011, Totsika et al. 2011, Clark et al. 2012) and PCR-based 
(Croxall et al. 2011a, Gibreel et al. 2012b, Lavigne et al. 2012) studies have 
recently demonstrated the variability in the VAGs possessed by E. coli 
ST131 strains, and that E. coli ST131 strains have been associated with 
moderate virulence capacity compared to other potential ExPEC STs such 
as ST73, ST69 and ST127. These findings call into question the role of VAG 
carriage in the current success of E. coli ST131, suggesting the presence of 
other factors that can contribute to its fitness. 
4.1.1 The role of metabolism in bacterial colonisation and 
pathogenesis 
Metabolism is an important factor in colonisation not only in the 
environment but also in human and animal hosts (Rohmer et al. 2011). 
Since the transition from environment to a host niche can impose 
challenges on bacteria in terms of pH, oxygen levels, and nutrient 
availability such as free iron, an extensive metabolic repertoire is required 
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to accommodate these changes (Rohmer et al. 2011). Additionally, it has 
recently been suggested that high metabolic capacity enhances bacterial 
fitness and contributes to pathogenesis (Le Bouguénec and Schouler 2011). 
Previous studies showed that sugar metabolism (Le Bouguénec and 
Schouler 2011), and the possession of specific metabolic enzymes (Pancholi 
and Chhatwal 2003), may increase the virulence of many bacterial species. 
In addition, it has been demonstrated that the utilisation of the amino acid 
D-serine by UPEC strains during UTI supports bacterial growth and acts as 
a signalling mechanism to trigger virulence gene expression (Roesch et al. 
2003, Anfora et al. 2007).  
4.1.2 The proposed role of E. coli ST131 metabolic potential in 
enhancing its fitness 
A recent study used the Vitek2 Advanced Expert System for metabolic 
profiling on a collection of 300 isolates representing the major UPEC STs 
(Gibreel et al. 2012a). The authors concluded that E. coli ST131 isolates 
had higher metabolic potential and biochemical profiles compared to other 
ExPEC ST isolates, which may contribute to the fitness of E. coli ST131. 
They also found a correlation between metabolic activity and antibiotic 
susceptibility profiles, with resistance isolates showing the highest 
metabolic potential (Gibreel et al. 2012a). Another study by Vimont et al. 
tested the ability of one E. coli ST131 strain to colonise the intestinal tract 
by measuring its maximal growth rate (MGR) using three different culture 
conditions: a rich medium and two minimal media containing either 
gluconate or glucose. By comparing the metabolic activity of the ST131 
strain with three other E. coli strains: the commensal K-12 E. coli strain 
MG1655 and the ExPEC CFT073 and HT7 strains, the study found that the 
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ST131 strain had a significantly higher MGR than the non-ST131 strains 
(Vimont et al. 2012). 
4.1.3 Overview of the phenotypic methods used for testing the 
bacterial metabolic potential 
4.1.3.1 Biotyping 
 
Biotyping is a method of subtyping bacterial isolates by using their 
metabolic profiles (Eberle and Kiess 2012). Generally, biotyping is based on 
sugar utilisation and fermentation patterns and enzyme profiles. 
Additionally, it has traditionally been used for identification of bacteria to 
the species level (Katouli et al. 1990), and can also be used to subdivide 
strains below the species level (Katouli et al. 1990). However this greatly 
depends on the biochemical variability within the species and the 
distribution of these variations (Lockhart and Liston 1970). E. coli has 
considerable biochemical variability, thus biotyping is reliable not only in 
the identification of its strains but also in reflecting its potential 
pathogenicity in humans (Reuter 2011). A previous study demonstrated 
that biotyping was useful in the characterisation of E. coli that cause UTI in 
humans and identified two biotypes, biotype 5,144,552 and biotype 
5,144,572, accounting for more than 40% of tested strains (Davies 1977). 
Another study found that using a biotyping scheme consisting of β-
glucuronidase, sorbitol, raffinose and dulcitol can differentiate the enteric 
pathogen E. coli O157:H7 from other E. coli serotypes (Ratnam et al. 1988). 
However the use of biotyping in epidemiological investigations is considered 
unreliable for some bacterial pathogens due to its low reproducibility and 
poor discriminatory power (Eberle and Kiess 2012, Gibreel et al. 2012a).  
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4.1.3.2 Phenotypic microarray (PM) technology  
 
Phenotypic microarray (PM) was first developed for E. coli by Bochner, 
Gadzinski and Panomitros. PM is a high-throughput technology used for 
testing a wide range of cellular phenotypes (Bochner et al. 2001). Unlike 
the biotyping method, PM technology allows the simultaneous testing of 
hundreds or even thousands of metabolites in an automated fashion 
(Bochner et al. 2001). Additionally, it has been utilised to study the 
metabolic flexibility of various bacterial species and provides the highest 
level of resolution currently available for the metabolic capacity of cells 
(Bochner et al. 2001). PM technology is based on cellular respiration that 
reflects cell activity (Bochner et al. 2001). The PM assay chemistry uses 
tetrazolium violet dye that is reduced in the presence of electrons leading 
to a colour change from colourless to purple. In the absence of nutrient 
transport or metabolism, there will be no electron flow and therefore no 
reduction of the dye (Figure 4.1). 
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Figure 4.1: Respiration is coupled to conversion of tetrazolium violet dye (taken 
from (Bochner et al. 2001)). 
 
4.1.4 Gene content analysis for the identification of unique ST131 
loci 
4.1.4.1 Bacterial “pan-genome” approach as a tool for gene content 
analysis 
 
Previous analysis of sequenced bacterial genomes showed that the size and 
content of these genomes vary greatly, even for closely related strains 
(Gordienko et al. 2013). For example, it has been shown that only 39% of 
the combined, non-redundant sets of proteins were common for three 
sequenced E. coli strains (Welch et al. 2002). Additionally, although whole-
genome sequencing can be a useful tool for studying the genetic makeup 
of bacterial strains (Reuter 2011), the inability to consistently assign a 
function to the predicted products of uncharacterised genes, such as 
virulence-associated genes, remains a main limitation (Rasko et al. 2008). 
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To accurately characterise and compare the gene content of large number 
of bacterial genomes, a pan-genome analysis approach was introduced in 
2005 (Medini et al. 2005). The term “pan-genome” is defined as the total 
complement of genes from all sequenced strains of the same species 
(Tettelin et al. 2005), genus (Snipen and Ussery 2010) or a larger group 
(Lapierre and Gogarten 2009). Pan-genome includes a core “backbone” 
genome composed of genes present in all strains and a dispensable 
“accessory” genome composed of genes absent from one or more strains 
and genes that are unique to each strain (Tettelin et al. 2005). The 
accessory genome is particularly important in population studies of 
pathogenic bacteria, as it may contain the key virulence and antimicrobial 
resistance genes of the organism (Mira et al. 2010). The basic step in pan-
genome analysis is the computation of gene families (Snipen and Ussery 
2010), and it can therefore provide detailed insights into bacterial evolution, 
adaptation, and population structure, vaccine design and the identification 
of virulence genes (Mira et al. 2010). Nowadays, there are many pipelines 
available for comprehensive gene content analysis using pan-genome 
concept such as the pan-genome analysis pipeline (PGAP) (Zhao et al. 
2012), Large-Scale Blast Score Ratio (LS-BSR) (Sahl et al. 2014) and 
Gegenees (Ågren et al. 2012).  
4.1.4.2 The genetic architecture of E. coli ST131 H30Rx clade 
 
Avasthi and colleagues published the first E. coli ST131 whole genome 
sequence in 2011, and it was for the Indian uropathogenic E. coli ST131 
strain NA114 (Avasthi et al. 2011). The NA114 chromosome had a size of 
4,935,666 bp with a G + C content of 51.16% and a coding percentage of 
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88.4%. It also had 4,875 protein-coding sequences, 67 tRNAs and 3 rRNAs 
genes (Avasthi et al. 2011). The NA114 chromosome was shown to carry a 
range of VAGs, such as malX, fimH, kpsM and iutA (Avasthi et al. 2011), 
which are commonly present in strains belonging to other major ExPEC STs 
such as ST73 and ST95 (Guyer et al. 1998, Avasthi et al. 2011). However 
it also carried other VAGs that are infrequently associated with ST131 
isolates such as cnf1, sfa, pap and an intact polyketide synthase (pks) island 
(Johnson et al. 2008). Additionally, the NA114 strain harboured a single 
plasmid that had a size of 3.5 kb, although it has not yet been analysed 
with respect to its antimicrobial resistance gene profiles (Avasthi et al. 
2011).  
Subsequently, whole genome sequencing for ten ST131 strains was 
performed by our research group (Clark et al. 2012). The genome of ST131 
strain UTI18 was chosen as a representative for these ten genomes since it 
is highly antimicrobial resistance and of average invasion capacity (Clark et 
al. 2012). The UTI18 genome is similar to NA114 in that it comprises no 
novel regions that may account for increased fitness or pathogenicity 
compared to other publically available ExPEC genomes, however UTI18 
lacked the pathogenicity island comprising the cfn1, sfa and the pap fimbrial 
operon in UTI18. It was also found that UTI18 genome contained an ISL3-
like transposase in the fimB gene of the type 1 fimbrial operon (Clark et al. 
2012), a fully intact high pathogenicity island (HPI) encoding the 
yersiniabactin locus, and two flagella-encoding regions (Clark et al. 2012).  
The genetic architecture of isolates belonging to the E. coli ST131 H30Rx 
clade has recently been examined (Petty et al. 2014), paying particular 
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attention to virulence associated genes of ExPEC and to mobile genetic 
elements not found in non-ST131 ExPEC. In general, the data of this study 
suggested no ST131 specific virulence gene repertoire, though did highlight 
the seemingly unique nature of the secondary flagellar cluster (Flag-2) that 
had been previously identified in E. coli ST131 genomes (Clark et al. 2012). 
Additionally, the analysis also demonstrated the role of intra-ST131 
recombination in shaping the lineage with a significant overrepresentation 
of fimbrial adhesins and motility genes in the identified recombinant 
fragments. It also identified a recombinant fragment common across ST131 
within the group II capsule synthesis locus (Petty et al. 2014).  
4.1.5 Aims of the study 
Given that many recent reports have proposed the role of high metabolic 
capacity in enhancing the fitness of E. coli ST131 and contributing to its 
pathogenesis (Gibreel et al. 2012a, Vimont et al. 2012), we aimed to test 
and compare the metabolic activity of a collection of ExPEC strains including 
ST131 and non-ST131 strains using all available API metabolic profiling 
substrates (Biomerieux, UK). We further sought to test the metabolic 
activity of ten E. coli strains to a more comprehensive level using the 
phenotypic microarray technology in order to provide a comparison 
between ST131 and E. coli of different STs in terms of their metabolic 
potential, and to examine the correlation between the antimicrobial 
resistance and the metabolic activity of ST131 strains. Additionally, given 
that the comparative genomics performed to date on E. coli ST131 have 
mainly focussed on virulence associated genes (Petty et al. 2014), and in 
attempt to identify the presence of ST131 unique loci that may account for 
increased fitness or pathogenicity compared to other publically available 
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ExPEC genomes, we sought to investigate the presence of other loci 
uniquely associated with the H30Rx clade of E. coli ST131 through 
comparing the gene content of a collection of E. coli strains including ST131 
and non-ST131.  
4.2 Material and Methods 
4.2.1 Bacterial strains 
A collection of fifty-two E. coli strains was used in this study. Fifty E. coli 
strains, twenty-five ST131 and twenty-five non-ST131, were included in the 
metabolic profiling assay using API test reagents. Thirty six of these strains 
were collected between October 2008 and June 2009 from urine samples of 
elderly patients from Queens Medical Centre, Nottingham (Croxall et al. 
2011b), while the other fourteen strains were collected between March 
2011 and June 2011 from urine samples of patients from Queens Medical 
Centre, Nottingham (Alhashash et al. 2013). Afterwards, a subset including 
ten E. coli, five ST131 and five non-ST131 strains, was used to carry out 
the Biolog phenotypic microarray assay. The five ST131 strains were 
previously genome sequenced (Clark et al. 2012), and varied in CTX-M-15 
gene carriage, source of isolation, and invasion levels. The non-ST131 
strains were chosen to represent the major ExPEC STs associated with 
human disease (Welch et al. 2002, Chen et al. 2006b, Croxall et al. 2011b, 
McNally et al. 2013a). Table 4.1 shows full details of the strains used in this 
study. 
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Table 4.1: The characteristics of strains used to carry out the metabolic 
profiling and PM assays in chapter 4. 
 
Strain 
ID 
ST Strain history Sample 
source 
CTX-M 
carriage 
Reference 
UTI18 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI24 ST131 Monomicrobial UTI Urine - A 
UTI32 
 
ST131 Monomicrobial UTI Urine CTX-M-15 A 
UTI39 
 
ST131 Polymicrobial UTI Urine - A 
UTI62 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI144 
 
ST131 Polymicrobial UTI Urine - A 
UTI149 
 
ST131 Polymicrobial UTI Urine - A 
UTI182 
 
ST131 Polymicrobial UTI Urine - A 
UTI188 
 
ST131 Monomicrobial UTI Urine - A 
UTI190 
 
ST131 Polymicrobial UTI Urine - A 
UTI226 
 
ST131 Polymicrobial UTI Urine - A  
UTI233 
 
ST131 Polymicrobial UTI Urine - A 
UTI263 
 
ST131 Polymicrobial UTI Urine - A 
UTI275 
 
ST131 Polymicrobial UTI Urine - A 
UTI306 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI383 
 
ST131 Polymicrobial UTI Urine - A 
UTI423 
 
ST131 Polymicrobial UTI Urine - A 
UTI445 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI453 
 
ST131 Polymicrobial UTI Urine - A 
UTI514 
 
ST131 Polymicrobial UTI Urine - A 
UTI524 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI531 
 
ST131 Polymicrobial UTI Urine - A 
UTI555 
 
ST131 Polymicrobial UTI Urine - A 
UTI570 
 
ST131 Polymicrobial UTI Urine - A 
UTI587 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
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Strain 
ID 
ST Strain history Sample 
source 
CTX-M 
carriage 
Reference 
UTI4 
 
ST95 Monomicrobial UTI Urine CTX-M A 
UTI14 ST10 Polymicrobial UTI Urine - A 
UTI50 ST73 Polymicrobial UTI Urine CTX-M A 
UTI56 ST69 Polymicrobial UTI Urine - A 
UTI147 ST73 Polymicrobial UTI Urine - A 
UTI220 ST73 Polymicrobial UTI Urine - A 
UTI243 ST69 Polymicrobial UTI Urine - A 
UTI284 ST73 Monomicrobial UTI Urine - A 
UTI337 ST95 Monomicrobial UTI Urine CTX-M A 
UTI396 ST393 Polymicrobial UTI Urine - A 
UTI501 ST69 Polymicrobial UTI Urine - A 
UTI565 ST69 Polymicrobial UTI Urine - A 
UTI89 ST95 Uncomplicated cystitis Urine - B 
E. coli 
CFT073 
ST73 Acute pyelonephritis Urine - C 
P5B ST10 Bacteraemia Blood - D 
U22 ST95 UTI Urine CTX-M E 
U60 ST95 UTI Urine CTX-M E 
U19 ST10 UTI Urine - E 
U95 ST10 UTI Urine - E 
U9 
 
ST69 UTI Urine - E 
U16 ST69 UTI Urine - E 
U23 ST69 UTI Urine CTX-M E 
U21 ST73 UTI Urine - E 
U24 ST73 UTI Urine - E 
U30 ST73 UTI Urine - E 
A: (Croxall et al. 2011b); B:(Chen et al. 2006b); C: (Welch et al. 2002); D: 
(McNally et al. 2013a); E: (Alhashash et al. 2013). 
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4.2.2 Comparative metabolic profiling assays 
The metabolic potential of a collection of E. coli strains was determined 
using two assays: the metabolic profiling using API test reagents and the 
Biolog phenotypic microarray assays. 
4.2.2.1 Metabolic profiling assay using API test reagents  
 
The metabolic profiling of fifty E. coli strains, twenty-five ST131 and twenty-
five non-ST131 strains, was carried out using four API kits: API 20E, ID32 
E, API 50 CH and API ZYM kits (Biomerieux, UK). This resulted in a total of 
120 biochemical tests, [information on these substrates are given in 
Appendix (chapter 7)], and allowed the measurement of carbon source 
utilisation, carbohydrate fermentation and enzymatic activity of E. coli 
strains. Preparation of bacterial suspensions and inoculation of test kits 
were performed according to the manufacturer’s instructions (Biomerieux, 
UK). The assays were performed in duplicate on two independent occasions 
giving completely concordant results.  
4.2.2.2 Biolog phenotypic microarray (PM) assay 
 
The PM assay was performed, with the help of Dr. Jane Newcombe 
(University of Surrey), using Biolog Inc. (Hayward, CA). This assay 
consisted of two 96 well PM panels (PM1, PM2A), which were used to test 
the ability of five E. coli ST131 and five non-ST131 strains to utilise 190 
carbon sources [information on these substrates are given in Appendix 
(chapter 7)]. E. coli strains were plated out on LB agar at 37°C prior to 
starting the assay. The bacterial cell suspension for each strain was 
prepared by transferring around 20–25 bacterial colonies into a sterile tube 
containing 15ml of sterile dH2O. A uniform suspension was made until a 
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turbidity of 42% transmittance (T) ± 1% in the Biolog turbidimeter was 
obtained. 2ml of this cell suspension was then added to 10ml of inoculation 
fluid-0 (IF-0)+120μl dye A to yield a final cell density of 85% T. Afterwards, 
100μl of the 85% T cell suspension was added to each well. The plates were 
then placed in the OmniLog reader (Biolog), and incubated for 48h. The 
OmniLog reader analyses the plates every 15 minutes, converting the pixel 
density in each well to a signal value reflecting cell growth and dye 
conversion. Figure 4.2 shows the workflow of the Biolog phenotypic 
microarray assay. 
Figure 4.2: Workflow of Biolog phenotypic microarray assay [adapted from 
(Bochner et al. 2001, Bochner 2003)]. 
 
4.2.2.3 Phenotypic Microarray data analysis 
 
Since its invention, the evaluation of phenotypic microarray data has not 
been standardised. Although previous studies used many approaches for 
phenotypic microarray data analysis (Lay Jr et al. 2006, Vaas et al. 2012), 
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the validity of the comparison between strains in terms of their metabolism 
remains one of the major challenges because substrate utilisation curves of 
the tested strains can show different shapes. Additionally, the possible 
interference of the background signal with the real utilisation signal 
produced by strains caused difficulties in detecting the presence of real 
metabolism. Therefore, this study evaluated the phenotypic microarray 
data set using the signal value analysis approach described previously 
(Homann et al. 2005). 
4.2.2.4 Statistical analysis 
 
The production of heat maps for API metabolic profiling results was 
performed using SPSS PAWS (version 20.0) statistics software. Phenotypic 
microarray results were analysed using R statistics package. Testing for 
correlation between metabolic profile and sequence type was performed by 
principal component analysis (PCA) in R. This part of study was performed 
with the help of Dr Richard Emes (University of Nottingham). 
4.2.2.5 Comparative genomics for the identification of the presence 
or absence of metabolic-associated loci 
 
To compare the metabolic potential between strains at a genomic level, an 
ST131 core genome was created to ensure any differences observed were 
conserved across all the ST131 strains. The ST131 genome sequences 
(Clark et al. 2012) were aligned using Mugsy (Sahl et al. 2011) and the 
core genome was extracted using Mothur (Schloss et al. 2009) as described 
previously (McNally et al. 2013b). The ST131 core genome was then 
compared against CFT073, UTI89, and P5B using ACT (Carver et al. 2005) 
in a pairwise fashion to determine metabolic loci uniquely present or 
uniquely absent to ST131. 
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4.2.3 Gene content analysis of a group of ST131 and non-ST131 
strains 
4.2.3.1 Bacterial genome data 
 
A total of twenty-five publically available E. coli genome sequences were 
used in this analysis (Table 4.2). Of these genome sequences, sixteen were 
reference genome sequences available from National Centre of 
Biotechnology Information (NCBI) website, whereas nine were ST131 
genomes produced during a previous study by our group (Clark et al. 2012). 
The data set of these nine ST131 genomes was used in this study. 
Table 4.2: List of E. coli genome data used to perform gene content 
analysis. 
 
Strain ST Pathotype Accession number 
E. coli UTI18 131a ExPEC ERP001095 
E. coli EC958 131b ExPEC CAFL01000001 
E. coli NA114 131c ExPEC CP002797.1 
E. coli UTI24 131a ExPEC ERP001095 
E. coli UTI32 131a ExPEC ERP001095 
E. coli UTI62 131a ExPEC ERP001095 
E. coli UTI188 131a ExPEC ERP001095 
E. coli UTI226 131a ExPEC ERP001095 
E. coli UTI306 131a ExPEC ERP001095 
E. coli UTI423 131a ExPEC ERP001095 
E. coli UTI587 131a ExPEC ERP001095 
E. coli JJ1886 131 ExPEC CP006784.1 
E. coli SE15 131a Human commensal AP009378.1  
E. coli LF82 135 AIEC NC_011993.1 
E. coli IHE3034 95 ST95 ExPEC CP001969.1 
E. coli UTI89 95 ST95 ExPEC CP000243.1 
E. coli S88 95 O45 ExPEC CU928161.2 
E. coli APEC01 95 APEC CP000468.1 
E. coli UM146 643 AIEC CP002167.1 
E. coli NRG857c 135 AIEC CP001855.1 
E. coli ED1a 452 O81 CU928162.2 
E. coli ABU89372 73 Asymptomatic CP001671 
E. coli CFT073 73 ExPEC AE014075.1 
E. coli Di14 73 ExPEC AE014075.1 
E. coli Di12 73 ExPEC CP002211.1 
a2009 UK ST131 strains; b2004 UK ST131 strain; cIndian ST131 strain. 
 
4.2.3.2 E. coli ST131 genome re-assembly  
 
Due to the improvements in assembly methodology since our initial study 
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(Clark et al. 2012), the nine ST131 genomes were re-assembled using the 
De Bruijn graph-based de novo assembler Velvet (Zerbino and Birney 2008) 
and Post Assembly Genome Improvement Toolkit (PAGIT) (Swain et al. 
2012). The De novo Velvet assembly was performed using the following 
parameters: a word length or k-mer length of 31, a short-paired read 
category, an average coverage of 75 and a coverage cut-off of 8. 
Afterwards, PAGIT was used to improve the quality of genome assemblies 
by ordering the previously assembled contigs against a reference genome 
(Swain 2009). In this study, the JJ1886 genome was used as a reference 
genome (Andersen et al. 2013). PAGIT was parallelised using a script 
written by Dr. Alan McNally including the use of four programs, ABACAS for 
ordering and orienting contigs previously aligned against a reference 
genome, IMAGE for closing the gaps within the scaffolds, ICORN for error 
correction at nucleotide level and RATT for annotation transfer from 
reference genome (Swain et al. 2012). All command lines used to perform 
this part of study are given in the appendix (Chapter 7). 
4.2.3.3 Comparative gene content analysis of a group of E. coli 
ST131 and non-ST131 strains using Gegenees software 
 
Gegenees (version 2.1.0) (Ågren et al. 2012) was used to compare the 
gene content of E. coli strains. Firstly, all against all fragmented alignment 
of all ExPEC genomes was performed and then used to look for genomic 
regions that are unique for the ST131 genomes. In detail, the fasta files of 
twenty-four ExPEC genomes (Table 4.2) were imported into Gegenees 
database and all against all fragmented alignment of the these genomes 
was performed using BLASTN method. An accurate fragmented alignment 
was achieved by using a fragment size of 200 and a step size of 100. 
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Afterwards, Gegenees alignment was used to identify genomic regions that 
are conserved in a specified target group (ST131 genomes) but not present 
in the background group (non-ST131 genomes). The ST131 JJ1886 
reference genome (Andersen et al. 2013) was defined within the target 
group to provide the genome coordinates required for describing target 
signature and to display signatures along with genome annotation. Finally, 
a pan-genome was created for all ExPEC genomes (Table 4.2) representing 
all sequence material in these genomes. The pan-genome was exhibited by 
fragmenting all genomes and analysing every fragment for similarity to the 
pan-genome, and only unique fragment was added to the pan-genome 
(Ågren et al. 2012). 
4.2.3.4 Core and pan-genome analysis of a group of E. coli ST131 
and non-ST131 genomes using LS-BSR software 
 
Core and pan-genome analysis of all ExPEC genomes listed in Table 4.2 was 
performed using LS-BSR software (Sahl et al. 2014). Firstly, a pan-genome 
for all ExPEC genomes was created by Dr. Alan McNally. Then, the 
“compare_BSR python” script implemented in the LS-BSR package was 
used to identify loci unique to genomes belonging to the ST131 H30Rx 
clade, with the exception of NA114 which has been shown to have known 
H30Rx genes missing from its assembly (Petty et al. 2014). Finally, the 
resulting loci that were only associated with ST131 H30Rx lineage were 
identified by performing BlastX search tool in Artemis against the genome 
of JJ1886 (Andersen et al. 2013). Information on the “compare_BSR 
python” script used to perform this part of study is given in the appendix 
(Chapter 7). 
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4.3 Results 
4.3.1 Metabolic activity of E. coli strains obtained from API test 
reagents 
120 API test reagents were used to perform comparative metabolic profiling 
on twenty-five ST131 and twenty-five non-ST131 strains belonging to the 
four major ExPEC sequence types: ST69, ST73, ST95 and ST10. Figure 4.3 
(A-D) shows a comparison of results obtained from 89 API biochemical tests 
for all the fifty E. coli ST131 and non-ST131 strains. All E. coli strains were 
positive for utilisation of thirty substrates, and negative for forty-three 
others, with variations between STs in terms of their capability of utilising 
the remaining forty-seven substrates. Examples of these differences were 
ST69 that was completely unable to utilise ODC, ST10 that was unable to 
utilise SBE and ST95 that was also unable to utilise SAC. 
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Figure 4.3 (A-D): Four heat maps show a comparison of results obtained from 89 
carbon sources for E. coli ST131 and four major E. coli STs. Darker shaded areas 
indicate higher percentage of strains under each ST that tested positive for each 
phenotype. Red circle in the heat map (A) showed the substrates that were under-
utilised by ST131 strains. 
 
C 
D 
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ST131 strains exhibited an inability to utilise five tested substrates: 5-keto-
D-gluconate (5KG), D-Arabinose (DARA), esculin (ESC), cellobiose (CEL) 
and dulcitol (DUL) (Figure 4.3 A), in comparison to other ST strains. With 
regard to 5KG utilisation, only 2 of the 25 ST131 strains (8%) were able to 
utilise this substrate, whilst the utilisation percentages for ST69, ST73, 
S795 and ST10 strains were 100%, 85%, 57% and 75%, respectively. 
Additionally ST131 strains exhibited poor DARA utilisation compared to 
other ST strains. Only 20% of ST131 strains were able to utilise this 
substrate compared to 100% for ST69 strains, 85% for ST73 strains, 100% 
for ST95 strains and 75% for ST10 strains. Similarly dulcitol utilisation 
percentage for ST131 strains was 36% compared to 100% for ST69 strains, 
85% for ST73 strains, 71% for ST95 strains and 75% for ST10 strains. The 
capability of ST131 strains to utilise esculin was 24% compared to 42% for 
ST69, 100% for ST73, 57% for ST95 and 100% for ST10 strains. The 
cellobiose utilisation percentage for ST131 strains was 0% compared to 
42% for ST69 strains, 42% for ST73 strains, 28% for ST95 strains and 50% 
for ST10 strains. 
 
ST131 strains did not show higher metabolic activity for any biochemical 
substrate tested when compared to other ST strains, which is in contrast to 
the previous study (Gibreel et al. 2012a). The ability of ST131 to utilise 
substrates for which it was more active in that study, such as ODC, βGUR 
and SAC, was not higher using API methodology, while some other 
substrates do not appear in the API substrate panel.  
 
 
 
Comparative studies on the metabolic potential and gene content of a group of E. coli ST131 and non-
ST131 strains 
 130 
4.3.2 Phenotypic Microarray data 
4.3.2.1 Choosing the signal value calculation approach for the PM 
data analysis 
 
An example of the current phenotypic microarray data set showing a 
comparison between the kinetic plots of the ST131 strain UTI226, and the 
ST73 strain, CFT073 is given in Figure 4.4. Considering for instance the H05 
well, there was a very low signal produced by the strains, which might 
reflect slight utilisation ability, but it was difficult to differentiate it from the 
background signal. This explains the reason behind the importance of 
subtracting the negative control signal value for each PM plate. 
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Figure 4.4: Example for utilisation of carbon sources in UTI226 and CFT073. A01 
is negative control. Overlapping curves are shown in yellow. UTI226 is shown in 
green, CFT073 is shown in red. 
 
In addition the curves also showed very different shapes. Some curves 
showed a steady rise from the start of cell respiration such as well G06, 
while others showed a quick rise such as well D01. Thus it was important 
to determine a way by which we can compare these curves and then to 
study the difference between them. Different approaches have been used 
for the analysis of PM data. For example, using the area under curve is a 
useful tool in comparing two utilisation curves (Vaas et al. 2012). However 
this could not be used in some cases such as in wells G04 and E08, where 
one strain utilised the substrate earlier while the other utilised it to a higher 
degree. In addition the measurement of the endpoint of the curve is also 
widely used for PM data analysis and it only gives a signal in the last hours 
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(Lay Jr et al. 2006), but this approach does not allow for obtaining a valid 
comparison between strain curves such as in well G04, where they almost 
have the same endpoint but their progression is completely different. For 
PM data analysis in our study, we chose an approach that depends on 
calculating the signal value to measure and compare the metabolism of 
strains (Homann et al. 2005). Firstly, the data was exported from the Biolog 
File Manager. Then, the average height and maximum height over 48h and 
the average height over 2h were extracted. The background control was 
then subtracted for each PM plate. The signal value was calculated using 
the following formula: Signal value = [(Average signal over 48h + 
maximum signal over 48h) /2] – average signal over 2h. This was done to 
firstly correct the average height for later data points, to take the 
progression of the curve into account and to reduce any background 
signals; therefore, a single number can therefore reflect the time course of 
metabolism.  
4.3.2.2 Metabolic activity of E. coli strains obtained from PM  
 
In light of the contrasting results above with a previous study showing an 
enhanced metabolic function for ST131 compared to non-ST131 (Gibreel et 
al. 2012a), we utilised the superior discriminatory power of the phenotypic 
microarray assay to fully characterise the metabolic capacity of five E. coli 
ST131 and five non-131 strains. The PM data showed that all the tested 
strains were positive for utilisation of seventy-nine carbon sources, and 
negative for thirty-six carbon sources, with variations between STs in terms 
of their capability of utilising the remaining seventy-three carbon sources. 
Among all tested strains, the ST95 strain UTI89 was the highest in terms 
of the metabolic activity, while the ST10 strain P5B had the lowest 
Comparative studies on the metabolic potential and gene content of a group of E. coli ST131 and non-
ST131 strains 
 133 
metabolic capacity. Figure 4.5 shows a heat map for all metabolites tested, 
with values corresponding to the intensity of utilisation for the different 
nutrient sources. There were very few detectable differences in the 
metabolic capacity between ST131 and other ST strains for the majority of 
tested carbon sources. As with the commercial test reagents there were 
some strain-specific differences in metabolite utilisation but these were not 
consistent in either ST131 or non-ST131 groups, and ST131 strains were 
not associated with a specific metabolic profile (Figure 4.5). 
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Figure 4.5: A cluster heat map showing the signal values of E. coli ST131 and non-
ST131 strains obtained from 190 biochemical tests using PM assay, with red 
showing no utilisation through to green showing high levels of utilisation. A UPGMA 
dendrogram informed by the metabolic profile is presented above the heat map. 
The ST131 strains are represented by red blocks and the non-ST131 strains by blue 
blocks. 
 
Considering the metabolic activity of CTX-M-15 producing ST131 strains, 
UTI32 showed a slightly higher metabolic potential in comparison to other 
ST131 strains. It was the only strain to utilise malonic acid and L-
phenylalanine, and its signal values were the highest for a range of 
substrates such as M-inositol, palatinose, D-tagatose, N-acetyl-L-glutamic 
acid, L-histidine and putrescine compared to the rest of ST131 strains. In 
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contrast, it was the only E. coli strain that was unable to utilise N-acetyl-D-
galactosamine, and its signal values for D-raffinose and L-malic acid were 
lower than that of all other tested ST131 and non-ST131 strains. UTI587 
showed a lower capacity of utilising the following substrates: dulcitol, 
glycyl-L-glutamic acid, 3-0-b-d-galacto-pyranosyl and melibionic acid. 
Additionally, the UTI18 strain had the lowest signal value for α-Keto-butyric 
acid substrate among the tested ST131 strains.  
 
However the ST131 CTX-M-15 negative strain UTI226 had the highest 
metabolic activity among the tested ST131 strains for pyroglutamic acid, 
chondroitin sulfate c, β-cyclodextin, amygadin and gentiobiose carbon 
sources. In contrast, it had the lowest ability to utilise β-hydroxy-butyric 
acid compared to other ST131 strains. Taken together, our data is strongly 
indicative that ESBL gene carriage is not associated with a specific 
metabolic activity profile within the ST131 strains, and that variation is on 
a more generic strain to strain level.  
 
With respect to the metabolic activity of non-ST131 strains, UTI89 exhibited 
an increased ability to metabolise some carbon sources compared to other 
strains, and was the only strain capable of utilising thirteen carbon sources 
such as tyramine, gelatin, xylitol, G-amino-butyric acid and D, L-
octopamine. Additionally, the signal values of UTI89 were higher than that 
of other strains for D-Arabitol, L-Arabitol and 3-methyl glucose. However 
the ST10 strain P5B was of low metabolic capacity compared to all other 
ST131 and non-ST131 strains. This was shown by its inability to utilise 102 
out of the 188 carbon sources used in the PM plates. The ST73 strain 
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CFT073 was also unable to utilise 101 out of the 188 carbon sources, and 
it was also exclusively incapable of metabolising three carbon sources.  
 
In short, although there were some differences in the metabolic potential 
between strains, these differences were very much strain-specific and were 
not detected at a sequence type level. The generation of a UPGMA 
dendrogram based on utilisation of metabolites confirmed this, with the 
ST131 and non-ST131 strains equally dispersed throughout the 
dendrogram (see Figure 4.5), providing strong evidence that ST131 are not 
a metabolically distinct group of ExPEC strains. Table 4.3 shows a summary 
of the strain-specific differences in the metabolic activity of the ST131 and 
non-ST131 strains as obtained by our PM analysis. 
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Table 4.3: Summary of the strain-specific differences in the metabolic 
activity of the ST131 and non-ST131 strains as obtained by our PM analysis. 
 
Strain  ST Exclusive positive tests Exclusive negative tests 
CFT073 ST73 None 
 
Tween 40 
Mono methyl succinate 
L-lyxose 
 
P5B ST10 None α-keto-glutaric acid 
 
UTI89 ST95 Tyramine 
b-Phenylethylamine 
Gelatine 
Glycogen 
Inulin 
D-fucose 
3-methyl glucose 
Xylitol  
G-amino-butyric acid  
Quinic acid 
4-Hydroxy-L-Proline 
L-Ornithine  
D, L-Octopamine 
 
None  
UTI396 ST393 None None 
 
UTI501 ST69 None L-galactonic acid -g-lactone 
Succinamic acid 
 
UTI18 ST131 None None 
 
UTI32 ST131 Malonic acid  
L-phenylalanine 
 
N-acetyl-D-galactosamine 
UTI226 ST131 None None 
 
UTI570 ST131 None None 
 
UTI587 ST131 None None 
 
4.3.2.3 Principal component analysis of PM data  
 
To further confirm that ST131 are not a metabolically distinct group of 
ExPEC strains, we performed principal component analysis (PCA) on the 
phenotypic microarray metabolic profile data set. PCA is a technique, which 
uses sophisticated mathematical principles to transform a number of 
possibly correlated variables into a smaller number of variables called 
principal components (Richardson 2009). The PCA1/PCA2 plot (Figure 4.6) 
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shows clearly that ST131 strains are not grouped based on metabolic 
properties, but rather are dispersed throughout the PCA plot amongst the 
non-ST131 strains. In conjunction with the heat-map based dendrogram 
our data provides strong evidence that E. coli ST131 are not a metabolically 
distinct clade of ExPEC. 
 
Figure 4.6: Principal component analysis for metabolic profiles obtained from an 
analysis of the phenotypic microarray data set. The ST131 strains are denoted by 
red blocks and the non-ST131 strains by blue blocks. 
 
4.3.2.4 Differences in the carbon source utilisation by ST131 strains 
obtained from using two measurement methods 
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Since some carbon sources that are included in API test panels are also 
present in the PM plates, we sought to determine if there is a difference in 
the capacity of ST131 strains to utilise these carbon sources as a result of 
using two different testing methodologies. The capacity of ST131 strains to 
utilise twelve carbon sources that are available in API test panels and in PM 
plates were compared, and the data showed a similar utilisation capacity of 
these strains in 9 out of 11 carbon sources (Table 4.4). All the ST131 strains 
were able to metabolise 6 out of 11 carbon sources, while all ST131 strains 
were unable to metabolise the remaining three carbon sources: inulin, 
gelatine and D-Arabitol. However there were few detectable differences 
between strains in the utilisation of 2 carbon sources: cellobiose and 
dulcitol. As mentioned earlier, our metabolic profiling data using API 
method found that the ST131 strains had the lowest capacity to utilise these 
substrates. The PM data showed that all but one ST131 strains were able 
to utilise cellobiose, which is in contrast to metabolic profiling data. 
Additionally, PM data found that ST131 strains were capable of utilising 
dulcitol to a higher level than that in API method.  
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Table 4.4: Comparison of sugar utilisation results of ST131 strains 
obtained from using two testing methods. 
 
Test Biotyping result PM result  Agreement 
Glucose + +  Yes 
Sucrose + + Yes 
L-Rhamnose + + Yes 
Cellobiose - + (expect in one 
ST131 strain) 
No 
D-Xylose + + Yes 
D-Mannitol + + Yes 
Dulcitol ST131 had the lowest 
utilisation capacity 
among other STs 
ST131 strains had a 
low utilisation capacity 
but higher than that 
of biotyping  
No 
L-Fucose + + Yes 
Inulin - - Yes 
Gelatine - - Yes 
D-Arabitol - - Yes 
 
4.3.2.5 Relating the metabolism observations to the 
presence/absence of ST131 associated metabolic loci 
 
Given that the vast majority of the strains analysed by phenotypic 
microarray in our study have been genome sequenced (Clark et al. 2012, 
McNally et al. 2013b), we sought to further confirm our metabolism 
observations by correlating them to gene presence/absence data at a whole 
genome level. We adapted an approach recently used to successfully 
identify clade-specific metabolic functions in Campylobacter (Sheppard et 
al. 2013) by constructing an ST131 core genome and then comparing this 
against the CFT073, UTI89, and P5B genomes using ACT (Carver et al. 
2005), concentrating on genes and operons with predicted or confirmed 
metabolic functions.  
 
We found only 3 differences in the idn, ydd, and asc operons, which we 
have previously reported (Clark et al. 2012). These three operons are 
involved in utilisation of two of the five metabolites (5KG and cellobiose) 
identified as being under-utilised in ST131 strains by API test panels. The 
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idn operon is a subsidiary pathway for the gntII gluconate metabolism 
system, and the yddA and yddB genes are transporters for the gntI 
gluconate system, whilst the asc operon encodes a combined 
arbutin/salicin/cellobiose uptake and metabolism pathway. Figure 4.7 
shows ACT comparisons of the three loci from CFT073 and the core ST131 
genome. Gene content differences relating to the other three differential 
metabolites could not be found. Therefore, our data suggests that presence 
or absence of loci does not correlate well with metabolic profile. This 
indicates that the subtle differences that have been observed in metabolism 
of substrates in ST131 compared to other ExPEC STs may not be clearly 
distinguishable at a genome level and may be down to discreet mutations 
in other upstream or downstream metabolic pathways which then impinge 
on metabolism of the identified differential substrate. 
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Figure 4.7 (A-C): ACT comparisons of the (A) idn (B) ydd and (C) asc loci from 
CFT073 and the core ST131 genome.  
 
A 
B 
C 
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4.3.3 Gene content analysis of E. coli strains 
4.3.3.1 E. coli ST131 genome re-assembly data 
 
The whole genome sequences for nine E. coli ST131 strains (Clark et al. 
2012) were re-assembled using Velvet (Zerbino and Birney 2008) and 
PAGIT (Swain et al. 2012) in order to improve the quality of ST131 genome 
assemblies prior to using them in the gene content analysis. Our final 
genome assembly data showed that the size of all ST131 genomes ranged 
from 5Mbp to 5.5Mbp (Table 4.5). Additionally, the number of contigs of 
ST131 genomes ranged from 57 to 787 contigs, while the N50 values of 
these contigs ranged from 10987 to 191894bp (Table 4.5).  
 
Table 4.5: Final genome assembly statistics for the nine E. coli ST131 
strains genomes used in this study. 
 
Strain ID Sequencing 
platform 
Total contig 
length (bp) 
N50 of contigs 
(bp) 
Number of 
contigs 
UTI18 lllumina  
454 
5150118 14394 592 
UTI24 lllumina  5272012 95669 144 
UTI32 lllumina  5203330 119581 110 
UTI62 lllumina  5307017 50730 229 
UTI188 lllumina  5182230 12544 657 
UTI266 lllumina  4958223 191894 57 
UTI306 lllumina  5292101 122653 112 
UTI423 lllumina  5262577 10987 787 
UTI587 lllumina  5454260 13172 691 
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4.3.3.2 Comparative genome analysis of E. coli strains using 
Gegenees software 
 
In order to examine and compare a collection of ExPEC genomes including 
ST131 and non-ST131 (Table 4.2), Gegenees software (Ågren et al. 2012) 
was used. The overall relationship between the ExPEC genomes based on 
performing all against all fragmented alignment was determined and shown 
in Figure 4.8. For the twelve ST131 genomes, the data demonstrated a high 
average similarity between them ranging from 85% to 99%. Similarly, the 
average similarity between the twelve non-ST131 genomes was high and it 
ranged from 80% to 99%. However our data shows the presence of some 
differences in the average similarity between genomes when compared with 
each others (Figure 4.8). For example when the UTI18 genome was 
compared with the UTI32 genome, the heat plot shows different average 
similarity between these strains. The average similarity between UTI18 and 
UTI32 was 93% while it was 94% when the UTI32 genome was compared 
with the UTI18 genome. This might indicate the presence of limitations in 
Gegenees software and call into question its reliability as a tool for 
comparative genome analysis. 
 
A phylogenomic overview of the average similarity between genomes in the 
alignment was also visualised in a heat-plot (Figure 4.8). All ST131 
genomes were grouped together at the top of the heat-plot. The non-ST131 
genomes were phylogenomically grouped together at the bottom of the 
heat-plot. Additionally, the heat-plot showed a further subgrouping for non-
ST131 genomes belonging to particular STs and this was observed for the 
four genomes belonging to ST73 (E. coli CFT073, E. coli ABU89372, E. coli 
Di12 and E. coli Di14), the four genomes belonging to ST95 (E. coli S88, E. 
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coli APEC01, E. coli UTI89 and E. coli IHE3034) and the two genomes 
belonging to ST135 (E. coli LF82 and E. coli NRG857c).  
Figure 4.8: A heat-plot showing the average similarity between ST131 and non-
ST131 genomes, based on a fragmented alignment using BLASTN made with 
settings 200/100 and using the default cut-off threshold for non-conserved 
material. Phylogenomic grouping for the ExPEC genomes is represented on the left 
of the heat-plot and the ST131 genome ID was shown in green while the non-
ST131 genome ID was shown in red.  
  
A Gegenees alignment for the ExPEC genomes was then mined to determine 
the unique regions associated only with ST131 genomes. The basis for the 
signature analysis was to compare the conservation pattern between the 
target (ST131) and background (non-ST131) groups for every fragment 
from the selected reference genome. All fragments were then given a 
biomarker score that can be plotted along the reference genome (Ågren et 
al. 2012). In order to obtain the stringent form of the biomarker score, a 
fragment’s maximum score against the background group (worst false 
positive) was divided by the minimum BLAST score against the target group 
genomes (worst false negative) and finally subtracted from 1 to yield a 
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value ranging from 1 (perfect conservation and no cross-reaction) to -∞ 
(Ågren et al. 2012). Prior to performing signature analysis in Gegenees, 
ST131 genomes were selected as a target group, non-ST131 genomes were 
selected as a background group, and the ST131 JJ1886 genome was used 
as a reference genome. Figure 4.9 shows a signature analysis of the target 
group (ST131 genomes) using two stringent forms of biomarker score: 
(maximum/minimum) that showed only the fully unique regions for the 
target group and (maximum/average) that showed regions in the signature 
which might be absent or less conserved in a portion of the target group. 
Interestingly, our data demonstrated the presence of few regions unique to 
ST131, and the green lines in the tubular view were indicative of this 
observation (Figure 4.9).  
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Figure 4.9: A tubular view showing the signature analysis of ST131 genomes. A 
fragmented alignment was firstly performed with 200/100 settings using BLASTN 
(BLAST+). Target group was defined to include the ST131 genomes and the 
background group was defined to include the non-ST131 genomes. The “maximum 
background/minimum target” and “maximum background/average target” settings 
were used for biomarker score calculation. The ST131 genome JJ1886 was used as 
a reference genome. Scale bar represents the size of the reference genome. The 
colour bar represents the biomarker score values where 1 is the highest biomarker 
score value and shown by green colour and 0 is the lowest biomarker score value 
and shown by red colour. 
 
Afterwards, a pan-genome for all the twenty-four ExPEC strains was created 
representing all sequence material of the ExPEC strains. The pan-genome 
statistics showed that it contained 43871 fragments and 8774200 
nucleotides. Figure 4.10 shows the pan-genome created for the ExPEC 
strains. The horizontal black line represents the pan-genome, while the 
vertical lines crossing it separate the sub-sequences of the pan-genome. 
The horizontal lines below the pan-genome line represent the genomes 
used in the analysis. If a fragment of the pan-genome is similar enough 
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(i.e. a BLAST score over the draw parameter, which was adjusted to 0.99) 
to a genome, Gegenees draws a dot over the genome. Several dots in a 
row become a peak. The colour of the peak indicates the mean distance 
over the draw parameter for all fragments represented by that peak. Thus, 
green peaks represent the similarity of the fragments between the strains 
and the pan-genome. The pan-genome viewer (Figure 4.10) showed that 
the core genome of ST131 strains formed more than 50% of overall size of 
the pan-genome. Additionally, comparing the similarity peaks of ExPEC 
genomes showed the presence of different gene content of ST131 compared 
to that of non-ST131.  
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Figure 4.10: A pan-genome viewer showing the pan-genome created for the 24 
ExPEC strains. The horizontal black line at the top represents the pan-genome while 
the vertical lines crossing it separate the sub-sequences of the pan-genome. The 
horizontal lines below the pan-genome line represent the genomes used in the 
analysis. The draw parameter used in this run was 0.99. 
 
4.3.3.3 Identification of genetic loci unique to the E. coli ST131 
H30Rx clade as shown by pan-genome analysis  
 
Given the focus on virulence-associated genes in previous gene content 
studies (Petty et al. 2014), and on the basis of our aforementioned findings 
obtained from using Gegenees showing the presence of some regions 
unique to ST131 H30Rx strains as well as a different gene content of these 
strains, this study aimed to determine genetic loci unique to ST131 H30Rx 
strains without bias for functionality of the encoding loci. An ExPEC pan-
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genome was constructed using the blast-score ratio method implemented 
in LS-BSR (Sahl et al. 2014) containing twelve ST131 genomes and all 
available non-ST131 reference genome sequences (Table 4.2). Using the 
resulting pan-genome matrix, the genetic loci uniquely associated with the 
ST131 group were determined versus the non-ST131 group using the 
compare_BSR python script implemented in the LS-BSR package. To define 
the ST131 group, the genome of NA114 was excluded on the basis that 
previous work has suggested the methodology used to assemble the 
genome has resulted in regions missing from that genome which are 
present in all other H30Rx strains (Petty et al. 2014). The analysis was 
performed with SE15 as a non-ST131 H30Rx strain to determine loci unique 
to the H30Rx clade to which SE15 does not belong (McNally et al. 2013b, 
Petty et al. 2014). The resulting data set identified a total of 150 loci unique 
to ST131 H30Rx strains in comparison to other ExPEC (Table 4.6), 
dominated by three phages common across the lineage which have most 
probably been acquired by the common ancestral H30Rx progenitor and 
then maintained in the lineage.  
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Table 4.6: List of loci identified as unique to E. coli ST131 H30Rx strains 
by our pan-genome analysis. 
 
Locus label Gene product Accession number 
centroid_24082 Flagellar export protein (FliJ) YP_ 006137319.1 
centroid_24111 Flagellar basal body-associated 
protein (FliL) 
YP_006137345.1 
centroid_15348 Hypothetical protein YP_006141838.1 
centroid_31178 Hypothetical protein YP_006140981.1 
centroid_15320 Hypothetical protein YP_006139096.1 
centroid_16303 Putative TRAP-type transport 
system 
YP_006140118.1 
centroid_20468 Putative phage tail protein PTP YP_006139077.1 
centroid_37714 Hypothetical protein YP_003348574.1 
centroid_21100 Hypothetical protein YP_006139841.1 
centroid_92180 Hypothetical protein YP_006138463.1 
centroid_32019 Hypothetical protein YP_006138454.1 
centroid_34817 Hypothetical protein YP_002293511.1 
centroid_92780 Hypothetical protein YP_006139086.1 
centroid_29292 Hypothetical protein YP_006138557.1 
centroid_32007 Hypothetical protein YP_006138465.1 
centroid_82289 Putative altronate hydrolyse (PAH) YP_006137747.1 
centroid_24504 Putative altronate hydrolyse (PAH) YP_006137748.1 
centroid_24000 Putative fimbrial usher protein 
(PFUP) 
YP_006137236.1 
centroid_35546 Sucrose operon repressor (SOR) YP_670644.1 
centroid_69872 Glycosyl hydrolase, Sucrose-6-
phosphate hydrolase  (S-6-PH) 
YP_006139921.1 
centroid_71285 Putative manganese transporter 
protein (mntH) 
YP_006141326.1 
centroid_18755 Flagellar hook protein (FliD) YP_006137341.1 
centroid_29649 Hypothetical protein YP_006138914.1 
centroid_82164 Transketolase C-terminal subunit YP_006137619.1 
centroid_23066 Ribose ABC transport ATP-binding 
component 
YP_006137615.1 
centroid_39946 Putative baseplate phage assembly 
protein (PBAP) 
YP_006139083.1 
centroid_33272 Hypothetical protein YP_006137366.1 
centroid_39971 Hypothetical protein YP_008722088.1 
centroid_67103 Hypothetical protein YP_006137152.1 
centroid_23723 Hypothetical protein YP_006137366.1 
centroid_19102 Flagellar motor protein (motA) YP_001742390.1 
centroid_92163 Hypothetical protein YP_008721382.1 
centroid_30405 Hypothetical protein YP_008723083.1 
centroid_239 Flagellar assembly protein (FliH) CP006784.1 
centroid_82288 3-oxoacyl-ACP reductase (OAR) YP_006137746.1 
centroid_67710 Putative demethylmenaquinone 
methyltransferase (PDM) 
YP_006137744.1 
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Locus label Gene product Accession number 
centroid_25685 Hypothetical protein YP_006139098.1 
centroid_83611 Hypothetical protein YP_006141849.1 
centroid_25661 Hypothetical protein YP_006139076.1 
centroid_29383 Hypothetical protein YP_002292777.1 
centroid_68972 Hypothetical protein WP_001554155.1 
centroid_34308 Hypothetical protein WP_001531630.1 
centroid_39984 Hypothetical protein YP_008722100.1 
centroid_3465 Putative phage DNA-packaging 
protein (Phage DNA-PP) 
YP_006139087.1 
centroid_91089 Flagellar protein (FliS) YP_006137342.1 
centroid_42743 Hypothetical protein YP_006138449.1 
centroid_4705 Hypothetical protein YP_006137153.1 
centroid_19083 Flagellar basal body rod protein 
(FlgC) 
YP_001726316.1 
centroid_29752 Putative bacteriophage lambda 
head decoration protein (BLHDP) 
YP_006139089.1 
centroid_11234 Putative DNA-binding protein 
(DNA-BP) 
YP_006140930.1 
centroid_24109 Hypothetical protein YP_006137343.1 
centroid_14081 Flagellar motor switch protein 
(FliN) 
YP_006167278.1 
centroid_34813 Hypothetical protein YP_006139097.1 
centroid_33222 Flagellar-hook basal body complex 
protein (FliE) 
YP_006137314.1 
centroid_34291 Hypothetical protein YP_006138445.1 
centroid_22108 Putative permease YP_006140852.1 
centroid_10576 Putative replication protein P 
(PRPP) 
YP_006141845.1 
centroid_18855 Putative transport protein (PTP) YP_006137103.1 
centroid_34792 Putative phage tail sheath protein 
(PPTSP) 
YP_006139078.1 
centroid_8361 Hypothetical protein YP_003348575.1 
centroid_33515 Lateral flagellar chaperon protein 
(FlgN) 
YP_008720325.1 
centroid_3436 HP YP_006141842.1 
centroid_91474 Putative transcriptional regulator 
(PTR) 
YP_006137743.1 
centroid_32613 Hypothetical protein YP_001742765.1 
centroid_67290 Putative lateral flagellar hook 
assembly protein (FlgD) 
YP_006137328.1 
centroid_18750 Putative RNA polymerase sigma 
factor for flagellar operon (FliA) 
YP_006137346.1 
centroid_6096 Hypothetical protein YP_006139085.1 
centroid_39980 Putative replication protein (PRP) YP_006141844.1 
centroid_16833 Hypothetical protein YP_006140650.1 
centroid_37776   Ribose ABC transporter ATP-
binding component (Ribose ATP-
bind co) 
YP_006137613.1 
centroid_29736 Hypothetical protein YP_006139074.1 
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Locus label Gene product Accession number 
centroid_24127 Hypothetical protein YP_003348238.1 
centroid_81857 Putative glycosyltransferase (PGT) YP_006137321.1 
centroid_90982 Putative outer membrane protein 
(omp) 
YP_006137235.1 
centroid_86055 Putative type 1 fimbriae anchoring 
protein (fimD) 
YP_006141432.1 
centroid_92998 Putative molybdate metabolism 
regulator (PMMR) 
YP_006139310.1 
centroid_29737 Hypothetical protein YP_008722053.1 
centroid_33503 Flagellar M-ring protein (FliF) YP_006137315.1 
centroid_3844 Putative oxidoreductase (ORD) YP_006137610.1 
centroid_24075 Putative Flagellar motor switch 
protein (FliM) 
YP_006137311.1 
centroid_9932 Hypothetical protein YP_006138455.1 
centroid_27155 Putative transcriptional regulator 
(PTR) 
YP_006140851.1 
centroid_67711 Alcohol dehydrogenase (ADH) YP_006137745.1 
centroid_9922 Hypothetical protein YP_006138446.1 
centroid_17334 Hypothetical protein YP_006141106.1 
centroid_18765 Flagellar basal-body rod protein 
(FlgF) 
YP_006137331.1 
centroid_82304 Transcriptional regulator of 
succinyl CoA synthetase operon 
(TRSCoA) 
YP_006137761.1 
centroid_27365 Hypothetical protein YP_006141053.1 
centroid_69020 Adenylosuccinate synthase (ADSS) YP_006141843.1 
centroid_14918 AraC family transcriptional 
regulator (AraC) 
WP_001296050.1 
centroid_19090 Hypothetical protein YP_006137335.1 
centroid_20505 Hypothetical protein YP_006141848.1 
centroid_24102 Flagellar hook-associated protein 
(FlgK) 
YP_006137336.1 
centroid_16115 PTS system, sucrose-specific IIBC 
component  
YP_670642.1 
centroid_26480 Maltoporin protein (MPP) YP_006139919.1 
centroid_33398 Putative glycosyl hydrolase (PPH) YP_006137102.1 
centroid_67730 Putative glycosyl hydrolase (PPH) YP_006137763.1 
centroid_2535 Hypothetical protein YP_006140853.1 
centroid_8303 Putative transcriptional regulator 
(PTR) 
YP_006137617.1 
centroid_3845 Putative oxidoreductase (ORD) YP_006137611.1 
centroid_82163 Transketolase N-terminal subunit 
(TK) 
YP_002383623.1 
centroid_68323 Phage integrase YP_006138452.1 
centroid_67582 Ribose ABC transporter permease 
component (RiboseABCTP) 
YP_006137612.1 
centroid_9391 Dihydrodipicolinate synthase 
(DHDPS) 
YP_006137151.1 
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Locus label Gene product Accession number 
centroid_27018 Hypothetical protein YP_006140681.1 
centroid_34807  Hypothetical protein YP_006139092.1 
centroid_29757 Hypothetical protein YP_008722074.1 
centroid_68331 Hypothetical protein YP_006138458.1 
centroid_38627 Hypothetical protein YP_006137364.1 
centroid_15349 Hypothetical protein YP_006141837.1 
centroid_81902 Putative phage integrase (PPI) YP_006137368.1 
centroid_82896 Hypothetical protein YP_003349147.1 
centroid_20507 Hypothetical protein YP_006141846.1 
centroid_9573 Anti-sigma-28 factor (FlgM) YP_006137324.1 
centroid_29781 Hypothetical protein YP_006141840.1 
centroid_19324 Hypothetical protein YP_006137575.1 
centroid_68999 Hypothetical protein YP_008722077.1 
centroid_84549 Fructokinase (FK) YP_003350555.1 
centroid_9611 Hypothetical protein YP_006137365.1 
centroid_34823 Hypothetical protein YP_008722089.1 
centroid_38568 Flagellar biosynthesis protein 
(FlhB) 
YP_006137306.1 
centroid_38574 Hypothetical protein YP_006137313.1 
centroid_82907 Hypothetical protein YP_008721389.1 
centroid_12469  Hypothetical protein YP_006137698.1 
centroid_27243 Hypothetical protein YP_006140929.1 
centroid_245 Hypothetical protein WP_001531418.1 
centroid_10531 Hypothetical protein YP_006139073.1 
centroid_20473 Putative phage baseplate 
assembly protein (PBAP) 
YP_006139081.1 
centroid_23065 Hypothetical protein YP_006137614.1 
centroid_15304 Putative phage tail protein (PTP) YP_006139080.1 
centroid_9128 Transposase IS30 YP_008721392.1 
centroid_68324 Hypothetical protein YP_006138453.1 
centroid_9926 Hypothetical protein YP_003349153.1 
centroid_3468 Hypothetical protein YP_006139084.1 
centroid_36304 Hypothetical protein YP_006140680.1 
centroid_25680 Hypothetical protein YP_008722073.1 
centroid_29782 Hypothetical protein YP_006141839.1 
centroid_81841 Lateral flagellar export/assembly 
protein (FliQ) 
YP_001726334.1 
centroid_42732 Hypothetical protein YP_006138459.1 
centroid_39935 Hypothetical protein YP_008722051.1 
centroid_69012 Hypothetical protein YP_006141850.1 
centroid_29742 Hypothetical protein YP_006139079.1 
centroid_19913 Hypothetical protein YP_006138460.1 
centroid_12407 PTS system, fructose-specific 
IIABC component 
YP_006137762.1 
centroid_6770 Hypothetical protein YP_006139974.1 
centroid_13920 
140 
Hypothetical protein YP_006137154.1 
centroid_23067 Glycerol kinase (GK) YP_006137616.1 
centroid_23136 Chaperone protein (hscC) YP_006137685.1 
centroid_67323 Hypothetical protein YP_006137363.1 
centroid_4877 Flagella basal body P-ring 
formation protein (FlgA) 
YP_008720327.1 
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4.3.3.4 Distribution of functional categories of genes unique to E. 
coli ST131 H30Rx strains 
 
With respect to the distribution of functional categories of genes unique to 
the ST131 H30Rx strains, our analysis showed that hypothetical proteins 
were the dominant functional category and they constituted 52.6% of the 
150 unique genes. Interestingly, the Flag-2 accessory flagella locus genes 
were the second most common functional category and they constituted 
13.3% of the total genes, followed by a small number of metabolic genes 
and they constituted 11.3% of the total 150 genes (Figure 4.11). 
Additionally, we identified a very small set of genes encoding for fimbrial 
proteins, transcriptional regulators, phage proteins and other proteins 
(Figure 4.11). 
 
 
 
Figure 4.11: Distribution of functional categories of genes unique to E. coli ST131 
H30Rx compared to a collection of ExPEC reference genomes. 
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With respect to the flagellar genes, our pan-genome analysis identified the 
presence of 20 flagellar genes (13.3%) unique to the ST131 strains 
belonging to H30Rx (Table 4.7). These genes encode for a second flagellar 
locus (Flag-2 locus) that has also been identified in several bacterial species 
including Vibrio parahaemolyticus (Stewart and McCarter 2003), E. coli 
(Ren et al. 2005), Yersinia enterolitica (Bresolin et al. 2008), Citrobacter 
rodentium (Petty et al. 2010) and Aeromonas hydrophila (Canals et al. 
2006). The vast majority of the Flag-2 genes, such as flhB, fliAJLHSNEFQM 
and flgCNFADKM, are responsible for the synthesis of the flagellar basal 
body and hook. While one gene, the motA gene encoding the H+ motor 
protein A, is involved in motility (Parthasarathy et al. 2007). 
 
Table 4.7: The flagellar genes identified as unique to the ST131 H30Rx 
strains and their products.  
 
Flagellar gene name Gene product 
fliJ Flagellar export protein (FliJ) 
fliL Flagellar basal body-associated protein (FliL) 
fliD Flagellar hook protein (FliD) 
motA Flagellar motor protein (motA) 
fliH Flagellar assembly protein (FliH) 
fliS Flagellar protein (FliS) 
flgC Flagellar basal body rod protein (FlgC) 
fliN Flagellar motor switch protein (FliN) 
fliE Flagellar-hook basal body complex protein (FliE) 
flgN Lateral flagellar chaperon protein (FlgN) 
flgD Putative lateral flagellar hook assembly protein (FlgD) 
fliA Putative RNA polymerase sigma factor for flagellar 
operon (FliA) 
fliF Flagellar M-ring protein (FliF) 
fliM Putative Flagellar motor switch protein (FliM) 
flgF Flagellar basal body rod protein (FlgF) 
flgK Flagellar hook-associated protein (FlgK) 
flhB Flagellar biosynthesis protein (FlhB) 
fliQ Lateral flagellar export/assembly protein (FliQ) 
flgA Flagella basal body P-ring formation protein (FlgA) 
flgM Anti-sigma-28 factor (FlgM) 
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With regard to the presence of Flag-2 locus in E. coli strains, a previous 
whole-genome based study on the enteroaggregative E. coli 042 strain 
demonstrated the presence of Flag-2 locus in this strain, although this locus 
was found to be inactive due to a frameshift mutation in the lfgC gene (flgC 
in other genera and in our data set). This gene encodes for a basal body 
rod protein that is required for protein export through the outer membrane 
(Ren et al. 2005). However some studies have shown the absence of the 
Flag-2 locus in many other E. coli strains. For example, the genome analysis 
of the E. coli K-12 MG1655 strain has found a deletion of a large region 
containing 44 genes encoding for the entire Flag-2 locus (Ren et al. 2005). 
This deletion was also identified in some other commensal, intestinal 
pathogenic and extraintestinal pathogenic E. coli strains (Ren et al. 2005). 
Taken together, these findings suggest that the entire Flag-2 locus was 
originally present in the last common ancestor of the species, which is 
thought to be the enteroaggregative E. coli 042 strain (Ren et al. 2005), 
although the reason of the Flag-2 locus deletion found in many E. coli strains 
remains unknown. The presence or absence of Flag-2 locus in different E. 
coli strains is shown in Table 4.8.  
 
Table 4.8: Summary showing the presence/absence of Flag-2 locus in E. 
coli strains as shown by previous whole-genome sequencing studies (Ren 
et al. 2005). 
 
E. coli strain Pathotype Flag-2 locus 
MG1655 Commensal  Absent 
ATCC 8739 Commensal  Absent 
W3110 Commensal  Absent 
DH10B Commensal Absent 
O157:H7 EDL933 EHEC  Absent 
O157:H7 Sakai EHEC Absent 
042 EAEC Present, but inactive 
E2348/69 EPEC Absent 
CFT073 ExPEC Absent 
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4.4 Discussion 
It has been known that metabolism is an important factor in triggering 
bacterial colonisation in any given environment particularly in animal and 
human hosts (Rohmer et al. 2011). Several studies have demonstrated the 
role of metabolism in enhancing the colonisation and virulence of E. coli. 
For example, a recent study has shown that enterohaemorrhagic E. coli 
(EHEC) uses fucose to modulate its virulence and metabolic genes (Pacheco 
et al. 2012). 
A recent study focussed on the metabolic potential of E. coli ST131, the 
most commonly isolated cause of ExPEC infections worldwide and a recently 
emerged clone of ExPEC associated with multi-drug resistance (Gibreel et 
al. 2012a). The study examined the ability of ST131 drug resistant and 
sensitive isolates to utilise 47 biochemical substrates in comparison to non-
ST131 ExPEC strains, using the Vitek2 Advanced Expert System for 
metabolic profiling. In total 300 UPEC isolates were compared, with the 
study concluding that ST131 isolates have higher metabolic potential in 
comparison to other ST isolates on the basis of their ability to utilise more 
of the substrates than non-ST131 isolates. The study showed a significant 
association between ST131 isolates and utilisation of eight biochemical tests 
including those for peptidase, decarboxylase, and alkalinisation activity. 
Additionally, the study also described a correlation between metabolic 
activity and antibiotic susceptibility profiles, with ESBL carrying, multi-drug 
resistant isolates showing the highest metabolic potential (Gibreel et al. 
2012a). 
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In the study we report here, we tested and compared the metabolic activity 
of a collection of ExPEC strains including ST131 and non-ST131 strains, 
employing another commonly used commercial metabolic profiling system 
(Biomerieux, UK). Our data agrees with that of Gibreel et al. (2012a) in 
that analysis of a limited number of metabolites can produce differential 
profiles for different sequence types. Our study showed reduced metabolic 
capacity of ST69 to utilise ODC, of ST95 to utilise SAC and of ST10 to utilise 
SBE. 
 
With respect to ST131, our data showed lower metabolic activity for five 
substrates, namely 5-keto-D-gluconate (5KG), D-Arabinose (DARA), 
esculin (ESC), cellobiose (CEL) and dulcitol (DUL) in comparison to other 
major ExPEC STs. Some of these findings are in direct agreement with the 
Gibreel study that also demonstrated a significant negative association 
between ST69 and ODC, between ST95 and SAC, and between ST131 and 
5KG (Gibreel et al. 2012a). However the major discussion point of the 
Gibreel study, that ST131 are more metabolically flexible and ‘‘fit’’ is in 
disagreement with the data produced using API biochemical tests. Of the 
Vitek positive association tests which also feature in the API test panel 
(ODC, βGUR and SAC), none showed higher levels of metabolism in ST131 
strains compared to non-ST131 strains. The most likely explanation for this 
is due to differences in the way substrate utilisation is measured between 
the fully automated Vitek system and the API test strip method. The validity 
of this as a potential explanation for the discrepancy is highlighted in this 
study by comparison of our results for some carbon source utilisation in 
ST131 when measured by API and by phenotypic microarray. For example, 
our PM data showed very little difference in dulcitol utilisation between 
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ST131 and other ST strains, in complete contrast to the API data. 
Additionally, our PM data demonstrated that all but one ST131 strains were 
able to utilise cellobiose, which is in opposition to the API data. This is 
almost certainly due to the fact that the PM plates are used to measure 
carbon source oxidation and not sugar fermentation as in the API test 
(Durso et al. 2004). Therefore, we suggest that different utilisation 
capabilities between strains could be observed depending on the principle 
of assay used to determine the metabolic activity. 
Using a total of 47 biochemical tests on 300 UPEC strains, the Gibreel study 
concluded ST131 strains are metabolically more flexible (Gibreel et al. 
2012a). However our data of 120 biochemical tests on 50 strains is 
suggestive of ST131 strains having slightly reduced metabolic potential. In 
an attempt to further determine the metabolic profile of ST131 E. coli 
compared to other ExPEC STs, we compared ten strains, five ST131 and 
five non-ST131 strains, using Biolog phenotypic microarray technology. 
Phenotypic microarrays have been utilised to study the metabolic flexibility 
of various bacterial species (Bochner 2003) and provides the highest level 
of resolution currently available for the metabolic capacity of cells. Heat 
map visualisation of our data indicates there is no distinct metabolic 
signature for E. coli ST131 and that any differences in metabolic repertoire 
are at an individual strain level rather than by sequence type grouping. This 
is further supported by a principal component analysis of the microarray 
data, showing there is no clustering of ST131 based on metabolic 
repertoire. An obvious caveat to our findings is the limited number of strains 
examined. However our comparison is of five ST131 strains, all of which 
have previously been shown to be genetically homogeneous and 
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phylogenetically clustered with the NA114 and EC958 genome sequenced 
strains (Avasthi et al. 2011, Totsika et al. 2011). Therefore, if ST131 were 
a metabolically distinct clade of ExPEC with enhanced metabolic potential 
we would expect to see some form of clustering of our 5 strains by principal 
component analysis of the phenotypic microarray data. 
Given that the genome sequences of almost all of the strains subjected to 
phenotypic microarray are available, we sought to contextualise our 
metabolism findings at a whole genome level. We created an ST131 core 
genome as previously described by our group (McNally et al. 2013b) the 
rationale being that any ST131-discriminating metabolic repertoire would 
have an accompanying genetic signature associated with the ST131 clade. 
This was then compared to the genomes of non-ST131 strains CFT073, 
UTI89, and P5B. Our data failed to uncover any substantial differences in 
the metabolic gene repertoire of ST131 compared to the three other ExPEC 
genomes. However when we focussed on operons responsible for the 5 
discriminatory tests identified by API (5KG, DARA, esculin, cellobiose and 
dulcitol) we could find genetic deletions that would account for only two of 
those phenotypes, in the idn and ydd operons involved in 5KG metabolism 
and the asc operon involved in cellobiose uptake. Our data appears to 
suggest that differences in metabolic repertoire between bacteria cannot 
simply be mapped to genome data and gene presence or absence. It is 
likely that small mutations in pathways complexly linked to the metabolic 
function observed could result in knock on effects which would be extremely 
difficult to pinpoint and associate with the phenotype under investigation. 
It is our opinion that the previous study of E. coli ST131 metabolism 
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performed by Gibreel et al. (2012a) excellently identifies metabolic markers 
that could have enormous importance in rapid identification or selection of 
ST131 isolates in human samples. In our study, we concurred that the use 
of a limited number of biochemical tests can produce differential profiles for 
different sequence types. Our metabolic profiling data using API tests 
supports this as we found clear differences in the metabolic activity between 
ST131 and non-ST131 strains for 5 of 120 biochemical substrates. However 
when we comprehensively tested the global metabolic repertoire of a 
limited number of E. coli strains using the phenotypic microarray system, 
we found no difference in the overall metabolic fitness between ST131 and 
non-ST131 strains. In addition, comparison of genomic data also suggested 
very little difference in the repertoire of metabolic gene loci between ExPEC 
sequence types. 
Our previous work describing the genetic homogeneity of ST131 (Clark et 
al. 2012) combined with the data presented here provide yet another 
confounding hypothesis that E. coli ST131 do not display altered metabolic 
fitness to other closely related ExPEC from a global metabolic and genomic 
perspective. An obvious caveat to both our findings and those of Gibreel et 
al. (2012a) is that different strain sets have been compared using different 
methodologies, and indeed this may be applicable to many of the 
dichotomous results in the literature regarding ST131. We propose that a 
coordinated international effort to fully understand the evolutionary 
mechanisms behind the emergence of E. coli ST131 is now imperative in 
order to combat this most serious of bacterial pandemics, and of future 
episodes of novel E. coli lineage emergence. 
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With regard to the gene content analysis of ST131, recent genomic studies 
have led to a deep understanding of the phylogeography of this lineage of 
ExPEC (Price et al. 2013, Petty et al. 2014) and the discovery of a sub-clade 
of ST131 which is globally dominant and associated with the CTX-M-15 
genotype which has been termed the H30Rx clade (Price et al. 2013). 
Despite these extensive studies, the only efforts at comparative genomics 
of the ST131 lineage have focussed solely on virulence associated genes 
and large mobile genetic elements unique to this lineage, and this was 
achieved by creating a pan-genome for 99 ST131 strains which was then 
compared with other non-ST131 genomes (Petty et al. 2014). Here we 
present an approach where we created an ExPEC pan-genome for 24 ST131 
and non-ST131 strains and then identified loci uniquely associated with the 
ST131 H30Rx clade. 
Firstly, all the E. coli ST131 genomes produced by our group (Clark et al. 
2012) were re-assembled using Velvet and PAGIT assemblers in order to 
improve the quality of ST131 genome assemblies prior to using them in the 
gene content analysis. The genome assembly data identified no difference 
between the size of the ST131 genomes and that of some previously 
published genomes of ST131 strains EC958 and JJ1886 (Totsika et al. 2011, 
Andersen et al. 2013). With respect to comparative genome analysis of a 
group of ST131 and non-ST131 strains, Gegenees software was used to 
perform all against all alignment for these strains in order to determine the 
phylogenomic relationship between these genomes, and our data showed 
that strains belonging to each ExPEC ST are phylogenomically grouped 
together. Mining the Gegenees alignment for E. coli strains identified the 
presence of few unique regions associated only with ST131 genomes. The 
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pan-genome created for all twenty-four ExPEC strains showed the presence 
of different gene content in ST131 compared to non-ST131 genomes.  
 
In order to identify the unique loci associated with ST131 and the functional 
categories they belong to, we present an approach where we created an 
ExPEC pan-genome using LS-BSR and then identified loci uniquely 
associated with the ST131 H30Rx clade. Although the pan-genome analysis 
identified the presence of 150 loci uniquely associated with ST131 H30Rx 
clade, our data is further suggestive that at a gene content level this clade 
is rather unremarkable in comparison to other ExPEC, as recently suggested 
for the clade at a metabolic level (Alqasim et al. 2014a), with the secondary 
flagellar locus Flag-2 the standout region unique to ST131 within ExPEC.  
 
Many previous whole-genome based studies examined the presence of 
Flag-2 locus in E. coli strains, and found that it was present in the 
enteroaggregative E. coli 042 strain although it was inactive due to a 
frameshift mutation in the lfgC gene encoding for a basal body rod protein 
(Ren et al. 2005). However others demonstrated the absence of the Flag-2 
locus in many other E. coli strains such as E. coli K-12 MG1655 as well as 
in some other commensal, intestinal pathogenic and extraintestinal 
pathogenic E. coli strains (Ren et al. 2005). Taken together, these findings 
suggest that the entire Flag-2 locus was originally present in the last 
common ancestor of the species, which is thought to be the 
enteroaggregative E. coli 042 strain (Ren et al. 2005), although the reason 
of the Flag-2 locus deletion found in many E. coli strains remains unknown. 
 
Our analysis showing the unique presence of secondary flagellar locus Flag-
2 loci in the ST131 H30Rx strains corroborates with some previous reports 
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that identified these loci in the ST131 H30Rx clade amongst ExPEC strains 
(Totsika et al. 2011, Clark et al. 2012, Petty et al. 2014). Additionally, it is 
likely that this is ancestral to the ST131 H30Rx clade but its acquisition 
within the larger ST131 lineage is suggestive of a possible role in the 
formation and dissemination of the H30Rx clade and merits a fuller bacterial 
genetics investigation of its importance and role in the H30Rx clade. Given 
the major role of flagella in the pathogenesis of E. coli strains (Haiko and 
Westerlund-Wikström 2013), the possession of functional Flag-2 locus may 
be a key factor for the survival of these strains in specific niches and/or 
hosts (Kirov 2003).  
 
Additionally, our data identified the presence of a small set of metabolic loci 
that confirms our previous finding demonstrating that ST131 H30Rx is not 
a metabolically distinct lineage of ExPEC (Alqasim et al. 2014a). Finally, we 
suggest that a fuller genetic investigation of all of the H30Rx loci identified 
as clade associated may be of merit. A saturated transposon mutant library 
has been constructed in an H30Rx strain and was utilised to determine the 
essential gene set for serum resistance (Phan et al. 2013). Using such a 
library to test a wider set of environmental and infection conditions would 
undoubtedly elucidate if the H30Rx unique loci do indeed play a formative 
role in the success of the lineage. 
4.5 Conclusion  
Given many recent reports showing the variable virulence potential of E. 
coli ST131 strains (Toh et al. 2010, Avasthi et al. 2011, Croxall et al. 2011a, 
Totsika et al. 2011, Gibreel et al. 2012b, Lavigne et al. 2012), and on the 
basis of many previous studies that proposed the association between high 
Comparative studies on the metabolic potential and gene content of a group of E. coli ST131 and non-
ST131 strains 
 166 
metabolic capacity and enhanced bacterial fitness (Le Bouguénec and 
Schouler 2011), this study tested and compared the metabolic activity of a 
collection of ST131 and non-ST131 strains using two different testing 
methodologies: API strips and PM technology. Our API data showed that 
ST131 strains had a lower metabolic activity for 5 substrates, which is in 
contrary to a recent finding by Gibreel et al. (2012a) that showed ST131 
strains with an increased metabolic potential compared to other ExPEC STs. 
Further testing of the metabolic activity of E. coli using phenotypic 
microarray system demonstrated the absence of specific metabolic profile 
for ST131 strains suggesting that ST131 is not a metabolically distinct 
lineage of ExPEC and thus metabolism might not contribute to the fitness 
of this clone.  
We investigated the gene content of a group of E. coli including ST131 and 
non-ST131 strains in order to identify the presence of other loci that are 
uniquely associated with ST131 H30Rx clade. Our gene content analysis of 
E. coli strains performed using Gegenees (Ågren et al. 2012) showed the 
presence of few genetic loci unique to ST131 H30Rx clade. Further 
investigation of these loci using LS-BSR (Sahl et al. 2014) identified the 
presence of 150 loci, the majority of which were hypothetical proteins, 
uniquely associated with this clade. Generally, our data demonstrated that 
this clade is rather unremarkable in terms of its gene content compared to 
other ExPEC. It also identified the presence of a small set of metabolic loci 
that confirms our previous finding demonstrating that ST131 H30Rx is not 
a metabolically distinct lineage of ExPEC (Alqasim et al. 2014a). However 
the most striking finding at a genomic-level was identification of the 
secondary flagellar locus Flag as a region uniquely associated with ST131 
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H30Rx strains (Totsika et al. 2011, Clark et al. 2012, Petty et al. 2014). 
This region merits further detailed bacterial genetics analysis to uncover its 
true importance to the emergence and success of the H30Rx clade.  
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Chapter five 
 
 Comparative studies on the serum resistance and 
capsule genetics of a group of E. coli ST131 and 
non-ST131 strains 
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5.1 Introduction 
ExPEC is a major etiological agent of bloodstream infections (BSIs) (Rogers 
et al. 2011), and it represents 17-37% of total bacteria isolated from 
patients with BSIs (Russo and Johnson 2003). The capability of ExPEC to 
cause these infections in humans can be attributed to the presence of many 
virulence determinants that allow ExPEC to survive in the blood and evade 
the host innate defences (Miajlovic and Smith 2014).  
5.1.1 E. coli resistance to human serum  
The ability to resist the bactericidal activity of serum, and therefore survive 
in the bloodstream, represents a crucial virulence determinant for ExPEC 
strains that cause bacteraemia (McCabe et al. 1978, Martinez et al. 1986, 
Jacobson et al. 1992). It has been suggested that E. coli strains isolated 
from blood are more serum-resistant than those associated with causing 
urinary tract infections or isolated from faecal samples (Johnson 1991, 
Jacobson et al. 1992). E. coli strains use many mechanisms to evade the 
innate defences present in serum including complement and antimicrobial 
peptides (Miajlovic and Smith 2014). For example, the role of cell surface 
polysaccharides, O antigens and K capsules in conferring resistance to 
human serum has been identified (Feingold 1969, Gemski et al. 1980, Opal 
et al. 1982). Other factors such as the major outer membrane protein OmpA 
(Weiser and Gotschlich 1991), plasmid-encoded proteins TraT (Moll et al. 
1980, Montenegro et al. 1985) and Iss (Smith 1974) and the phage 
membrane protein Bor (Barondess and Beckwith 1995), have also been 
reported to contribute to serum resistance in E. coli. Additionally, a recent 
study on the serum resistance of the ExPEC strain E. coli CFT073 has 
identified the role of three extracytoplasmic stress response pathways Rcs, 
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Cpx two-component systems and the alternate sigma factor σE in providing 
protection against the bactericidal effect of serum (Miajlovic et al. 2014). It 
has been reported that the presence of all of these mechanisms in a single 
bacterial strain is not necessarily required to make it serum-resistant since 
the presence of one or more factors can lead to serum resistance in E. coli 
(Cross et al. 1986, Stawski et al. 1990). 
5.1.2 The proposed role of E. coli cell surface polysaccharides in 
serum resistance  
Bacterial lipopolysaccharide (LPS) comprises the highly conserved lipid A-
core and repeating O antigen subunits (Stenutz et al. 2006). More than 180 
distinct O antigen serotypes have been identified for E. coli (Orskov et al. 
1977, Stenutz et al. 2006). ExPEC strains are commonly associated with 
particular O antigen types such as O1, O2, O4, O6, O7, O8, O16, O18, O25, 
and O75 (Totsika et al. 2012). Previous reports proposed the role of O 
antigen in providing protection against serum killing either by activating 
complement away from its target sites on the bacterial outer membrane or 
by blocking antibody-binding sites (Sansano et al. 1985, Johnson 1991). A 
recent study has shown that the surface expression of some O antigen 
types, such as O1, O6 and O18, is important for bacterial survival in human 
serum (Sarkar et al. 2014). 
Exopolysaccharides (EPSs) have a distinct sugar composition and are 
loosely associated with the cell surface (Whitfield 2006). The 
exopolysaccharide colanic acid is regulated by the two-component Rcs 
phosphorelay, and has been associated with biofilm formation and 
protection from desiccation (Clarke 2010). A recent study has shown that 
colanic acid was protective against the bactericidal effect of human serum 
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in the ExPEC strains CFT073 and RS218 (Miajlovic et al. 2014).  
E. coli strains that cause bacteraemia are commonly associated with the 
expression of surface-associated capsule polysaccharide (Miajlovic and 
Smith 2014). Bacterial capsule acts as a barrier protecting the bacterial 
outer membrane from various host defences involving deposition of 
complement factors (Buckles et al. 2009). Capsules frequently contain 
capsular (K) antigen, and like the O antigens, K antigens have a remarkable 
diversity with more than 80 serologically different K antigens identified in 
E. coli (Whitfield 2006). K antigens belong to four distinct groups that are 
defined on the basis of genetic assembly, biochemical and physical 
attributes (Whitfield and Roberts 1999). Although the group I capsules are 
associated with commensal E. coli strains, group II and III capsules are 
associated with ExPEC strains (Johnson and O'Bryan 2004). The group 4 
capsules are frequently identical to that of the cognate lipopolysaccharide 
O side chain and have, therefore, also been called the O-antigen capsule. 
These capsules are associated with strains belonging to some IPEC 
pathotypes such as EPEC (Peleg et al. 2005). Comparison of the capsule 
locus of the ExPEC strain CFT073 with that of other E. coli strains is shown 
in Figure 5.1. 
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Figure 5.1: Schematic representation of the capsule gene cluster of E. coli CFT073 
compared with that of other E. coli strains. The K1 capsule is represented by the 
UTI89 isolate; K5 by the Nissle 1917 isolate and K15 by extraintestinal pathogenic 
E. coli strain 536. Enteroaggregative E. coli (EAEC) isolates Ec042 and 101–1 K 
serotype are also included. The ExPEC strain CP9 K54 group 3 capsule cluster is 
shown for comparison. Blue genes denote region 1; red genes denote region 2 and 
green genes denote region 3 of the kps locus of CFT073 strain [Taken from (Buckles 
et al. 2009)]. 
 
Previous studies demonstrated the role of capsule in protecting ExPEC 
strains from phagocytosis (Howard and Glynn 1971, Weiss et al. 1982, 
Sarkar et al. 2014). However its role in complement-mediated killing is 
unclear. Previous reports investigated the role of many capsule types in 
protecting ExPEC strains from the bactericidal effect of human serum, and 
identified the role of some capsule types such as the K2 capsule of the 
ExPEC strain CFT073 and the K1 capsule associated with other strains 
causing neonatal meningitis in human serum survival (Leying et al. 1990, 
Buckles et al. 2009). However other capsule types such as K27 and K15 
have been found to confer no protective role against serum-mediated killing 
(Opal et al. 1982, Schneider et al. 2004).  
5.1.3 E. coli ST131 resistance to human serum 
The recent emergence of E. coli ST131 as a multi-drug-resistant pathogen 
with an increased capability of causing bloodstream infections (Phan et al. 
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2013) highlights the importance of studying the mechanisms that underpin 
the fitness of this clone at a molecular-level. The combination of next 
generation sequencing and transposon mutagenesis approaches has 
recently been used to study the essential genes required for many bacterial 
species to survive in particular niches (Langridge et al. 2009, Christen et 
al. 2011). For example, Langridge et al. (2009) used the transposon 
directed insertion-site sequencing (TraDIS) method to identify the essential 
genes required for the survival of S. typhi in the presence of bile salts. 
A recent study has used TraDIS to define the essential gene set required 
for growth and survival of the E. coli ST131 strain EC958 in human serum 
(Phan et al. 2013), and identified a set of fifty-six genes required for the 
survival of this strain in human serum. Of these fifty-six genes, twenty-two 
belong to three operons responsible for LPS production (including O25-
antigen biosynthesis and lipid A-core biosynthesis) and enterobacterial 
common antigen (ECA) biosynthesis. The TraDIS screen also identified 
three genes encoding for colanic acid biosynthesis, however K capsular 
biosynthesis genes were not present in the essential gene set (Phan et al. 
2013).  
5.1.4 Genetic and biochemical diversity of E. coli ST131 capsule 
locus 
A recent study has examined the genetic architecture of E. coli ST131 
H30Rx clade strains and has identified a recombinant fragment, encoding 
the group II capsule synthesis locus, common across E. coli ST131, with 
several variant region 2 gene clusters were observed between region 1 
(kpsFEDUCS) and region 3 (kpsTM) of ST131 H30Rx genomes (Petty et al. 
2014). Additionally, although PCR-based methods have identified K2 
Comparative studies on the serum resistance and capsule genetics of a group of E. coli ST131 and 
non-ST131 strains 
 174 
antigen type in E. coli ST131 via using kpsMII primers (Johnson and O'Bryan 
2004, Croxall et al. 2011a), classical capsule typing of a collection of E. coli 
ST131 strains, many of which belong to the H30Rx clade, has shown a high 
degree of diversity in the biochemical profile of K antigens (Olesen et al. 
2013). There were a total of 7 different K antigen types identified within the 
44 E. coli ST131 isolates tested. Indeed, none of the strains biochemically 
tested were identified as K2 but rather as K100 despite testing K2 positive 
by PCR (Olesen et al. 2013). 
5.1.5 Aims of the study 
Since this PhD project mainly aimed to determine the factors that give E. 
coli ST131 clone a competitive fitness advantage over other potential ExPEC 
clones, and given the importance of serum resistance in contributing to the 
virulence of ExPEC strains that cause bacteraemia, we aimed to test and 
compare the ability of a collection of ExPEC strains, including E. coli ST131 
and non-ST131 strains, to resist the bactericidal effect of human serum.  
Additionally, given that some previous studies proposed the important role 
of ExPEC capsular polysaccharides in providing protection against the 
serum-mediated killing, we aimed to examine the capsule region of a 
collection of ExPEC strains, including ST131 and non-ST131 strains, at a 
genomic level in order to identify and compare loci present in the capsule 
region of these strains. Moreover, on the basis of the confusing data 
available to date on the diversity of the capsule locus of E. coli ST131 H30Rx 
clade, we sought to investigate the genetic architecture for the diversity 
observed in the capsule locus of E. coli ST131 strains belonging to the 
H30Rx clade using previously published genomes (Avasthi et al. 2011, 
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Totsika et al. 2011, Clark et al. 2012, Andersen et al. 2013). We also sought 
to investigate the diversity in the biochemical profile of K antigens of these 
strains using the classical capsule typing method (Olesen et al. 2013).  
5.2 Material and Methods 
5.2.1 Bacterial strains 
Forty-two E. coli, twenty E. coli ST131 and twenty E. coli non-ST131 strains, 
were used to carry out the serum resistance assay. The highly invasive 
ST73 strain CFT073 was used as a positive control, while the E. coli K12 
strain MG1655 was used a negative control. Afterwards, nine whole-
genome sequenced E. coli ST131 strains were used to perform the capsule 
production and biofilm formation assays. Of these nine ST131 strains, five 
strains were selected to perform the classical capsule-typing assay 
representing each of the genetic capsule type. Information on E. coli strains 
used in this study is given in Table 5.1. 
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Table 5.1: The characteristics of strains used to perform the experimental 
work in chapter 5. 
 
Strain 
ID 
ST Strain history Sample 
source 
CTX-M 
carriage 
Reference 
E. coli 
CFT073 
ST73 UTI Urine - A 
UTI18 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI32 
 
ST131 Monomicrobial UTI Urine CTX-M-15 A 
UTI62 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI188 
 
ST131 Monomicrobial UTI Urine - A 
UTI226 
 
ST131 Polymicrobial UTI Urine - A  
UTI587 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
B3 ST131 Bacteraemia Blood - B 
B5 ST131 Bacteraemia Blood CTX-M-15 B 
B16 ST131 Bacteraemia Blood CTX-M-15 B 
B22 ST131 Bacteraemia Blood - B 
B37 ST131 Bacteraemia Blood - B 
B44 ST131 Bacteraemia Blood - B 
B64 ST131 Bacteraemia Blood CTX-M-15 B 
B65 ST131 Bacteraemia Blood CTX-M-15 B 
B75 ST131 Bacteraemia Blood CTX-M-15 B 
B89 ST131 Bacteraemia Blood CTX-M-15 B 
U2 ST131 UTI Urine CTX-M-15 B 
U5 ST131 UTI Urine - B 
U12 ST131 UTI Urine CTX-M-15 B 
U79 ST131 UTI Urine CTX-M-15 B 
B12 ST73 Bacteraemia Blood - B 
B14 ST73 Bacteraemia Blood - B 
U1 ST73 UTI Urine - B 
U7 ST73 UTI Urine - B 
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Strain 
ID 
ST Strain history Sample 
source 
CTX-M 
carriage 
Reference 
B31 ST69 Bacteraemia Blood - B 
B33 ST69 Bacteraemia Blood - B 
U64 ST69 UTI Urine - B 
U67 ST69 UTI Urine - B 
UTI89 ST95 Uncomplicated 
cystitis 
Urine - C 
B34 ST95 Bacteraemia Blood - B 
B38 ST95 Bacteraemia Blood - B 
U22 ST95 UTI Urine - B 
U60 ST95 UTI Urine - B 
B9 ST10 Bacteraemia Blood - B 
B20 ST10 Bacteraemia Blood - B 
U19 ST10 UTI Urine - B 
U95 ST10 UTI Urine - B 
U18 ST3451 UTI Urine - B 
U58 ST91 UTI Urine - B 
U104 ST3452 UTI Urine - B 
E. coli 
MG1655 
ST10 na1 na - A  
UTI24 ST131 Monomicrobial 
UTI 
Urine - A 
UTI306 
 
ST131 Polymicrobial UTI Urine CTX-M-15 A 
UTI423 
 
ST131 Polymicrobial UTI Urine - A 
B31 ST69 Bacteraemia Blood - B 
B33 ST69 Bacteraemia Blood - B 
U64 ST69 UTI Urine - B 
U67 ST69 UTI Urine - B 
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UTI89 ST95 Uncomplicated 
cystitis 
Urine - C 
1na: not available; A: (Croxall et al. 2011b); B: (Alhashash et al. 2013); C: (Chen 
et al. 2006b). 
 
5.2.2 Bacterial genome data 
A total of twenty-one publically available ExPEC genome sequences were 
used in this analysis. Of these genome sequences, nine were reference non-
ST131 genome sequences available from National Centre of Biotechnology 
Information (NCBI) website, while twelve were ST131 genomes produced 
during previous studies in our group (Clark et al. 2012, Alqasim et al. 
2014b) and from other sources (Totsika et al. 2011, Andersen et al. 2013). 
Information on genomes used in this study is shown in Table 5.2. 
Table 5.2: List of E. coli genomes involved in capsule genetics work. 
 
Strain ST Pathotype Accession number 
E. coli UTI18 131a ExPEC ERP001095 
E. coli EC958 131b ExPEC CAFL01000001 
E. coli UTI24 131a ExPEC ERP001095 
E. coli UTI32 131a ExPEC ERP001095 
E. coli UTI62 131a ExPEC ERP001095 
E. coli UTI188 131a ExPEC ERP001095 
E. coli UTI226 131a ExPEC ERP001095 
E. coli UTI306 131a ExPEC ERP001095 
E. coli UTI423 131a ExPEC ERP001095 
E. coli UTI587 131a ExPEC ERP001095 
E. coli JJ1886 131 ExPEC CP006784.1 
E. coli JIE168 131 ExPEC ERP001095 
E. coli IHE3034 95 ExPEC CP001969.1 
E. coli UTI89 95 ExPEC CP000243.1 
E. coli S88 95 O45 ExPEC CU928161.2 
E. coli SMS35 8 Multidrug-resistant ExPEC CP000970.1 
E. coli ED1a 452 O81 CU928162.2 
E. coli CFT073 73 ExPEC AE014075.1 
E. coli Di14 73 ExPEC AE014075.1 
E. coli Di12 73 ExPEC CP002211.1 
E. coli CE10 62 K1 ExPEC NC_017646 
a2009 UK ST131 strains; b2004 UK ST131 strain. 
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5.2.3 Identification of capsule loci in E. coli ST131 genomes 
The nine ST131 genomes produced in our group (Clark et al. 2012) were 
re-assembled using the De Bruijn graph-based de novo assembler Velvet 
(Zerbino and Birney 2008) and Post Assembly Genome Improvement 
Toolkit (PAGIT) (Swain et al. 2012). The genome re-assembly method was 
described previously in this thesis (Materials and methods section, chapter 
4). Afterwards, the assembled genomes were then annotated using Prokka 
(Seemann 2014) and the capsule regions written to new embl files using 
Artemis. The capsule encoding regions were visually compared by Dr. Alan 
McNally using Easyfig (Sullivan et al. 2011) and variable genes were 
searched against the non-redundant database by BlastX search. All 
software scripts and command lines used to perform this part of study are 
given in the appendix (Chapter 7). 
5.2.4 Whole genome phylogeny 
This part of study was performed by Dr. Alan McNally. All ST131 genome 
sequences were aligned using Mugsy (Sahl et al. 2011) and the core 
genome extracted using Mothur (Schloss et al. 2009) with the default 
parameters of the methods. Maximum likelihood phylogeny was determined 
using RaxML (Stamatakis et al. 2005) using the rapid bootstrap function 
and the general time reversible (GTR) model with Gamma correction, with 
100 bootstraps performed. The resulting phylogeny was visualised using 
Figtree. All command lines used to perform this part of study are given in 
the appendix (Chapter 7). 
5.2.5 Phenotypic assays 
5.2.5.1 Classical capsule typing 
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Serotyping was done according to the method of Ørskov and Ørskov 
(Orskov and Orskov 1984) at Statens Serum Institute, Denmark using five 
E. coli ST131 strains. The K antigen was determined by countercurrent 
immunoelectrophoresis involving K-specific antisera, except for the K1 and 
K5 antigens, which were detected using K1- and K5-specific bacteriophages 
(Olesen et al. 2013).  
5.2.5.2 Comparative serum resistance assay 
 
Bacterial strains were plated out on LB agar plates and incubated overnight 
at 37oC. A single colony of each strain was inoculated into 5ml of LB broth 
followed by overnight incubation for 18h at 37°C with shaking. Cells were 
harvested by centrifugation at 16000 rcf and resuspended in 1ml of PBS to 
~ 1 x 106 CFU/ml. 0.5ml of diluted bacterial cells was added to 1.5ml of 
undiluted human serum (Sigma Aldrich, UK). Viable cell count (CFU/ml) 
values were obtained immediately after adding the serum (T0) and after 3 
hours of incubation (T3). To assess the levels of serum resistance, the log 
CFU/ml value obtained after T3 was compared with that obtained at T0. The 
serum resistance values were representative values of log CFU/ml at T0 and 
T3 obtained from performing this assay in duplicate on three independent 
occasions. 
5.2.5.3 Capsule production assay 
 
Bacterial strains were grown on LB and CLED media and incubated 
overnight at 37°C and 25°C. Capsule production was determined using a 
scoring system through testing the ability of each strain to form mucoid 
colonies in LB and in CLED agar plates using two incubation temperatures, 
37°C and 25°C. Each strain was tested for its ability to produce capsule in 
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triplicate on three independent occasions. 
5.2.5.4 Biofilm formation assay 
 
Bacterial strains were grown on LB medium and incubated overnight at 
37°C. Then, a single colony of each strain was inoculated into 2ml of LB and 
BHI broth and incubated statically at 37°C for 24h. Bacterial cultures were 
then diluted 1/100 and aliquots of 130μl were placed in a 96-well plate, 
with 5 wells per strain followed by overnight static incubation at 37°C. The 
bacterial growth was estimated by obtaining the OD values at 600nm. Wells 
were washed once using 200μl sterile PBS and stained with 130μl of 1% 
crystal violet solubilised in ethanol for 5 minutes at room temperature 
without shaking. Wells were washed five times using 200μl sterile PBS and 
130μl of absolute ethanol was added to each well followed by incubation for 
5 minutes at room temperature without shaking. Biofilm formation values 
were determined using scoring system and they were representative values 
of measured levels of crystal violet retention as measured at A600 
(Chassaing and Darfeuille-Michaud 2013). Assays were performed in 
triplicate on three independent occasions. 
5.2.6 Statistical analysis for serum resistance data 
The significance of difference in the levels of serum resistance between E. 
coli ST131 and non-ST131 strains was determined using the two-way 
analysis of variance (ANOVA) test available in Prism software (version 
6.0e), and the threshold for statistical significance was a P value of ≤0.05. 
Firstly, the significance of difference in the levels of serum resistance values 
at different time points was determined for each tested strain. Then, group 
analysis was carried out using two-way ANOVA test in order to determine 
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the significance of difference in the levels of serum resistance at different 
time points between ST131 and non-ST131 strains, and between ST131 UTI 
and bacteraemia strains.  
5.3 Results 
5.3.1 Serum resistance profiles of E. coli strains  
Forty-two E. coli strains, twenty E. coli ST131 and twenty E. coli of different 
ST type isolated from urine and blood samples, were tested for their ability 
to resist the human serum. The highly invasive ST73 strain CFT073 was 
used as a positive control, while the E. coli K12 strain MG1655 was used a 
negative control. The data showed that the CFT073 strain was serum-
resistant and this was exhibited by the increase in the log CFU/ml value 
after 3h of incubating the bacterial suspension with human serum compared 
to that at T0, while the MG1655 strain failed to survive in human serum, as 
it did not show any sign of growth on agar plates at T3 (Figure 5.2). 
Additionally, all the twenty E. coli ST131 strains (100%) were associated 
with high serum resistance phenotype, shown by the almost 2-log increase 
in the log/CFU values at T3 compared to that at T0 (Figure 5.1). The data 
also showed that the levels of serum resistance in the E. coli ST131 strains 
isolated from blood were almost similar to those isolated from urine. With 
respect to the E. coli non-ST131 strains, all four E. coli ST73 strains (100%) 
were serum-resistant, while there was variation in the levels of serum 
resistance in the ExPEC strains belonging to other STs such as ST69, ST95 
and ST10. Additionally, three non-ST131 strains U18, U58 and U104 that 
belong to ST3451, ST91, and ST3452 respectively were serum-sensitive 
(Figure 5.2). 
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Figure 5.2: Serum resistance levels of E. coli strains given in log (CFU/ml). These 
values obtained from calculating the average of 3 log (CFU/ml) values for each E. 
coli strain. Blue bars indicate the value of serum resistance at the beginning of the 
assay (T0) and red bars indicate the value of serum resistance after 3h of 
incubation (T3). 
 
In summary, the data showed that all tested E. coli ST131 and ST73 strains 
were highly serum-resistant, and the levels of serum resistance in strains 
belonging to these two STs were higher than that of other E. coli strains of 
different STs (Table 5.3). It also showed that there was variability in the 
levels of serum resistance of strains belonging to other major ExPEC STs 
such as ST69, ST95 and ST10. 
Table 5.3: A summary of serum resistance profiles of E. coli strains 
belonging to different STs. 
 
E. coli ST  Number of 
tested strains 
Number of serum-
resistant strains 
Percentage 
E. coli ST131 20 20 100% 
E. coli ST73 4 4 100% 
E. coli ST69 4 1 25% 
E. coli ST95 5 3 60% 
E. coli ST10 4 1 25% 
E. coli ST3451 1 0 0% 
E. coli ST91 1 0 0% 
E. coli ST3452 1 0 0% 
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5.3.2 Comparative statistical analysis of the serum resistance 
profiles of E. coli strains  
The significance of difference between the levels of serum resistance at T0 
and T3 of each E. coli strain tested in this study was determined using the 
two-way ANOVA test. Firstly, the levels of serum resistance at T0 and T3 of 
each E. coli strain were compared to that of the negative control E. coli 
MG1655 strain. The data showed that there was a statistically significant 
difference between the levels of serum resistance at T0 and T3 for the 
positive control CFT073 strain and for all the twenty ST131 strains (Figure 
5.3A). With respect to the non-ST131 strains, there was also a significant 
difference between the levels of serum resistance at T0 and T3 for the four 
E. coli strains belonging to ST73 (Figure 5.3B). However the difference 
between the levels of serum resistance at different time points for the 
strains belonging to other ExPEC STs was insignificant (Figure 5.3B). The 
graph shows that this insignificant difference is surprising given the 
detectable difference in the levels of serum resistance at different time 
points for some non-ST131 serum-sensitive strains such as U67 and U58. 
This might be explained by the way used by the statistics software to 
calculate the significance of difference in the levels of serum resistance for 
strains at different time points. 
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Figure 5.3 (A-B): Statistical analysis of the levels of serum resistance at T0 and 
T3 for each E. coli strain compared to that of the negative control strain E. coli 
MG1655. (A) The graph shows the significance of difference between the levels of 
serum resistance at T0 and T3 for the positive control strain E. coli CFT073 and the 
20 E. coli ST131 strains as tested by the two-way ANOVA test. (B) The graph shows 
the significance of difference between the levels of serum resistance at T0 and T3 
for the positive control strain E. coli CFT073 and the 20 non-ST131 strains as tested 
by the two-way ANOVA test. The presence of significant difference between the 
levels of serum resistance at T0 and T3 is shown by the asterisks [* (P<0.05), ** 
(P<0.01), *** (P<0.001) and **** (P<0.0001)]. ns means not significant. 
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Afterwards, the significance of difference between the levels of serum 
resistance of E. coli ST131 and non-ST131 strains was determined by a 
group analysis using two-way ANOVA test. Our data showed that the 
difference in the levels of serum resistance at T3 between ST131 and non-
ST131 strains was statically significant (P value < 0.0001), whereas there 
was no significant difference in these levels between ST131 and non-ST131 
strains at T0 (Figure 5.4A). Further group analysis showed that there was 
no statistical difference between ST131 strains isolated from blood and 
ST131 strains isolated from urine in terms of their serum resistance levels 
at T0 and T3 (Figure 5.4B). 
Figure 5.4 (A-B): Serum resistance group analysis performed using the two-way 
ANOVA test. (A) Group analysis showing the significance of difference between the 
levels of serum resistance at T0 and T3 for ST131 and non-ST131 strains as tested 
by the two-way ANOVA test. (B) Group analysis showing the significance of 
difference between the levels of serum resistance at T0 and T3 for ST131 blood 
isolates and ST131 urine isolates as tested by the two-way ANOVA test. The 
presence of significant difference between the levels of serum resistance at T0 and 
T3 is shown by the asterisks [* (P<0.05), ** (P<0.01), *** (P<0.001) and **** 
(P<0.0001)]. ns means not significant. 
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ST131 strains isolated from blood and ST131 strains isolated from urine in 
terms of the serum resistance levels at different time points.  
5.3.3 Identification and comparison of genetic loci present in the 
capsule region of a collection of ExPEC strains 
Given the proposed role of group II capsule polysaccharides of some ExPEC 
strains in conferring resistance the human serum, we examined the capsule 
region of twenty ExPEC strains, including ST131 and non-ST131 (Table 
5.4), at a genomic level to identify and compare genetic loci present in the 
capsule region of these strains. Using Artemis, the capsule region of each 
strain was extracted from each genome and a separate embl file for the 
capsule locus of each strain was created. For all ExPEC strains, twenty-
seven capsule loci, either with known or putative functions, were identified 
in the capsule region. Additionally, there were a number of other loci 
encoding for hypothetical proteins of unknown functions. Table 5.4 shows 
the twenty-seven capsule loci identified for ExPEC strains with their known 
or putative functions. 
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Table 5.4: The capsule loci identified for the twenty ExPEC strains and their 
known or putative functions. 
 
 
Subsequently, the distribution of these twenty-seven capsule loci was 
compared between all strains and our data showed that eight loci were 
found to be present in all ExPEC strains (Figure 5.5). These were the highly 
conserved kps loci, including the region 1 (kpsFEDUCS) and the region 3 
(kpsTM) loci, which encode for the capsule polysaccharides biosynthesis and 
export proteins. However the other nineteen region 2 loci were variably 
distributed among ExPEC strains (Figure 5.5). Although some of these loci, 
such as the neu gene family, were only found to be present in the non-
Locus tag Function 
KpsF Arabinose 5-phosphate isomerase 
KpsE Vi polysaccharide export inner membrane protein 
KpsD Polysialic acid transport protein precursor 
KpsU 3-deoxy-manno-octulosonate cytidylyltransferase 
KpsC Capsule polysaccharide biosynthesis protein 
KpsS Capsule polysaccharide biosynthesis protein 
KpsT Polysialic acid transport ATP-binding protein  
KpsM Polysialic acid transport protein  
HAD superfamily Putative hydrolase 
LPSBP LPS biosynthesis protein 
TagD_2 Glycerol-3-phosphate cytidylyltransferase 
VatD Streptogramin A acetyltransferase 
CBP Capsule biosynthesis phosphatase  
DG1P D-glucose-1-phosphatase 
POLNAT Putative O-linked N-acetylglucosamine 
Transferase 
Ugd_1 UDP-glucose 6-dehydrogenase 
SpsA Pore coat polysaccharide biosynthesis protein  
IspD_2 Putative 2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase 2 
tagB Putative CDP-glycerol:glycerophosphate 
glycerophosphotransferase 
galE_2 UDP-glucose 4-epimerase 
galE_3 
 
UDP-glucose 4-epimerase 
neu family 
neuS 
neuE 
neuC 
neuA 
nueB 
neuD 
- 
Poly-alpha-2, 8 sialosyl sialyltransferase 
Polysialic acid biosynthesis protein  
Polysialic acid biosynthesis protein P7 
Acylneuraminate cytidylyltransferase 
Sialic acid synthase  
Sialic acid synthase  
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ST131 strains, the vast majority of them were found to be only present in 
the ST131 strains belonging to H30Rx clade.  
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Figure 5.5 (A-B): Heat maps showing the distribution of loci identified in the 
capsule region of twenty ExPEC strains including ST131 and non-ST131 strains. 
Red blocks indicate the presence of the loci in the capsule region of each strain, 
while the white blocks indicate the absence of loci in the capsule region of each 
strain. 
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5.3.4 Genetic and biochemical diversity of capsule locus in the E. 
coli ST131 H30Rx clade 
On the basis of our result above showing the presence of several region 2 
loci that were only associated with ST131 H30Rx strains, and given the 
reported variability of capsule loci (Petty et al. 2014) and capsular antigen 
type (Olesen et al. 2013) in E. coli ST131 H30Rx clade strains, these loci 
were investigated in more detail. The recently released JJ1886 genome 
(Andersen et al. 2013) was selected as a reference genome given it is the 
only E. coli ST131 genome sequenced and assembled to a standard of 
quality commensurate with being a high quality genome (Chain et al. 2009). 
Using this reference, the contigs of the ST131 genomes previously reported 
by our group (Clark et al. 2012) were re-ordered to ensure the genome 
architecture was as accurate as possible. The capsule loci of all of the ST131 
genomes were identified and separate embl files for each capsule locus of 
each strain were created which were then compared using Easyfig (Sullivan 
et al. 2011). The comparison of the capsule loci (Figure 5.6) showed a high 
degree of diversity between the conserved kpsFEDUCS and kpsTM regions, 
with no observable similarity between strains in the variable central genes. 
To ascertain how this genetic architecture reflected upon biochemical 
typing, the K antigen type of each of the genetic capsule types for strains 
was determined by classical capsule typing (Figure 5.6), and also overlaid 
any available capsule type information on the other sequenced strains. The 
data revealed the presence a high degree of diversity in the biochemical 
profiles of K antigens. This diversity was reflected by the presence of several 
K antigen variants in the tested ST131 strains belonging to H30Rx clade, 
despite the previous use of PCR-based methods has identified K2 antigen 
type in E. coli ST131 via using kpsMII primers (Johnson and O'Bryan 2004, 
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Croxall et al. 2011a). 
 
 
Figure 5.6: Capsule locus genetics of a collection of E. coli ST131 H30Rx genomes. 
The figure shows all of the capsule loci identified in available E. coli ST131 genomes. 
The CDS marked in green are the kpsFEDUCS cluster, and those in red the kpsTM 
cluster, both of which are highly conserved across all E. coli capsules. The CDS 
marked in cyan are unique CDS to that capsule type. The grey shading indicates 
the level of identity between any given pair of CDS. The K antigen identified for 
each genetic capsule type is indicated in letters to the left, whilst the strain that 
the capsule locus belongs to is indicated in letters to the right.  
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Generally, blast analysis of each of the variable central genes in each 
genetic capsule type returned no significant hits with any reference E. coli 
sequences (Table 5.5). The only exception here was the presence of the 
TagD-2 gene that was found in the ST131 UTI32 strain and also in the non-
ST131 reference strain CFT073. More importantly for this study, our data 
showing the presence of significant genetic diversity within the capsule 
locus in E. coli ST131 H30Rx strains suggests frequent and targeted 
recombination in this region that was previously suggested (Petty et al. 
2014). 
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Table 5.5: Blast search results for the variable central genes identified in 
the capsule locus of E. coli ST131 strains. 
 
Gene ST131 strain  Present in  ID % 
TagD-2 UTI32 E. coli CFT073 
E. coli KTE220 
100% 
100% 
LPSBP UTI32 E. coli KTE87 99% 
HAD 
superfamily 
UTI18 
UTI62 
UTI226 
UTI306 
UTI587 
E. coli KTE76 
E. coli PCN033 
E. coli IS29 
E. coli HVH190 
100% 
99% 
99% 
99% 
CBP UTI24 
UTI62 
UTI306 
E. coli KTE76 100% 
DG1P UTI188 E. coli LAU-EC8 100% 
VatD UTI188 
JJ1886 
E. coli LAU-EC8 
E. coli HVH 186 
100% 
100% 
POLNAT UTI226 E. coli HVH177 
E. coli UMEA3656-1 
E. coli UMEA3200-1 
100% 
100% 
100% 
Ugd_1 
 
 
UTI423 
 
 
E. coli KTE21 
E. coli sp_1_1_43 
100% 
99% 
SpsA UTI423 KFiC E. coli str. clone Di14 
E. coli HVH7 
100% 
 
99% 
IspD2 EC958 E. coli KTE173 
E. coli KTE175 
100% 
100% 
TagB EC958 E. coli BIDMC 38 
E. coli 907701 
100% 
100% 
galE_2  JJ1886 E. coli HVH 186 
E. coli 908632 
100% 
100% 
galE_3 JJ1886 E. coli HVH 186 
E. coli HVH 152 
100% 
100% 
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5.3.5 Whole genome phylogeny of E. coli ST131 H30Rx strains 
To examine the diversity of capsule locus in more detail, a core genome 
phylogeny for E. coli ST131 was created using all the ST131 genome 
sequences in Table 5.2 using SE15 as the root of the phylogeny given its 
phylogenetic position relative to ST131 H30Rx clade (Petty et al. 2014). 
The resulting phylogenetic tree (Figure 5.7) confirms that all of the strains 
in the analysis, including those previously sequenced by our group prior to 
the discovery of H30Rx (Clark et al. 2012), did indeed belong the H30Rx 
clade. More importantly when the capsule loci genetics were superimposed 
on the phylogenetic tree it clearly demonstrated that the capsule loci were 
randomly distributed across the phylogeny. The only exceptions to this were 
the small cluster of strains containing UTI18 that have been previously 
shown to be essentially a single clone (Clark et al. 2012).  
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Figure 5.7: Phylogenetic distribution of K-antigen types in E. coli ST131 H30Rx 
core-genome phylogeny of the E. coli ST131 genomes analysed in this study, with 
the SE15 strain included as an outlier. The H30Rx strains are indicated by red 
colouration of tree branches. The Nottingham “outbreak” strains previously 
sequenced by our group are indicated by cyan colouration of the tree branches. 
The K-antigen type and accompanying capsule locus genetics are superimposed to 
the right of the tree.  
 
5.3.6 The effect of E. coli ST131 capsule locus diversity on other 
virulence-associated phenotypes 
On the basis of the extensive recombination at the capsule region of the E. 
coli ST131 H30Rx clade, this study sought to determine any obvious effect 
of this recombination on the ability of ST131 strains to produce capsule and 
form biofilms. The ability of ST131 strains to form capsules at 25°C and 
37°C on LB and CLED agar plates over a 14-day period was compared. The 
data showed that all strains had almost similar capsulation morphology on 
different agar plates at different incubation temperatures, suggesting that 
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there was no association between the capsule loci present in the different 
H30Rx strains and levels of capsulation morphology (Table 5.6). 
Additionally, classical 96 well-plate biofilm formation assays also failed to 
reveal any significant pattern between different H30Rx capsular variants 
(Table 5.6). 
Table 5.6: Results of capsule-associated phenotype tests for a collection 
of E. coli ST131 strains. 
 
Strain ID Capsule 
formation 
 
37°C              25°C 
Biofilm 
formation 
 
37°C 
Serotype 
UTI18 +++              +++ + O 25: K+: H- 
UTI24 +++              +++ ++ NT1 
UTI32 ++++            +++ + O 25: K-: H 4 
UTI62 ++                   ++ + NT 
UTI188 ++                   ++ + O 25:K 20,K 23:H 4 
UTI226 +++                 ++ +++++ O 25: K 16: H- 
UTI306 +++                 ++ + NT 
UTI423 +++               +++ ++ O 25: K 5: H 4 
UTI587 ++                   ++ ++ NT 
1 NT: not tested. 
5.4 Discussion  
E. coli ST131 is now the dominant causative agent of extra-intestinal 
infection by E. coli in the developed world, and is also heavily responsible 
for the increase in prevalence in multi-drug resistance in E. coli due to 
extended carriage of the CTX-M-15 ESBL gene (Rogers et al. 2011). 
Although many studies have ascribed the rapid emergence and successful 
spread of E. coli ST131 to the increased antimicrobial resistance of this 
clone, this phenotype alone is unlikely to provide an explanation for its 
predominance among other potential MDR uropathogens (Phan et al. 2013). 
Therefore, determining the factors that can drive the success of this clone 
and give it a fitness advantage over other major ExPEC clones is of great 
importance. 
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It has been shown that serum resistance is a major virulence trait for ExPEC 
strains that are associated with causing bacteraemia, as it allows them to 
survive in the blood and overcome the host innate defences (Miajlovic and 
Smith 2014). The ability of E. coli strains to resist the bactericidal effect of 
human serum was tested in this study, and the data showed that all tested 
E. coli ST131 strains were associated with high serum resistance 
phenotype. Similarly, all ST73 strains were highly serum-resistant, while 
there was a variation in the levels of serum resistance in other strains 
belonging to other ExPEC STs ST69, ST95 and ST10. The high serum 
resistance phenotype observed in ST131 strains concurs with the previous 
findings showing a high serum resistance phenotype in two matched E. coli 
ST131 strains obtained from urine and blood of a patient identified with 
urosepsis (McNally et al. 2013a), and in the ST131 strain EC958 (Phan et 
al. 2013). According to a previous report by our research group 
demonstrating the increased association of ST131 and ST73 strains with 
causing bacteraemia in comparison to other ExPEC STs such as ST69 and 
ST95 (Alhashash et al. 2013), the data of this study suggests that serum 
resistance might be an important factor in driving the current success of E. 
coli ST131 clone as a major etiological agent of bloodstream infections.  
With regard to the difference in the levels of serum resistance between E. 
coli ST131 and non-ST131 strains, our data found a significant difference 
in the levels of serum resistance at T3 between ST131 and non-ST131 
strains, although all the ST73 strains were highly serum resistant. Despite 
previous studies identifying a high serum resistance phenotype in some 
ST131 strains (McNally et al. 2013a, Phan et al. 2013), our comparative 
study was the first to report the significant difference in the serum 
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resistance between ST131 and non-ST131 strains. Additionally, although all 
tested E. coli ST131 strains were highly serum-resistant, the data showed 
no significant difference in the levels of serum resistance between the E. 
coli ST131 strains isolated from blood and those isolated from urine at 
either T0 or T3. This observation corroborates with the recent finding 
showing that the levels of serum resistance of the E. coli ST131 bacteraemia 
isolate were not significantly higher than that of the E. coli ST131 UTI isolate 
(McNally et al. 2013a). Our data seems to be in disagreement with some 
previous reports suggesting that E. coli bacteraemia isolates are more 
serum-resistant than E. coli UTI isolates (Johnson 1991, Jacobson et al. 
1992).  
Looking at the genetic determinants of serum resistance in E. coli ST131, 
two previous studies by our research group tested the VAG carriage of a 
collection of UTI and bacteraemia E. coli isolates using the multiplex PCR 
screening assay and found that 83% of ST131 bacteraemia isolates and 
80% of ST131 UTI isolates were associated with carrying the plasmid-
encoded protein (traT) (Croxall et al. 2011a, Alhashash et al. 2013). The 
traT gene has been identified as an important factor that can contribute to 
serum resistance in E. coli (Moll et al. 1980, Montenegro et al. 1985), and 
the high traT carriage among the E. coli ST131 strains may be one factor 
accounting for the high serum resistance phenotype observed in all E. coli 
ST131 strains in this study.  
A previous study defined the essential genes required for in vitro growth 
and serum resistance of the E. coli ST131 strain EC958 using TraDIS (Phan 
et al. 2013), and identified fifty-six genes essential for the serum resistance 
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of the EC958 strain. The majority of these genes encode membrane proteins 
or factors involved in the LPS biosynthesis (including O25-antigen 
biosynthesis and lipid A-core biosynthesis) and enterobacterial common 
antigen (ECA) biosynthesis. This corroborates with the previous report 
showing the major role of LPS and its components in conferring the E. coli 
resistance to human serum (Sarkar et al. 2014). 
The TraDIS screen also identified three genes encoding for colanic acid 
biosynthesis confirming the previously described role of colanic acid in the 
serum resistance of E. coli (Miajlovic et al. 2014). However the K capsular 
biosynthesis genes were not present in the essential gene set responsible 
for the serum resistance of EC958 strain suggesting that K antigen does not 
contribute to the serum resistance of this strain (Phan et al. 2013). This 
result concurs with a previous study on the serum resistance of O75:K5 
UPEC strain GR-12, which found that alterations in O75 LPS had more effect 
on serum resistance than K5 null mutation (Burns and Hull 1998). 
Additionally, it adds to the previous conflicting findings that showed a 
variation in the role of capsules in the serum resistance of ExPEC (Opal et 
al. 1982, Leying et al. 1990, Stawski et al. 1990, Schneider et al. 2004, 
Buckles et al. 2009, Sarkar et al. 2014). 
Given the proposed role of group II capsule polysaccharides of some ExPEC 
strains in conferring resistance the human serum, we examined the capsule 
region of twenty ExPEC strains, including ST131 and non-ST131 (Table 
5.2), at a genomic level to identify and compare genetic loci present in the 
capsule region of these strains. Our data identified the presence of twenty-
seven capsule loci, either with known or putative functions, in the capsule 
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region of all ExPEC ST131 and non-ST131 strains. Our data also identified 
a number of capsule loci that were encoding for hypothetical proteins of 
unknown functions. Comparing the distribution of these twenty-seven 
capsule loci between ST131 and non-ST131 strains showed the common 
presence of the eight highly conserved region 1 (kpsFEDUCS) and region 3 
(kpsTM) loci in all ExPEC strains (Figure 5.4). However the other nineteen 
region 2 loci were variably distributed among ExPEC strains (Figure 5.4), 
the vast majority of which were found to be only present in the ST131 
strains belonging to H30Rx clade. The observed difference in the 
distribution of capsule loci between ST131 and non-ST131 strains was 
interesting and drove us to examine the capsule region of ST131 H30Rx 
strains in more detail.  
 
On the basis of previous reports showing a genetic (Petty et al. 2014) and 
biochemical (Olesen et al. 2013) diversity of the capsule region within E. 
coli ST131 strains belonging to H30Rx clade, the genetic architecture of 
capsule locus of E. coli ST131 was investigated in this study. Surprisingly, 
a high degree of diversity was observed between the conserved kpsS and 
kpsTM regions of the capsule locus, with no noticeable similarity between 
strains in the variable central genes. Blast analysis of each of the variable 
central genes in each genetic capsule type also showed no significant hits 
with any reference E. coli sequences expect for the TagD-2 gene that was 
found in ST131 strain UTI32 and in the non-ST131 E. coli CFT073 strain. 
The diversity in the capsule locus of ST131 strains concurs the previous 
finding demonstrating the presence of several variant region 2 gene clusters 
between the conserved region 1 (kpsFEDUCS) and region 3 (kpsTM) of 
ST131 capsule locus (Petty et al. 2014). 
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To determine how this genetic architecture reflected upon biochemical 
typing, classical capsule typing was used to identify the K antigen type of 
each of the genetic capsule types for strains. The data revealed the 
presence a high degree of diversity in the biochemical profile of K antigens 
that was previously described in members belonging to ST131 H30Rx clade 
(Olesen et al. 2013). Although PCR-based methods have identified K2 
antigen type in E. coli ST131 via using kpsMII primers (Johnson and O'Bryan 
2004, Croxall et al. 2011a), the use of classical capsule typing was useful 
in the identification of diverse K antigen types in ST131 strains belonging 
to H30Rx clade. This finding seems surprising given the monomorphic 
nature of the H30Rx clade described previously by our research group 
(Clark et al. 2012). In general, our data showed a correlation between the 
genetic capsular type and the biochemical typing data, and provides a 
framework for which to contextualise E. coli capsule types from genomic 
data. More importantly for this study, the data clearly showed significant 
diversity within the capsule locus in E. coli ST131 H30Rx strains suggestive 
of frequent and targeted recombination in this region (Petty et al. 2014).  
 
To investigate the genetic diversity of capsule locus in more details, a core 
genome phylogeny for E. coli ST131 was created using all the ST131 
genome sequences and previously published methodology (Sahl et al. 
2011). The resulting phylogenetic tree confirms that all of the strains in the 
analysis, including those previously sequenced by our group prior to the 
discovery of H30Rx (Clark et al. 2012), belonged to the H30Rx clade. It also 
showed that the capsule loci were randomly distributed across the 
phylogeny with the exception of the small cluster of strains containing 
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UTI18 that have been previously shown to be essentially a single clone 
(Clark et al. 2012). Such a random dispersal of the capsule loci across the 
phylogenetic tree can only be explained by extensive and targeted 
recombination events at this discreet location on the genome, suggesting 
there is some pressure acting on the capsule locus resulting in constant 
switching of capsule genes as the H30Rx clade evolves. Such extensive 
recombination has been well characterised in Streptococcus pneumonia 
where capsule locus switching has been shown to play a significant role in 
vaccine escape (Croucher et al. 2013) and in the evolutionary dynamics of 
densely populated infection foci (Chewapreecha et al. 2014). However such 
dynamism in capsular recombination in E. coli is hitherto uncharacterised 
particularly in such a genetically monomorphic clade as ST131 H30Rx.  
 
Finally, to determine the effect of the extensive recombination at the 
capsule region of the ST131 H30Rx clade on other virulence-associated 
phenotypes in-vitro, this study tested the ability of members of ST131 
strains belonging to H30Rx clade to form capsules and biofilm. The data 
showed no association between the capsule loci present in the different 
H30Rx strains and levels of capsulation morphology on agar plates. 
Similarly, classical 96-well plate biofilm formation assays also failed to 
identify any significant pattern between different H30Rx capsular variants. 
These observations, combined with the high serum resistance phenotype 
identified previously by this study for all ST131 strains, suggest that the 
presence of different capsular variants in ST131 strains belonging to H30Rx 
clade had no effect on the capability of these strains to form capsules, 
biofilm, and to resist the bactericidal activity of human serum. As mentioned 
earlier, although several reports have described the important role of 
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capsules in the serum resistance of ExPEC strains (Leying et al. 1990, 
Buckles et al. 2009), our data suggests that capsule type may be less 
important, and that the extensive capsular recombination demonstrated in 
the ST131 H30Rx clade has no effect on the ability of these pathogens to 
survive exposure to human serum. 
5.5 Conclusion  
E. coli ST131 has recently emerged as a globally disseminated, multi-drug-
resistant clone responsible for a high proportion of urinary tract and 
bloodstream infections (Rogers et al. 2011). It has been shown that serum 
resistance is a major virulence trait for ExPEC that cause bloodstream 
infections (Phan et al. 2013), and investigation into serum resistance of E. 
coli has identified several factors that contribute to this phenotype 
(Miajlovic and Smith 2014). This study showed that all ST131 strains were 
associated with high serum resistance phenotype, and this might suggest 
serum resistance as an important factor in driving the current success of 
this clone. 
Based on many reports showing the genetic and biochemical diversity in 
the capsule region of ST131 strains, testing the genetic architecture and K 
antigen biochemical profiles of the capsule region of these strains shows a 
surprising level of diversity within the capsule locus of the H30Rx clade with 
a phylogenetic distribution highly suggestive of frequent recombination at 
the locus. This recombination has no obvious detectable effect on virulence-
associated phenotypes in-vitro. Given the level of diversity observed at the 
capsule locus it is tempting to speculate that there is significant selective 
pressure occurring at this site during the life cycle of the H30Rx clade, and 
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that frequent recombination allows the clade to subvert that pressure. This 
has been documented to occur in other capsulated pathogens 
(Chewapreecha et al. 2014) and also ties in with previous data from our 
group showing that ST131 strains did not exhibit inter-species 
recombination across the E. coli species but that rather recombination 
events were focussed within the ST131 lineage (McNally et al. 2013b). 
Temporal studies of ST131 populations from patients and environmental 
reservoirs may allow us to determine if capsular switching does occur in 
vivo and if it is an important mechanism in the successful and prolonged 
dissemination of this important human pathogen. 
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6. Final conclusions and future directions 
The current success of E. coli ST131 as a globally disseminated pathogen 
and its association with causing a wide range of difficult-to-treat infections 
(Rogers et al. 2011) highlight the importance of studying the factors that 
lead to this success and make it such a unique ExPEC clone. The 
experimental work of this PhD project started with performing a range of 
comparative assays in order to characterise and compare the traits of 
ST131 and non-ST131 at a phenotypic-level. 
Firstly, the growth rates of a collection of E. coli strains, including E. coli 
ST131 and non-ST131 strains, were determined using two different growth 
assays, turbidity measurement assay and viable cell count assay, in order 
to examine the association between E. coli ST131 and differential growth 
profile in vitro. Our data obtained from measuring the OD value of 49 E. 
coli strains using 4 different growth conditions showed that all ST131 and 
non-ST131 strains had almost similar growth rates. This was subsequently 
confirmed by the growth curves obtained from performing viable cell 
counting assay on five ST131 and five non-ST131 strains, which also 
showed undetectable difference in the growth rates of the tested ST131 and 
non-ST131 strains. 
Afterwards, on the basis of a previous study by our research group that 
identified the presence a fimB transposon insertion mutation in ten ST131 
isolates (Clark et al. 2012), PCR screening of the fimB insertion in twenty-
five E. coli ST131 strains showed that 21 of 25 ST131 strains (83.33%) had 
this insertion. Yeast cell agglutination assay was then performed to test the 
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effect of this insertion on the ability of E. coli ST131 strains to produce type 
1 fimbriae, and our data showed that all strains were able to express 
functional type 1 fimbriae after two rounds of static growth, suggesting no 
effect of the fimB transposon insertion mutation on the capacity of E. coli 
ST131 strains to produce functional type 1 fimbriae. 
Previous work by our research group that used gentamicin protection assay 
to compare the ability of a collection of E. coli strains to associate with and 
to invade T24 bladder epithelial cells (Croxall et al. 2011a), and identified 
the presence of a hyper-invasive phenotype in 56% of the tested ST131 
strains. Based on that, we tested and compared the capacity of ten GFP-
tagged ST131 and non-ST131 strains to attach to, invade and form IBCs 
within T24 cells using confocal microscopy, and identified the presence of 
strain-specific differences between strains, with no difference at ST-level 
between strains. Afterwards, determining the ability of ten ST131 and non-
ST131 strains to persist within U937 macrophages showed also strain-
specific difference between strains, with no specific ST131 persistence 
profile. Taken together, our comprehensive phenotypic characterisation of 
a collection of ExPEC strains belonging to different STs suggested no 
difference between ST131 and non-ST131 at a phenotypic-level, and 
highlighted the presence of other factors that can contribute to ST131 
fitness. 
Subsequently, given many previous studies demonstrating the association 
between high metabolic capacity and enhanced bacterial fitness (Le 
Bouguénec and Schouler 2011), and on the basis of a previous study 
showing that E. coli ST131 isolates had higher metabolic potential and 
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biochemical profiles compared to other ExPEC ST isolates, which may 
contribute to the fitness of E. coli ST131 (Gibreel et al. 2012a), this PhD 
project tested and compared the metabolic activity of a collection of ST131 
and non-ST131 strains using two different testing methodologies: API strips 
and PM technology. Our API data showed that ST131 strains had a lower 
metabolic activity for 5 substrates, which is in contrary to a recent finding 
by Gibreel et al. (2012a) showing that ST131 strains had an increased 
metabolic potential compared to other ExPEC STs. Further testing of the 
metabolic activity of E. coli using phenotypic microarray demonstrated the 
absence of specific metabolic profile for ST131 strains suggesting that 
ST131 is not a metabolically distinct lineage of ExPEC and thus metabolism 
might not contribute to the fitness of this clone. In addition, comparative 
genome analysis also suggested very little difference in the repertoire of 
metabolic gene loci between ST131 and no-ST131. Our previous work 
describing the genetic homogeneity of ST131 (Clark et al. 2012) combined 
with the data presented here provide yet another confounding suggestion 
that E. coli ST131 do not display altered metabolic fitness to other closely 
related ExPEC from a global metabolic and genomic perspective. Since our 
findings and those of Gibreel et al. (2012a) were obtained from testing 
different strain sets using different methodologies, we propose that a 
coordinated international effort to fully understand the evolutionary 
mechanisms behind the emergence of E. coli ST131 is now crucial in order 
to combat this most serious of bacterial pandemics, and of future episodes 
of novel E. coli lineage emergence. 
Based on a recent comparative genome study that only focussed on 
virulence associated genes and large mobile genetic elements unique to the 
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ST131 H30Rx clade (Petty et al. 2014), we investigated the gene content 
of a group of E. coli including ST131 and non-ST131 strains in order to 
identify the presence of other loci that are uniquely associated with ST131 
H30Rx clade. Our gene content analysis of E. coli strains performed using 
Gegenees (Ågren et al. 2012) showed the presence of few genetic loci 
unique to ST131 H30Rx clade. Further investigation to identify these loci 
and the functional categories to which these loci belong to was performed 
using LS-BSR (Sahl et al. 2014), and our data identified the presence of 
150 loci, the majority of which were hypothetical proteins, uniquely 
associated with this clade. In the future, it would be interesting to 
investigate the potential role of the hypothetical proteins identified as 
unique to ST131 H30Rx strains.  
 
Generally, our data demonstrated that this clade is rather unremarkable in 
terms of its gene content compared to other ExPEC. Additionally, it 
identified the presence of a small set of metabolic loci that confirms our 
previous finding demonstrating that ST131 H30Rx is not a metabolically 
distinct lineage of ExPEC (Alqasim et al. 2014a). However the most striking 
finding at a genomic level was the identification of the secondary flagellar 
locus Flag 2 as a region uniquely associated with ST131 H30Rx strains 
(Totsika et al. 2011, Clark et al. 2012, Petty et al. 2014). Given the major 
role of flagella in the pathogenesis of E. coli strains (Haiko and Westerlund-
Wikström 2013), and that the possession of Flag-2 locus may be a key 
factor for the survival of these strains in specific niches and/or hosts (Kirov 
2003), this region merits further detailed bacterial genetics analysis to 
uncover its true importance to the emergence and success of the H30Rx 
clade.  
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It has been known that serum resistance is a major virulence trait for ExPEC 
that cause bloodstream infections (Phan et al. 2013), and investigation into 
serum resistance of E. coli has identified several factors that contribute to 
this phenotype (Miajlovic and Smith 2014). In this study, we tested the 
ability of a collection of ST131 and non-ST131 strains to resist human 
serum. Our data showed that all ST131 and ST73 strains were associated 
with high serum resistance phenotype, and this might suggest serum 
resistance as an important factor in driving the current success of this 
ST131 as a major cause of bloodstream infections worldwide. 
The high serum resistance phenotype identified for ST131 strains drove us 
to explore the mechanisms involved in the serum resistance of E. coli. Given 
many reports showing that polysaccharide capsules might be a major factor 
allowing E. coli to resist the human serum (Leying et al. 1990, Buckles et 
al. 2009), and based on many studies demonstrating the genetic (Petty et 
al. 2014) and biochemical (Olesen et al. 2013) diversity in the capsule 
region of ST131 strains, the capsule region of a collection of ExPEC 
belonging to ST131 H30Rx clade and non-ST131 was tested in more detail 
at a genomic and biochemical levels. Our capsule genetics data showed a 
surprising level of diversity within the capsule locus of the H30Rx clade with 
a phylogenetic distribution highly suggestive of frequent recombination at 
the locus. Subsequent analysis demonstrated that this recombination has 
no obvious detectable effect on virulence-associated phenotypes in-vitro. 
Given the level of diversity observed at the capsule locus of ST131 H30Rx 
strains, it is tempting to speculate that there is significant selective pressure 
occurring at this site during the life cycle of the H30Rx clade, and that 
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frequent recombination allows the clade to subvert that pressure. This has 
recently been reported to occur in other capsulated pathogens 
(Chewapreecha et al. 2014) and also ties in with previous data from our 
group showing that ST131 strains did not exhibit inter-species 
recombination across the E. coli species but that rather recombination 
events were focussed within the ST131 lineage (McNally et al. 2013b). 
Temporal studies of ST131 populations from patients and environmental 
reservoirs may allow us to determine if capsular switching does occur in 
vivo and if it is an important mechanism in the successful and prolonged 
dissemination of this important human pathogen. 
In conclusion, this PhD project characterised the traits that might give 
ST131 a fitness advantage over other successful ExPEC STs, and generally 
found no detectable difference at a phenotypic-level between ST131 and 
non-ST131. The only exception was the increased ability of ST131 strains 
to resist the bactericidal effect of human serum, although this finding was 
also observed for strains belonging to other successful ExPEC clone ST73.  
Our capsule genetics data showed a surprising level of diversity within the 
capsule locus of the H30Rx clade proposing the presence of frequent and 
extensive recombination at the locus. This recombination suggests that 
there is significant selective pressure occurring at this site during the life 
cycle of the ST131 H30Rx clade, which might provide a fitness advantage 
to ST131. Finally, our findings obtained from pan-genome analysis of a 
collection of ExPEC genomes identified the presence of the secondary 
flagellar locus Flag 2 in the functional category of genes uniquely associated 
with ST131 H30Rx strains, which might be a key factor for the survival of 
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these strains in specific niches and/or hosts and therefore in the 
pathogenesis.  
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7. Appendix  
7.1 Metabolism work supplementary information  
Supplementary table 7.1: List of the 120 API biochemical substrates used 
in the metabolic profiling assay. 
 
Test Substrate  Reaction 
ONPG  ONPG β-galactosidase production 
ADH  Arginine Arginine dihydrolase production 
LDC  Lysine Lysine decarboxylase production 
ODC  Ornithine Ornithine decarboxylase 
production 
CIT Citrate Citrate utilisation  
H2S  Sodium thiosulfate  H2S production 
URE Urea  Urea hydrolysis  
TDA Tryptophan  Deaminase production 
Indole  Tryptophan Indole production  
VP  Sodium pyruvate  Acetoin production  
GEL  Charcoal gelatine  Gelatinase production 
GLU Glucose  Fermentation/oxidation  
MAN  Mannitol  Fermentation/oxidation  
INO  Inositol  Fermentation/oxidation  
SOR  Sorbitol  Fermentation/oxidation  
RHA  Rhamnose  Fermentation/oxidation  
SAC  Sucrose  Fermentation/oxidation  
MEL  Melibiose  Fermentation/oxidation  
AMY  Amygdalin  Fermentation/oxidation  
ARA  Arabinose  Fermentation/oxidation  
LARL  L-Arabitol  Acidification 
GAT  Galacturonate Acidification 
5KG  Potassium 5-keto-
gluconate  
Acidification 
LIP  Lipase Lipase production 
RP  Phenol red  Acidification 
βGLU  β-glucose β-glucosidase 
MAL  Maltose Acidification 
ADO  Adonitol Acidification 
PLE  Palatinose Acidification 
βGUR  β-glucuronidase β-glucuronidase production 
MNT  Malonate  Acidification 
βNAG  N-acetyl-β-
glucosaminidase 
N-acetyl-β-glucosaminidase 
production 
βGAL  β-galactosidase β-galactosidase production 
LARA  L-Arabinose Acidification 
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DARL  D-Arabitol Acidification 
αGLU  α-glucosidase α-glucosidase production 
αGAL  α-galactosidase α-galactosidase production 
TRE  Trehalose  Acidification 
CEL  Cellobiose  Acidification 
αMAL  α-Maltosidase α-Maltosidase production 
AspA L-Aspartic acid 
arylamidase 
L-Aspartic acid arylamidase 
GLY  Glycerol Fermentation  
ERY  Erythritol Fermentation 
DARA  D-arabinose Fermentation 
RIB  D-ribose Fermentation 
DXYL  D-xylose Fermentation 
LXYL  L-xylose Fermentation  
MDX  Methyl-β-D-
xylopyranoside 
Fermentation 
GAL  D-galactose Fermentation 
FRU  D-fructose Fermentation 
MNE  D-mannose Fermentation 
SBE  L-sorbose Fermentation  
DUL Dulcitol  Fermentation 
MDM  Methyl-α-D-
mannopyranoside 
Fermentation 
MDG  Methyl-α-D-
glucopyranoside 
Fermentation 
NAG  N-acetyl-glucosamine Fermentation 
AMY  Amygdalin Fermentation 
ARB  Arbutin Fermentation 
ESC  Esculin Fermentation 
SAL  Salicin Fermentation 
LAC  D-lactose Fermentation  
INU  Inulin Fermentation 
MLZ  D-melezitose Fermentation 
RAF D-raffinose Fermentation 
AMD  Amidon Fermentation 
GLYG  Glycogen Fermentation  
XLT  Xylitol Fermentation 
GEN  Gentiobiose Fermentation 
TUR  D-turanose Fermentation 
LYX  D-lyxose Fermentation 
TAG  D-tagatose  Fermentation  
DFUC  D-fucose  Fermentation 
LFUC  L-fucose  Fermentation 
GNT  Potassium gluconate Fermentation 
2KG  Potassium 2-keto-
gluconate  
Fermentation 
ALP Alkaline phosphatase  Enzyme production 
ESTC4 Esterase C 4 Enzyme production 
ESTLipC8 Esterase Lipase C8 Enzyme production 
LipC14 Lipase C 14 Enzyme production 
Leu arylamidase Leucine arylamidase  Enzyme production 
Val arylamidase Valine arylamidase Enzyme production 
Cys arylamidase Cysteine arylamidase Enzyme production 
Trypsin Trypsin Enzyme production 
α -chymotrypsin α -chymotrypsin Enzyme production 
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ACP Acid phosphatase Enzyme production 
Naphthol-AS-BI- 
phosphohydrolyse 
Naphthol-AS-BI-
phosphohydrolyse 
Enzyme production 
α - galactosidase α - galactosidase Enzyme production 
β - galactosidase β - galactosidase Enzyme production 
β – glucuronidase β – glucuronidase Enzyme production 
α – glucosidase α – glucosidase Enzyme production 
β – glucosidase β – glucosidase Enzyme production 
A-acetyl-β– 
glucosaminidase 
N-acetyl-β– 
glucosaminidase 
Enzyme production 
α – mannosidase α – mannosidase Enzyme production 
α - fucosidase α - fucosidase Enzyme production 
 
Supplementary table 7.2: List of the 190 carbon sources used in the 
Biolog phenotypic microarray assay. 
 
Well 
no. 
Test Well no. Test 
A01 Negative control E01 L-Glutamine 
A02 L-Arabinose E02 m-Tartaric Acid 
A03 N-Acetyl-D-
glucosamine 
E03 D-Glucose-1-Phosphate 
A04 D-Saccharic Acid E04 D-Fructose-6-Phosphate 
A05 Succinic Acid E05 Tween 80 
A06 D-Galactose E06 a-Hydroxy Glutaric Acid-g-
Lactone 
A07 L-Aspartic Acid E07 a-Hydroxy-Butyric Acid 
A08 L-Proline E08 b-Methyl-D-Glucoside 
A09 D-Alanine E09 Adonitol 
A10 D-Trehalose E10 Maltotriose 
A11 D-Mannose E11 2`-Deoxy-Adenosine 
A12 Dulcitol E12 Adenosine 
B01 D-serine F01 Glycyl-L-Aspartic Acid 
B02 D-sorbitol F02 Citric Acid 
B03 Glycerol F03 m-Inositol 
B04 L-Fucose F04 D-Threonine 
B05 D-Glucuronic Acid F05 Fumaric Acid 
B06 D-Gluconic Acid F06 Bromo-Succinic Acid 
B07 
D, L-a-Glycerol- 
Phosphate 
F07 Propionic Acid 
B08 D-xylose F08 Mucic Acid 
B09 L-Lactic Acid F09 Glycolic Acid 
B10 Formic Acid F10 Glyoxylic Acid 
B11 D-mannitol F11 D-cellobiose 
B12 L-Glutamic Acid F12 Inosine 
C01 D-glucose-6-phosphate G01 Glycyl-L-Glutamic Acid 
C02 D-Galactonic Acid-g-
Lactone 
G02 Tricarballylic Acid 
C03 D, L-Malic Acid G03 L-Serine 
C04 D-Ribose G04 L-Threonine 
C05 Tween 20 G05 L-Alanine 
C06 L-rhamnose G06 L-Alanyl-Glycine 
C07 D-Fructose G07 Acetoacetic Acid 
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C08 Acetic Acid G08 N-Acetyl-b-D-Mannosamine 
C09 α-D-glucose G09 Mono Methyl Succinate 
C10 Maltose G10 Methyl Pyruvate 
C11 D-Melibiose G11 D-Malic Acid 
C12 Thymidine G12 L-Malic Acid 
D01 L-Asparagine H01 Glycyl-L-Proline 
D02 D-Aspartic Acid H02 p-Hydroxy-Phenylacetic Acid 
D03 D-Glucosaminic Acid H03 m-Hydroxy-Phenylacetic Acid 
D04 1,2-Propanediol H04 Tyramine 
D05 Tween 40 H05 D-Psicose 
D06 a-Keto-Glutaric Acid H06 L-Lyxose 
D07 a-Keto-Butyric Acid H07 Glucuronamide 
D08 a-Methyl-D-Galactoside H08 Pyruvic Acid 
D09 a-D-Lactose H09 L-Galactonic Acid-g-Lactone 
D10 Lactulose H10 D-Galacturonic Acid 
D11 Sucrose H11 b-Phenylethylamine 
D12 Uridine H12 Ethanolamine 
 
 
Supplementary table 7.3: Metabolic profiling results for 50 E. coli ST131 
and non-ST131 strains obtained from using 120 API biochemical substrates.  
 
Test ST131 
(n=25)  
ST69  
(n=7) 
ST73  
(n=7) 
ST95  
(n=7) 
ST10 
 (n=4) 
ONPG + 25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
ADH + 13/13 
52%/52% 
2/2 
28%/28% 
4/4 
57%/57% 
1/1 
14%/14% 
1/1 
25%/25% 
LDC + 22/22 
88%/88% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
ODC + 25/25 
100%/100% 
1/1 
14%/14% 
7/7 
100%/100% 
7/7 
100%/100% 
2/2 
50%/50% 
Citrate + 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
H2S + 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
Urease + 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
TDA+ 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
Indole + 24/24 
96%/96% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
VP + 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
GEL + 0/0 0/0 0/0 0/0 0/0 
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0%/0% 0%/0% 0%/0% 0%/0% 0%/0% 
Glucose + 25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
MAN + 25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
INO + 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
SOR + 24/24 
96%/96% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
3/3 
75%/75% 
RHA + 25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
SAC + 24/24 
96%/96% 
7/7 
100%/100% 
3/3 
42%/42% 
1/1 
14%/14% 
1/1 
25%/25% 
MEL + 23/23 
92%/92% 
7/7 
100%/100% 
5/5 
71%/71% 
7/7 
100%/100% 
4/4 
100%/100% 
AMY + 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
ARA + 24/24 
96%/96% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
Nitrate → nitrites  25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
LARL + 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
GAT + 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
5KG + 
 
2/2 
8%/8% 
7/7 
100%/100% 
6/6 
85%/85% 
4/4 
57%/57% 
3/3 
75%/75% 
Lipase + 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
RP + 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
βglu + 
  
2/2 
8%/8% 
1/1 
14%/14% 
1/1 
14%/14% 
1/1 
14%/14% 
1/1 
25%/25% 
MAL + 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
ADO + 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
PLE + 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
βGUR + 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
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MNT + 
 
1/1 
4%/4% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
βNAG + 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
βGAL + 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
LARA + 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
DARL + 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
αGLU + 
  
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
αGAL + 
  
24/24 
96%/96% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
TRE + 
  
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
RHA + 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
INO + 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
CEL + 
 
0/0 
0%/0% 
3/3 
43%/43% 
3/3 
43%/43% 
2/2 
28%/28% 
2/2 
50%/50% 
αMAL + 
  
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
ASPA + 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
GLY 
  
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
ERY  
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
DARA 
 
3/5 
12%/20% 
0/7 
0%/100% 
0/6 
0%/85% 
0/7 
0%/100% 
1/3 
25%/75% 
LARA  
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
RIB 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
DXYL 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
5/5 
71%/71% 
4/4 
100%/100% 
LXYL 
  
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
ADO  0/0 1/1 1/2 1/1 0/0 
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 0%/0% 14%/14% 14%/28% 14%/14% 0%/0% 
MDX  
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
GAL 
  
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
GLU 
  
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
FRU 
  
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
MNE  
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
SBE  
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
5/5 
71%/71% 
1/1 
25%/25% 
RHA  
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
DUL  
 
4/9 
16%/36% 
6/7 
85%/100% 
5/6 
71%/85% 
4/5 
57%/71% 
3/3 
75%/75% 
INO  
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
MAN 
  
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
SOR  
 
24/24 
96%/96% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
3/3 
75%/75% 
MDM  
 
0/0 
0%/0% 
0/1 
0%/14% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
MDG  
 
1/2 
4%/8% 
0/1 
0%/14% 
0/0 
0%/0% 
1/1 
14%/14% 
0/0 
0%/0% 
NAG 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
AMY  
 
0/2 
0%/8% 
2/3 
28%/42% 
1/1 
14%/14% 
3/3 
43%/43% 
1/2 
25%/50% 
ARB  
 
2/5 
8%/20% 
3/3 
42%/42% 
2/4 
28%/57% 
2/2 
28%/28% 
2/3 
50%/75% 
ESC 
 
4/6 
16%/24% 
3/3 
42%/42% 
3/7 
42%/100% 
4/4 
57%/57% 
4/4 
100%/100% 
SAL 
  
2/7 
8%/28% 
3/3 
42%/42% 
2/7 
28%/100% 
2/3 
28%/43% 
2/4 
50%/100% 
CEL 
 
0/0 
0%/0% 
3/3 
43%/43% 
2/3 
28%/43% 
2/2 
28%/28% 
1/2 
25%/50% 
MAL  
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
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LAC  
 
23/23 
92%/92% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
MEL  
 
23/23 
92%/92% 
7/7 
100%/100% 
5/7 
71%/100% 
5/5 
71%/71% 
4/4 
100%/100% 
SAC 
 
25/25 
100%/100% 
7/7 
100%/100% 
5/6 
71%/85% 
3/3 
43%/43% 
3/3 
75%/75% 
TRE  
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
INU  
 
0/0 
0%/0% 
1/2 
14%/28% 
1/1 
14%/14% 
3/3 
43%/43% 
1/1 
25%/25% 
MLZ 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
RAF 
 
15/23 
60%/92% 
7/7 
100%/100% 
5/6 
71%/85% 
4/4 
57%/57% 
3/3 
75%/75% 
AMD  
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
GLYG  
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
XLT 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
GEN  
 
4/4 
16%/16% 
3/3 
42%/42% 
2/5 
28%/71% 
2/2 
28%/28% 
1/1 
25%/25% 
TUR  
 
1/3 
4%/12% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
LYX  
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
TAG 
 
24/24 
96%/96% 
1/2 
14%/28% 
7/7 
100%/100% 
4/5 
57%/71% 
1/1 
25%/25% 
DFUC 
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/1 
0%/14% 
0/0 
0%/0% 
LFUC 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
DARL  
 
0/0 
0%/0% 
1/1 
14%/14% 
1/2 
14%/28% 
1/1 
14%/14% 
0/0 
0%/0% 
LARL  
 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
GNT 
 
25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
2KG 
  
1/3 
4%/12% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
5KG  2/2 7/7 6/6 4/4 3/3 
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 8%/8% 100%/100% 85%/85% 57%/57% 75%/75% 
ALP 24/24 
96%/96% 
7/7 
100%/100% 
6/6 
85%/85% 
7/7 
100%/100% 
4/4 
100%/100% 
EST C4 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
EST LIP C8 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
Lipase C14 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
LAR 24/24 
96%/96% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
VAR 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
CAR 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
Trypsin 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
α–c-trypsin 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
ACP 25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
Naph-AS-BI-
phosph 
1/1 
2%/2% 
2/2 
28%/28% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
α- galactosidase 5/5 
20%/20% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
1/1 
25%/25% 
β- galactosidase 25/25 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
7/7 
100%/100% 
4/4 
100%/100% 
β– 
glucuronidase 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
2/2 
50%/50% 
α– glucosidase 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
β – glucosidase 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
N-acetyl-β– 
glucosaminidase 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
α – mannosidase 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
α - fucosidase 0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
0/0 
0%/0% 
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7.2 Bioinformatics software scripts and command lines 
 
1. De novo Velvet assembly (Zerbino and Birney 2008) 
De novo Velvet assembly was performed using a script involving these 
command lines: 
Head -n 20000000 sampleR1.fastq > sampleshort.fastq 
Head -n 20000000 sampleR2.fastq > sampleshort2.fastq  
Perl shuffleSequences_fastq.pl sampleshort.fastq sampleshort2.fastq 
sampleinput.fastq 
Velveth: sample assem 31 -shortPaired -fastq sampleinput.fastq  
Velvetg: /home/alan/Desktop/sample assem -exp_cov 75 -cov_cutoff 8   
 
 
2. PAGIT assembly script  
The PAGIT assembly script was written by Dr. Alan McNally. Firstly, 
(velv.fa), (strainfor.fq), (strainrev.fq), (reference.fasta) and 
(reference.embl) files were moved into PAGIT (or PAGIT.V1.64bit) folder. 
Now you open PAGIT folder and double click on dorun.sh file and choose 
display, and on top you write the exact strain name, the velv.fa name, the 
reference.fasta name and the reference.embl name and then save. Open 
the terminal type cd and run PAGIT from the terminal using these command 
lines: 
cd Desktop 
cd PAGIT (or PAGIT.V1.64bit) 
ls 
source sourceme.pagit 
./dorun.sh     
 
3. Prokka annotation (Seemann 2014) 
Prokka annotation was performed using the command line: 
./prokka --outdir sample ID _prokka --genus Escherichia --locustag sample 
ID sample ID.fasta  
 
 
 
4. Mugsy alignment command line (Angiuoli and Salzberg 2011) 
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Mugsy alignment was performed using the command line: 
source mugsyenv.sh 
./mugsy --directory /home/alan/Desktop sample1.fasta sample2.fasta 
sample3.fa sample4.fa sample5.fa sample6.fa sample7.fa sample8.fa 
sample9.fa sample10.fa sample11.fa  
 
5. RaxML maximum likelihood phylogeny command line 
(Stamatakis et al. 2005) 
 
RaxML maximum likelihood phylogeny was performed using the command 
line: 
raxmlHPC -f a -m GTRGAMMA -x 12345 -# 100 -s Alan_ Escherichia 
_align.phy -n Alan _ Escherichia _raxml 
 
 
     6. Compare_bsr.py script in LS-BSR software (Sahl et al. 2014) 
     
This script is used to looks for CDS differences between two user-defined 
populations. The “names.txt” file contains the names, as they should be 
listed in your separate groups file. The compare_bsr.py script requirements 
include: BSR matrix, two new-line delimited group files, taken from 
“names.txt” and FASTA file of all CDS sequences. The command line used 
was: 
$phyton compare_BSR .py -1 group1.txt -2 group2.txt –f consensus.fasta 
–b_bsr_matrix_values.txt 
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